Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders

ABSTRACT

The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.

This application is a 371 of International Patent Application No.PCT/EP2013/003064, filed Oct. 11, 2013, which claims foreign prioritybenefit under 35 U.S.C. §119 of the European Patent Application No.12007118.8, filed Oct. 11, 2012, the disclosures of which patentapplications are incorporated herein by reference.

The invention relates to certain compounds for the use in the treatmentand/or prophylaxis of diseases and/or disorders that are, at leastpartially, mediated by TSPO activity.

The translocator protein (18 kDa) (TSPO), also known as peripherial-typebenzodiazepine receptor, peripheral BZD receptor or mitochondrialbenzodiazepine receptor, is a five transmembrane domain protein that islocalized primarily in the outer mitochondrial membrane and expressedpredominantly in steroid-synthesizing tissues, including the brain. TSPOis involved in the translocation of cholesterol from the outer to theinner mitochondrial membrane, which is the rate-limiting step in thesynthesis of steroids and one of the most well-characterized functionsof this protein.

Radiolabeled TSPO ligands are used as neuroimaging agents and are knownas important diagnostic tools. TSPO also seems to be a sensitivebiomarker of brain damage and neurodegeneration. The binding of labeledTSPO ligands can be visualized and quantified by in vivo imagingtechniques such as positron emission tomography (PET) and single photonemission computed tomography (SPECT). Altered TSPO expression has beenshown in numerous neurological and psychiatric disorders.

Therefore, the modulation of the activity of this protein provides anoption for treatment of diseases related to disturbed cholesterolmetabolism and steroidogenesis, but also aptotosis and cellproliferation.

Furthermore, its potential use for neuroprotection, limitingimmunological disorders, inflammatory diseases includingneuroinflammation and arthritis, encephalomyelitis, irritable bowelsyndrome, promoting regeneration, and treating dysfunctions of thenervous system has been envisaged (Rupprecht et al., Nature Reviews,2010, Vol. 9, 971).

TSPO ligands also provide therapeutic potential in neuroregeneration,and anxiety, particularily for the treatment of neurodegenerativedisorders such as Alzheimer's disease, head trauma, frontotemporaldementia, multiple sclerosis, Huntington's disease, amyotrophic lateralsclerosis, Morbus Parkinson, cerebrovascular disorders, cerebralischemia, stroke, tumours including brain tumours, andneuro-degenerative diseases related to peripheral nervous system lesionsand neuropathologies.

Various TSPO ligands have been shown to exert acuteanxiolytic/anticonflict activity in rodents and humans. Therefore, themodulation of TSPO activity additionally offers treatment options forpsychiatric disorders such as anxiety disorders including panic attacks,stress disorders including posttraumatic stress disorder, depressionincluding major depressive disorders, dysthymia, angina pectoris(Rupprecht et al., Nature Reviews, 2010, Vol. 9, 971).

It was therefore an object of the invention to provide compounds havingadvantages over the compounds known for TSPO activity. These compoundsshould be suitable in particular as pharmacological active ingredientsin pharmaceutical compositions, preferably in pharmaceuticalcompositions for the treatment and/or prophylaxis of disorders and/ordiseases which are, at least partially, mediated by TPSO activity.

That object is achieved by the subject-matter of the patent claims. Ithas been found, surprisingly, that compounds of the general formula (I)given below are suitable for the use in the treatment and/or prophylaxisof disorders and/or diseases which are, at least partially, mediated byTPSO activity.

Compounds according to general formula (I) are known and have beendescribed for their activity on KCNQ2/3 K⁺ channels (WO 2010/102809 A1;WO 2010/102811 A1; WO 2012/025236 A1; WO 2012/025237 A1; WO 2012/025238A1; WO 2012/025239 A1; WO 2012/0052167 A1).

No hint for modulation of TSPO activity and the treatment and/orprophylaxis of disorders and/or diseases, which are, at least partially,mediated by TPSO activity, however, is provided in the prior art.

The first aspect of the present invention therefore relates to acompound of general formula (I),

for the use in the treatment and/or prophylaxis of disorders and/ordiseases which are mediated, at least in part, by TSPO (translocatorprotein 18 kDa),

-   -   wherein

-   X—Y represents N(R⁵)—C(═O) or N(R⁵)—C(═S) or N═C(R⁶)

-   R¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;

-   R² represents H; F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;

-   R³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;

-   R⁴ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   or represents N(R⁷)(R⁸),    -   wherein    -   R⁷ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono-        or polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10        membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted and in each case        optionally bridged via a C₁₋₈ aliphatic group, which in turn may        be unsubstituted or mono- or polysubstituted; aryl or        heteroaryl, in each case unsubstituted or mono- or        polysubstituted and in each case optionally bridged via a C₁₋₈        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted;    -    on the condition that if R⁷ denotes a 3 to 10 membered        heterocycloaliphatic residue or a heteroaryl, the 3 to 10        membered heterocycloaliphatic residue or the heteroaryl is        linked via a carbon atom;    -   R⁸ denotes H or a C₁₋₁₀-aliphatic residue, unsubstituted or        mono- or polysubstituted;    -   or    -   R⁷ and R⁸ form together with the nitrogen atom connecting them a        3 to 10 membered heterocycloaliphatic residue, unsubstituted or        mono- or polysubstituted;

-   or R³ and R⁴ represent CH═CH—CH═CH,    -   wherein one or more H-Atoms independently of one another may be        replaced by one a radical selected from the group consisting of        F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; C(═O)—NH₂; SCF₃;        S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄        aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a        C(═O)—NH—C₁₋₄ aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic        residue)₂, wherein the C₁₋₄ aliphatic residue may be in each        case be unsubstituted or mono- or polysubstituted; a        O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a        S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a        S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic        residue may be in each case be unsubstituted or mono- or        polysubstituted; a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄        aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a        NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic        residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic        residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄        aliphatic residue may in each case be unsubstituted or mono- or        polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6        membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted and in each case        optionally bridged via a C₁₋₄ aliphatic group, which in turn may        be unsubstituted or mono- or polysubstituted;

-   R⁵ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;

-    on the condition that if R⁵ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,

-   R⁶ represents a C₂₋₁₀-aliphatic residue or a C₂₋₁₀-heteroaliphatic    residue, in each case unsubstituted or mono- or polysubstituted; a    C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₈    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   or    -   denotes S—R¹¹, O—R¹² or N(R⁹R¹⁰),        -   wherein        -   R¹¹ and R¹² in each case represent a C₁₋₁₀-aliphatic            residue, unsubstituted or mono- or polysubstituted; a            C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered            heterocycloaliphatic residue, in each case unsubstituted or            mono- or polysubstituted and in each case optionally bridged            via a C₁₋₈ aliphatic group or a C₂₋₈-heteroaliphatic group,            which in turn may be unsubstituted or mono- or            polysubstituted;            -   on the condition that if R¹¹ or R¹² denotes a 3 to 10                membered heterocycloaliphatic residue, the 3 to 10                membered heterocycloaliphatic residue is linked via a                carbon atom,        -   R⁹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or            mono- or polysubstituted; a C₃₋₁₀-cycloaliphatic residue or            a 3 to 10 membered heterocycloaliphatic residue, in each            case unsubstituted or mono- or polysubstituted and in each            case optionally bridged via a C₁₋₈ aliphatic group, which in            turn may be unsubstituted or mono- or polysubstituted;            -   on the condition that if R⁹ denotes a 3 to 10 membered                heterocycloaliphatic residue, the 3 to 10 membered                heterocycloaliphatic residue is linked via a carbon                atom;        -   R¹⁰ denotes a C₁₋₁₀-aliphatic residue, unsubstituted or            mono- or polysubstituted;        -   or        -   R⁹ and R¹⁰ form together with the nitrogen atom connecting            them a 3 to 10 membered heterocycloaliphatic residue,            unsubstituted or mono- or polysubstituted;    -   in the form of the free compounds, the racemate, the        enantiomers, diastereomers, mixtures of the enantiomers or        diastereomers in any mixing ratio, or of an individual        enantiomer or diastereomer, or in the form of the salts of        physiologically acceptable acids or bases.

The term “mono- or polysubstituted” with respect to an “aliphatic group”and an “aliphatic residue”, “alkyl group”, “alkyl residue”,“heteroaliphatic group”, “heteroalipahtic residue”, “heteroalkyl group”,“heteroalkyl residue”, “heterocyloaliphatic group”,“heterocycloalipahtic residue”, “heterocycloalkyl group”,“heterocycloalkyl residue”, “cycloalipahtic residue” and “cycloalkyl”within the scope of the present invention is the substitution of one ormore hydrogen atoms, in each case independently of one another, by F;Cl; Br; I; NO₂; CF₃; CN; ═O; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl;heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- orC₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl orheterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H;C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂;C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂;C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl);C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH;O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl;O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl;O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂;NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂;NH—C(═O)-aryl; NH—C(═O)-heteroaryl; NH—S(═O)₂—C₁₋₈-alkyl;NH—S(═O)₂-aryl; NH—S(═O)₂-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl;S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl;S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl;S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; and S(═O)₂—NH—C₁₋₈-heteroaryl.

The term “mono- or polysubstituted” with respect to “aryl” and a“heteroaryl” within the scope of the present invention is thesubstitution of one or more hydrogen atoms, in each case independentlyof one another, by F; Cl; Br; I; NO₂; CF₃; CN; C₁₋₈-alkyl;C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl;C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl,C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl;C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl;C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂;C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂;C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl);C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH;O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl;O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl;N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl;N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; SCF₃;S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl;S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl;S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl;S(═O)₂—NH—C₁₋₈-heteroaryl;

Within the scope of this invention, the terms “alkyl” and “aliphaticresidue” or “aliphatic group” or “C₁₋₁₀-alkyl”, “C₁₋₈-alkyl”,“C₁₋₆-alkyl”, “C₁₋₄-alkyl”, “C₁₋₂-alkyl” and “C₂₋₆-alkyl” includeacyclic saturated or unsaturated aliphatic hydrocarbon radicals, whichcan be branched or unbranched as well as unsubstituted or mono- orpoly-substituted, having from 1 to 10 or from 1 to 8 or from 1 to 6 orfrom 1 to 4 or from 1 to 2 or from 2 to 6 carbon atoms, that is to sayC₁₋₁₀-alkanyls, C₂₋₁₀-alkenyls and C₂₋₁₀-alkynyls or C₁₋₈-alkanyls,C₂₋₈-alkenyls and C₂₋₈-alkynyls or C₁₋₆-alkanyls, C₂₋₆-alkenyls andC₂₋₆-alkynyls or C₁₋₄-alkanyls, C₂₋₄-alkenyls and C₂₋₄-alkynyls orC₁₋₂-alkanyls, C₂-alkenyls and C₂-alkynyls or C₂₋₆-alkanyls,C₂₋₆-alkenyls and C₂₋₆-alkynyls. Alkenyls contain at least one C—Cdouble bond and alkynyls contain at least one C—C triple bond. Alkyl ispreferably selected from the group comprising methyl, ethyl, n-propyl,2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl,neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, ethenyl(vinyl), ethynyl, propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃),propynyl (—CH—C≡CH, —C≡C—CH₃), butenyl, butynyl, pentenyl, pentynyl,hexenyl and hexynyl, heptenyl, heptynyl, octenyl, octynyl, nonenyl,nonynyl, decenyl and decynyl.

Within the scope of this invention, the terms “heteroalkyl” or“C₂₋₁₀-heteroalkyl” and “C₂₋₈-heteroalkyl” or “heteroaliphatic” or“C₂₋₁₀-heteroaliphatic” and “C₂₋₈-heteroaliphatic” include acyclicaliphatic saturated or unsaturated hydrocarbon radicals having from 2 to10 carbon atoms, that is to say C₂₋₁₀-heteroalkanyls,C₂₋₁₀-heteroalkenyls and C₂₋₁₀-heteroalkynyls, or having from 2 to 8carbon atoms, that is to say C₂₋₈-heteroalkanyls, C₂₋₈-heteroalkenylsand C₂₋₈-heteroalkynyls, which in each case can be branched orunbranched as well as unsubstituted or mono- or poly-substituted and inwhich at least one carbon atom, optionally also two or three carbonatoms, have been replaced by a heteroatom or heteroatom group in eachcase selected independently of one another from the group consisting ofO, N, NH and N(C₁₋₈-alkyl), preferably N(CH₃), wherein the initialcarbon atom of a C₂₋₁₀-heteroalkyl or of a C₂₋₈-heteroalkyl, via whichthe C₂₋₁₀-heteroalkyl or C₂₋₈-heteroalkyl is bonded to the respectivegeneral structure of higher order, cannot be replaced by a heteroatom orheteroatom group and adjacent carbon atoms cannot simultaneously bereplaced by a heteroatom or heteroatom group. The heteroatom groups NHand N(C₁₋₈-alkyl) of the heteroalkyl can optionally be mono- orpoly-substituted. C₂₋₁₀-Heteroalkenyls and C₂₋₈-heteroalkenyls containat least one C—C or C—N double bond and C₂₋₁₀-heteroalkynyls andC₂₋₈-heteroalkynyls contain at least one C—C triple bond. Heteroalkyl ispreferably selected from the group comprising —CH₂—O—CH₃,—CH₂—CH₂—O—CH₃, —CH₂—CH₂—O—CH₂—CH₃, —CH₂—CH₂—O—CH₂—CH₂—O—CH₃,—CH═CH—O—CH₃, —CH═CH—O—CH₂—CH₃, ═CH—O—CH₃, ═CH—O—CH₂—CH₃,═CH—CH₂—O—CH₂—CH₃, ═CH—CH₂—O—CH₃, —CH₂—NH—CH₃, —CH₂—CH₂—NH—CH₃,—CH₂—CH₂—NH—CH₂—CH₃, —CH₂—CH₂—NH—CH₂—CH₂—NH—CH₃, —CH═CH—NH—CH₃,—CH═CH—NH—CH₂—CH₃, —CH═CH—N(CH₃)—CH₂—CH₃, ═CH—NH—CH₃, ═CH—NH—CH₂—CH₃,═CH—CH₂—NH—CH₂—CH₃, ═CH—CH₂—NH—CH₃, —CH₂—N(CH₃)—CH₃,—CH₂—CH₂—N(CH₃)—CH₃, —CH₂—CH₂—N(CH₃)—CH₂—CH₃,—CH₂—CH₂—N(CH₃)—CH₂—CH₂—N(CH₃)—CH₃, CH₂—CH₂—NH—CH₂—CH₂—O—CH₃,CH₂—CH₂—O—CH₂—CH₂—NH—CH₃, CH₂—CH₂—N(CH₃)—CH₂—CH₂—O—CH₃,CH₂—CH₂—O—CH₂—CH₂—N(CH₃)—CH₃, CH₂—NH—CH₂—O—CH₃, CH₂—O—CH₂—NH—CH₃,CH₂—N(CH₃)—CH₂—O—CH₃, CH₂—O—CH₂—N(CH₃)—CH₃, —CH═CH—N(CH₃)—CH₃,═CH—N(CH₃)—CH₃, ═CH—N(CH₃)—CH₂—CH₃, ═CH—CH₂—N(CH₃)—CH₂—CH₃,═CHCH₂—N(CH₃)—CH₃, —CH₂CH₂═N(CH₃) and —CH₂═N(CH₃).

For the purposes of this invention, the terms “cycloalkyl” or“C₃₋₁₀-cycloalkyl”, “C₃₋₇-cycloalkyl” and “C₃₋₈-cycloalkyl” or“cycloaliphatic” denote cyclic aliphatic hydrocarbons having 3, 4, 5, 6,7, 8, 9 or 10 carbon atoms or having 3, 4, 5, 6 or 7 carbon atoms orhaving 3, 4, 5, 6, 7 or 8 carbon atoms, wherein the hydrocarbons can besaturated or unsaturated (but not aromatic), unsubstituted or mono- orpoly-substituted. The bonding of the cycloalkyl to the general structureof higher order can take place via any desired and possible ring memberof the cycloalkyl radical. The cycloalkyl radicals can also be fusedwith further saturated, (partially) unsaturated, (hetero)cyclic,aromatic or heteroaromatic ring systems, that is to say with cycloalkyl,heterocyclyl, aryl or heteroaryl, which can themselves be unsubstitutedor mono- or poly-substituted. The cycloalkyl radicals can further bebridged one or more times, as, for example, in the case of adamantyl,bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Cycloalkyl is preferablyselected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl,

cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

The term “heterocyclyl” or “heterocycloalkyl” or “heterocycloaliphatic”includes aliphatic saturated or unsaturated (but not aromatic)cycloalkyls having from three to ten, that is to say 3, 4, 5, 6, 7, 8, 9or 10, ring members, in which at least one carbon atom, optionally alsotwo or three carbon atoms, has been replaced by a heteroatom orheteroatom group in each case selected independently of one another fromthe group consisting of O, S, N, NH and N(C₁₋₈-alkyl), preferablyN(CH₃), wherein the ring members can be unsubstituted or mono- orpoly-substituted. The bonding of the heterocyclyl to the generalstructure of higher order can take place via any desired and possiblering member of the heterocyclyl radical. The heterocyclyl radicals canalso be fused with further saturated, (partially) unsaturated(hetero)cyclic or aromatic or heteroaromatic ring systems, that is tosay with cycloalkyl, heterocyclyl, aryl or heteroaryl, which canthemselves be unsubstituted or mono- or poly-substituted. Heterocyclylradicals are preferably selected from the group comprising azetidinyl,aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl,dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl,dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl,dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl,morpholinyl, oxiranyl, oxetanyl, pyrrolidinyl, piperazinyl, piperidinyl,pyrazolidinyl, pyranyl, tetrahydropyrrolyl, tetrahydropyranyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroindolinyl,tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl,tetrahydropyridoindolyl, tetrahydronaphthyl, tetrahydrocarbolinyl,tetrahydroisoxazolopyridinyl, thiazolidinyl and thiomorpholinyl.

Within the scope of this invention, the term “aryl” denotes aromatichydrocarbons having up to 14 ring members, inter alia phenyls andnaphthyls. Each aryl radical can be unsubstituted or mono- orpoly-substituted, it being possible for the aryl substituents to beidentical or different and to be in any desired and possible position ofthe aryl. The aryl can be bonded to the general structure of higherorder via any desired and possible ring member of the aryl radical. Thearyl radicals can also be fused with further saturated, (partially)unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems,that is to say with cycloalkyl, heterocyclyl, aryl or heteroaryl, whichcan themselves be unsubstituted or mono- or poly-substituted. Examplesof fused aryl radicals are benzodioxolanyl and benzodioxanyl. Aryl ispreferably selected from the group containing phenyl, 1-naphthyl and2-naphthyl, each of which can be unsubstituted or mono- orpoly-substituted. A particularly preferred aryl is phenyl, unsubstitutedor mono- or poly-substituted.

The term “heteroaryl” denotes a 5- or 6-membered cyclic aromatic radicalwhich contains at least 1 heteroatom, optionally also 2, 3, 4 or 5heteroatoms, wherein the heteroatoms are in each case selectedindependently of one another from the group S, N and O and theheteroaryl radical can be unsubstituted or mono- or poly-substituted; inthe case of substitution on the heteroaryl, the substituents can beidentical or different and can be in any desired and possible positionof the heteroaryl. Bonding to the general structure of higher order cantake place via any desired and possible ring member of the heteroarylradical. The heteroaryl can also be part of a bi- or poly-cyclic systemhaving up to 14 ring members, wherein the ring system can be formed withfurther saturated, (partially) unsaturated, (hetero)cyclic or aromaticor heteroaromatic rings, that is to say with cycloalkyl, heterocyclyl,aryl or heteroaryl, which can themselves be unsubstituted or mono- orpoly-substituted. It is preferred for the heteroaryl radical to beselected from the group comprising benzofuranyl, benzoimidazolyl,benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl,benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl,quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl,imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl,isoxazolyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl,oxadiazolyl, phenazinyl, phenolthiazinyl, phthalazinyl, pyrazolyl,pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrrolyl, pyridazinyl,pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl (thiophenyl),triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl,pyridyl and thienyl are particularly preferred.

Within the scope of the invention, the expressions “C₁₋₄-alkyl- orC₁₋₈-alkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyl” meanthat C₁₋₄-alkyl or C₁₋₈-alkyl and aryl or heteroaryl or heterocyclyl orcycloalkyl have the meanings defined above and the aryl or heteroaryl orheterocyclyl or cycloalkyl radical is bonded to the general structure ofhigher order via a C₁₋₄-alkyl or C₁₋₈-alkyl group. The alkyl chain canin all cases be saturated or unsaturated, branched or unbranched,unsubstituted or mono- or poly-substituted. C₁₋₄-Alkyl or C₁₋₈-alkyl ispreferably selected from the group comprising —CH₂—, —CH₂CH₂—,—CH(CH₃)—, —CH₂CH₂CH₂—, —CH(CH₃)—CH₂—, —CH(CH₂CH₃)—, —CH₂—(CH₂)₂—CH₂—,—CH(CH₃)—CH₂—CH₂—, —CH₂—CH(CH₃)—CH₂—, —CH(CH₃)—CH(CH₃)—,—CH(CH₂CH₃)—CH₂—, —C(CH₃)₂—CH₂—, —CH(CH₂CH₂CH₃)—, —C(CH₃)(CH₂CH₃)—,—CH₂—(CH₂)₃—CH₂—, —CH(CH₃)—CH₂—CH₂—CH₂—, —CH₂—CH(CH₃)—CH₂—CH₂—,—CH(CH₃)—CH₂—CH(CH₃)—, —CH(CH₃)—CH(CH₃)—CH₂—, —C(CH₃)₂—CH₂—CH₂—,—CH₂—C(CH₃)₂—CH₂—, —CH(CH₂CH₃)—CH₂—CH₂—, —CH₂—CH(CH₂CH₃)—CH₂—,—C(CH₃)₂—CH(CH₃)—, —CH(CH₂CH₃)—CH(CH₃)—, —C(CH₃)(CH₂CH₃)—CH₂—,—CH(CH₂CH₂CH₃)—CH₂—, —C(CH₂CH₂CH₃)—CH₂—, —CH(CH₂CH₂CH₂CH₃)—,—C(CH₃)(CH₂CH₂CH₃)—, —C(CH₂CH₃)₂—, —CH₂—(CH₂)₄—CH₂—, —CH═CH—,—CH═CH—CH₂—, —C(CH₃)═CH₂—, —CH═CH—CH₂—CH₂—, —CH₂—CH═CH—CH₂—,—CH═CH—CH═CH—, —C(CH₃)═CH—CH₂—, —CH═C(CH₃)—CH₂—, —C(CH₃)═C(CH₃)—,—C(CH₂CH₃)═CH—, —CH═CH—CH₂—CH₂—CH₂—, —CH₂—CH═CH₂—CH₂—CH₂—,—CH═CH═CH—CH₂—CH₂—, —CH═CH₂—CH—CH═CH₂—, —C≡C—, —C≡C—CH₂—, —C≡C—CH₂—CH₂—,—C≡C—CH(CH₃)—, —CH₂—C≡C—CH₂—, —C≡C—C≡C—, —C≡C—C(CH₃)₂—,—C≡C—CH₂—CH₂—CH₂—, —CH₂—C≡C—CH₂—CH₂—, —C≡C—C≡C—CH₂— and —C≡C—CH₂—C≡C—.

Within the scope of the invention, the expressions“C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyl”mean that C₂₋₈-heteroalkyl and aryl or heteroaryl or heterocyclyl orcycloalkyl have the meanings defined above and the aryl or heteroaryl orheterocyclyl or cycloalkyl radical is bonded to the general structure ofhigher order via a C₂₋₈-heteroalkyl group. The heteroalkyl chain can inall cases be saturated or unsaturated, branched or unbranched,unsubstituted or mono- or poly-substituted. If a terminal carbon atom ofthe C₂₋₈-heteroalkyl group has been replaced by a heteroatom orheteroatom group, then the bonding of a heteroaryl or heterocyclyl tothe heteroatom or heteroatom group of the C₂₋₈-heteroalkyl always takesplace via a carbon atom of the heteroaryl or heterocyclyl. The terminalcarbon atom is understood as being the carbon atom within theC₂₋₈-heteroalkyl that is furthest in the chain from the generalstructure of higher order. If the terminal carbon atom of aC₂₋₈-heteroalkyl has been replaced, for example, by an N(CH₃) group,that group is located within the C₂₋₈-heteroalkyl furthest from thegeneral structure of higher order and is bonded to the aryl orheteroaryl or heterocyclyl or cycloalkyl radical. C₂₋₈-Heteroalkyl ispreferably selected from the group comprising —CH₂—NH—, —CH₂—N(CH₃)—,—CH₂—O—, —CH₂—CH₂—NH—, —CH₂—CH₂—N(CH₃)—, —CH₂—CH₂—O—, —CH₂—CH₂—CH₂—NH—,—CH₂—CH₂—CH₂—N(CH₃)—, —CH₂—CH₂—CH₂—O—, —CH₂—O—CH₂—, —CH₂—CH₂—O—CH₂—,—CH₂—CH₂—O—CH₂—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—O—CH₂—, —CH═CH—O—CH₂—,—CH═CH—O—CH₂—CH₂—, ═CH—O—CH₂—, ═CH—O—CH₂—CH₂—, ═CH—CH₂—O—CH₂—CH₂—,═CH—CH₂—O—CH₂—, —CH₂—NH—CH₂—, —CH₂—CH₂—NH—CH₂—, —CH₂—CH₂—NH—CH₂—CH₂—,—CH₂—CH₂—NH—CH₂—CH₂—NH—CH₂, —CH═CH—NH—CH₂—, —CH═CH—NH—CH₂—CH₂—,—CH═CH—N(CH₃)—CH₂—CH₂—, ═CH—NH—CH₂—, ═CH—NH—CH₂—CH₂—,═CH—CH₂—NH—CH₂—CH₂—, ═CH—CH₂—NH—CH₂—, —CH₂—N(CH₃)—CH₂—,—CH₂—CH₂—N(CH₃)—CH₂—, —CH₂—CH₂—N(CH₃)—CH₂—CH₂—,—CH₂—CH₂—N(CH₃)—CH₂—CH₂—N(CH₃)—CH₂—, CH₂—CH₂—NH—CH₂—CH₂—O—CH₂—,CH₂—CH₂—O—CH₂—CH₂—NH—CH₂—, CH₂—CH₂—N(CH₃)—CH₂—CH₂—O—CH₂—,CH₂—CH₂—O—CH₂—CH₂—N(CH₃)—CH₂—, CH₂—NH—CH₂—O—CH₂—, CH₂—O—CH₂—NH—CH₂—,CH₂—N(CH₃)—CH₂—O—CH₂—, CH₂—O—CH₂—N(CH₃)—CH₂—, —CH═CH—N(CH₃)—CH₂—,═CH—N(CH₃)—CH₂—, ═CH—N(CH₃)—CH₂—CH₂—, ═CH—CH₂—N(CH₃)—CH₂—CH₂— and═CH—CH₂—N(CH₃)—CH₂—.

In connection with “alkyl”, “heteroalkyl”, “heterocyclyl” and“cycloalkyl”, the expression “mono- or poly-substituted” is understoodas meaning within the scope of this invention the substitution of one ormore hydrogen atoms one or more times, for example two, three or fourtimes, in each case independently of one another, by substituentsselected from the group comprising F; Cl; Br; I; NO₂; CF₃; CN; ═O;C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl;heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl,C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl;C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl;C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂;C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂;C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl);C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH;O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl;O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl;N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl;N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH;S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl;S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl;S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl;and S(═O)₂—NH—C₁₋₈-heteroaryl; wherein polysubstituted radicals are tobe understood as being radicals that are substituted several times, forexample two, three or four times, either on different atoms or on thesame atom, for example three times on the same carbon atom, as in thecase of CF₃ or CH₂CF₃, or at different places, as in the case ofCH(OH)—CH═CH—CHCl₂. A substituent can itself optionally be mono- orpoly-substituted. Polysubstitution can take place with the same or withdifferent substituents.

Preferred “alkyl”, “heteroalkyl”, “heterocyclyl” and “cycloalkyl”substituents are selected from the group comprising F; Cl; Br; I; NO₂;CH₂CF₃; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; phenyl; naphthyl;pyridyl; thienyl; furyl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- orC₂₋₈-heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl,C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; CO₂H;C(═O)O—C₁₋₈-alkyl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; OH;═O; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl;O-benzyl; O-phenyl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; NH₂; NH—C₁₋₈-alkyl;N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl;N(C(═O)C₁₋₈-alkyl)₂; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-phenyl;S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl;S(═O)₂—NH—C₁₋₈-alkyl.

In connection with “aryl” and “heteroaryl”, “mono- or poly-substituted”is understood within the scope of this invention as meaning thesubstitution of one or more hydrogen atoms of the ring system one ormore times, for example two, three or four times, in each caseindependently of one another, by substituents selected from the groupcomprising F; Cl; Br; I; NO₂; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl;aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- orC₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl orheterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H;C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂;C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂;C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl);C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH;O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl;O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl;O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂;NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂;NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; SCF₃; S-benzyl; S-aryl;S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH;S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl;S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; S(═O)₂—NH—C₁₋₈-heteroaryl; on oneatom or optionally on different atoms, wherein a substituent can itselfoptionally be mono- or poly-substituted. Polysubstitution is carried outwith the same or with different substituents.

Preferred “aryl” and “heteroaryl” substituents are F; Cl; Br; I; NO₂;CH₂CF₃; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; phenyl; naphthyl;pyridyl; thienyl; furyl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- orC₂₋₈-heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl,C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; CO₂H;C(═O)O—C₁₋₈-alkyl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; OH;O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl;O-benzyl; O-phenyl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; NH₂; NH—C₁₋₈-alkyl;N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl;N(C(═O)C₁₋₈-alkyl)₂; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-phenyl;S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl;S(═O)₂—NH—C₁₋₈-alkyl.

The compounds according to the invention are defined by substituents,for example by R¹, R² and R³ (1st generation substituents), which arethemselves optionally substituted (2nd generation substituents).Depending on the definition, these substituents of the substituents canin turn themselves be substituted (3rd generation substituents). If, forexample, R¹=aryl (1st generation substituent), aryl can itself besubstituted, for example by C₁₋₈-alkyl (2nd generation substituent).This yields the functional group aryl-C₁₋₈-alkyl. C₁₋₈-Alkyl can then inturn itself be substituted, for example by Cl (3rd generationsubstituent). Overall, this then yields the functional grouparyl-C₁₋₈-alkyl-Cl.

In a preferred embodiment, however, the 3rd generation substituentscannot themselves be substituted, that is to say there are no 4thgeneration substituents.

In another preferred embodiment, the 2nd generation substituents cannotthemselves be substituted, that is to say there are not even any 3rdgeneration substituents. In other words, in this embodiment, for examplein the case of the general formula (1), the functional groups for R¹ toR¹³ can in each case optionally be substituted, but the substituents ineach case cannot themselves be substituted.

In some cases, the compounds according to the invention are defined bysubstituents which are or carry an aryl or heteroaryl radical, in eachcase unsubstituted or mono- or poly-substituted, or which, together withthe carbon atom(s) or heteroatom(s) joining them as ring member(s), forma ring, for example an aryl or heteroaryl, in each case unsubstituted ormono- or poly-substituted. Both these aryl or heteroaryl radicals andthe aromatic ring systems so formed can optionally be fused withC₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated,that is to say with a C₃₋₁₀-cycloalkyl such as cyclopentyl or with aheterocyclyl such as morpholinyl, it being possible for theC₃₋₁₀-cycloalkyl or heterocyclyl radicals so fused to be unsubstitutedor mono- or poly-substituted.

In some cases, the compounds according to the invention are defined bysubstituents which are or carry a C₃₋₁₀-cycloalkyl or heterocyclylradical, in each case unsubstituted or mono- or poly-substituted, orwhich, together with the carbon atom(s) or heteroatom(s) joining them asring member(s), form a ring, for example a C₃₋₁₀-cycloalkyl orheterocyclyl, in each case unsubstituted or mono- or poly-substituted.Both these C₃₋₁₀-cycloalkyl or heterocyclyl radicals and the aliphaticring systems formed can optionally be fused with aryl or heteroaryl,that is to say with an aryl such as phenyl or with a heteroaryl such aspyridyl, it being possible for the aryl or heteroaryl radicals so fusedto be unsubstituted or mono- or poly-substituted.

The expression “salt formed with a physiologically acceptable acid” isunderstood within the scope of this invention as meaning salts of theactive ingredient in question with inorganic or organic acids that arephysiologically acceptable in particular when used in humans and/ormammals. The hydrochloride is particularly preferred. Examples ofphysiologically acceptable acids are: hydrochloric acid, hydrobromicacid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid,oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid,maleic acid, lactic acid, citric acid, glutamic acid, saccharinic acid,monomethylsebacic acid, 5-oxo-proline, hexane-1-sulfonic acid, nicotinicacid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethyl-benzoic acid,α-liponic acid, acetylglycine, hippuric acid, phosphoric acid and/oraspartic acid. Citric acid and hydrochloric acid are particularlypreferred.

Physiologically acceptable salts with cations or bases are salts of thecompound in question—in the form of the anion with at least one,preferably inorganic cation—that are physiologically acceptable—inparticular when used in humans and/or mammals. Particular preference isgiven to the salts of the alkali and alkaline earth metals but also toammonium salts, but in particular to (mono-) or (di-)sodium, (mono-) or(di-)potassium, magnesium or calcium salts.

The first aspect of the present invention relates to a compoundaccording the general formula (I) for the treatment and/or theprophylaxis of disorders and/or diseases which are mediated, at least inpart, by TSPO (translocator protein 18 kDa).

Hence, the compounds according to the present invention are useful forthe treatment and/or the prophylaxis of disorders and/or diseases whichare mediated, at least in part, by TSPO activity.

Disorders and/or diseases, which are mediated, at least in part, by TSPOactivity, include

-   -   neurological and neurodegenerative disorders,    -   psychiatric disorders,    -   brain tumours,    -   immunological disorders        and inflammatory diseases.

Neurological and Neurodegenerative Disorders Include

Ischaemic stroke, Alzheimer's disease, frontotemporal dementia,Huntington's disease, amyotrophic lateral sclerosis, Parkinson'sdisease, multiple sclerosis, diabetic peripheral neuropathy,chemotherapy-induced peripheral neuropathy, amyotrophic lateralsclerosis, exictotoxic brain injury, traumatic brain injury, ischaemicbrain damage, cerebrovascular disorders and cerebral ischemia.

Psychiatric Disorders Include

anxiety disorders, particularily panic disorders, post traumatic stressdisorder,

panic and adult separation disorder, social anxiety, major depressionwith adult separation anxiety disorder and bipolar disorder with adultseparation anxiety disorder, dysthymia, angina pectoris, suicidality andschizophrenia.

Immunological Disorders and Inflammatory Diseases Include

neuroinflammation and arthritis, encephalomyelitis and irritable bowelsyndrome.

Another embodiment of the present invention therefore relates to acompound according to general formula (I) for the treatment and/or theprophylaxis of disorders and/or diseases, wherein the disorder and/orthe disease is selected from the group consisting of

-   -   (i) neurological and neurodegenerative disorders, including    -   Ischaemic stroke, Alzheimer's disease, frontotemporal dementia,        Huntington's disease, amyotrophic lateral sclerosis, Parkinson's        disease, multiple sclerosis, diabetic peripheral neuropathy,        chemotherapy-induced peripheral neuropathy, amyotrophic lateral        sclerosis, exictotoxic brain injury, traumatic brain injury,        ischaemic brain damage, cerebrovascular disorders and cerebral        ischemia;    -   (ii) psychiatric disorders, including    -   anxiety disorders, particularily panic disorders, post traumatic        stress disorder, panic and adult separation disorder, social        anxiety, major depression with adult separation anxiety disorder        and bipolar disorder with adult separation anxiety disorder,        dysthymia, angina pectoris, suicidality and schizophrenia;    -   (iii) brain tumours;    -   (iv) immunological disorders and inflammatory diseases,        including    -   neuroinflammation and arthritis, encephalomyelitis and irritable        bowel syndrome.

A preferred embodiment of the present invention relates to a compoundaccording to general formula (I) for the treatment and/or theprophylaxis of

-   -   (i) neurological and neurodegenerative disorders, including    -   ischaemic stroke, Alzheimer's disease, frontotemporal dementia,        Huntington's disease, amyotrophic lateral sclerosis, Parkinson's        disease, multiple sclerosis, diabetic peripheral neuropathy,        chemotherapy-induced peripheral neuropathy, amyotrophic lateral        sclerosis, exictotoxic brain injury, traumatic brain injury,        ischaemic brain damage, cerebrovascular disorders and cerebral        ischemia;    -   (ii) psychiatric disorders, including    -   anxiety disorders, particularly panic disorders, post traumatic        stress disorder, panic and adult separation disorder, social        anxiety, major depression with adult separation anxiety disorder        and bipolar disorder with adult separation anxiety disorder,        dysthymia, angina pectoris, suicidality and schizophrenia;    -   (iii) brain tumours;    -   (iv) immunological disorders and inflammatory diseases,        including    -   neuroinflammation and arthritis, encephalomyelitis and irritable        bowel syndrome.

Another preferred embodiment of the present invention relates to acompound according to general formula (I) for the treatment and/or theprophylaxis of neurological and neurodegenerative disorders,

including ischaemic stroke, Alzheimer's disease, frontotemporaldementia, Huntington's disease, amyotrophic lateral sclerosis,Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy,chemotherapy-induced peripheral neuropathy, amyotrophic lateralsclerosis, exictotoxic brain injury, traumatic brain injury, ischaemicbrain damage, cerebrovascular disorders and cerebral ischemia.

Another preferred embodiment of the present invention relates to acompound according to general formula (I) for the treatment and/or theprophylaxis of psychiatric disorders, including anxiety disorders,particularily panic disorders, post traumatic stress disorder, panic andadult separation disorder, social anxiety, major depression with adultseparation anxiety disorder and bipolar disorder with adult separationanxiety disorder, dysthymia, angina pectoris, suicidality andschizophrenia.

Yet another preferred embodiment of the present invention relates to acompound according to general formula (I) for the treatment and/or theprophylaxis of brain tumours.

Yet another preferred embodiment of the present invention relates to acompound according to general formula (I) for the treatment and/or theprophylaxis of immunological disorders and inflammatory diseases,

including neuroinflammation and arthritis, encephalomyelitis andirritable bowel syndrome.

One embodiment of the present invention relates to a compound of generalformula (I), wherein the compound is selected from a compound accordingto general formula (1-I).

whereinA¹⁰¹ represents CR¹¹⁰R¹¹¹ or S;A¹⁰² represents CR¹¹²R¹¹³, C(═O), O, S, S(═O) or S(═O)₂;R¹⁰¹ represents C₁₋₁₀-alkyl or C₂₋₁₀-heteroalkyl, in each case saturatedor unsaturated, branched or unbranched, unsubstituted or mono- orpoly-substituted; C₃₋₁₀-cycloalkyl or heterocyclyl, in each casesaturated or unsaturated, unsubstituted or mono- or poly-substituted;aryl or heteroaryl, in each case unsubstituted or mono- orpoly-substituted; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridgedC₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated,unsubstituted or mono- or poly-substituted, wherein the alkyl orheteroalkyl chain can in each case be branched or unbranched, saturatedor unsaturated, unsubstituted or mono- or poly-substituted; orC₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl or heteroaryl, in each caseunsubstituted or mono- or poly-substituted, wherein the alkyl orheteroalkyl chain can in each case be branched or unbranched, saturatedor unsaturated, unsubstituted or mono- or poly-substituted;R¹⁰², R¹⁰³ and R¹⁰⁴ each independently of the others represents H; F;Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; CH₂—O-methyl;CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl, S—C₁₋₆-alkyl, in each case saturatedor unsaturated, branched or unbranched, unsubstituted or mono- orpoly-substituted; C₃₋₇-cycloalkyl, saturated or unsaturated, branched orunbranched, unsubstituted or mono- or poly-substituted; NR^(1a)R^(1b),wherein R^(1a) and R^(1b) each independently of the other represents Hor C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched,unsubstituted or mono- or poly-substituted, or R^(1a) and R^(1b),together with the nitrogen atom joining them, form a heterocyclyl,saturated or unsaturated, branched or unbranched, unsubstituted or mono-or poly-substituted;R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹⁰⁹, R¹¹¹, R¹¹² and R¹¹³ each independently ofthe others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃;C₁₋₁₀-alkyl, C₂₋₁₀-heteroalkyl, O—C₁₋₁₀-alkyl or S—C₁₋₁₀-alkyl, in eachcase saturated or unsaturated, branched or unbranched, unsubstituted ormono- or poly-substituted; C₃₋₁₀-cycloalkyl, saturated or unsaturated,branched or unbranched, unsubstituted or mono- or poly-substituted;with the proviso that when R¹⁰⁵, R¹⁰⁶, R¹⁰⁷ and R¹⁰⁸ each denotes H andA¹ represents S, A² may not denote S, S(═O) or S(═O)₂;or R¹⁰⁵ and R¹⁰⁶ or R¹⁰⁷ and R¹⁰⁸ or R¹¹⁰ and R¹¹¹ or R¹¹² and R¹¹³ orR¹⁰⁵ and R¹¹¹ or R¹⁰⁵ and R¹⁰⁷ or R¹⁰⁵ and R¹¹³ or R¹⁰⁷ and R¹¹³ or R¹⁰⁷and R¹¹¹ or R¹¹¹ and R¹¹³, together with the carbon atom(s) joiningthem, form a C₃₋₈-cycloalkyl or a heterocyclyl having from three toeight ring members, in each case saturated or unsaturated, unsubstitutedor mono- or poly-substituted; wherein the remaining substituents R¹⁰⁵,R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹¹⁰, R¹¹¹, R¹¹² and R¹¹³ in each case have themeaning given above;R¹⁰⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturatedor unsaturated, unsubstituted or mono- or poly-substituted; aryl orheteroaryl, in each case unsubstituted or mono- or poly-substituted; orrepresents CR^(1c)R^(1d), wherein R^(1c) and R^(1d) each independentlyof the other denotes C₁₋₄-alkyl, saturated or unsaturated, branched orunbranched, unsubstituted or mono- or poly-substituted;with the proviso that when A¹⁰² represents O or S and R¹⁰⁹ representsheterocyclyl, saturated or unsaturated, unsubstituted or mono- orpoly-substituted; or heteroaryl, unsubstituted or mono- orpoly-substituted, the bonding of the heteroaryl or heterocyclyl takesplace via a carbon atom of the heteroaryl or heterocyclyl;wherein “alkyl substituted”, “heteroalkyl substituted”, “heterocyclylsubstituted” and “cycloalkyl substituted” denote the substitution of oneor more hydrogen atoms, in each case independently of one another, by F;Cl; Br; I; NO₂; CF₃; CN; ═O; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl;heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- orC₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl orheterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H;C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂;C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂;C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl);C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH;O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl;O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl;O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂;NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂;NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl;S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl;S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl;S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; and S(═O)₂—NH—C₁₋₈-heteroaryl;wherein “aryl substituted” and “heteroaryl substituted” denote thesubstitution of one or more hydrogen atoms, in each case independentlyof one another, by F; Cl; Br; I; NO₂; CF₃; CN; C₁₋₈-alkyl;C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl;C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl,C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl;C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl;C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂;C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂;C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl);C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH;O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl;O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl;N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl;N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH;S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl;S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl;S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl;S(═O)₂—NH—C₁₋₈-heteroaryl.

The compounds according to general formula (1-I) are known from WO2010/102809 A1, which is fully included by reference.

In preferred embodiments of the compounds of the general formula (1-I)according to the invention

A¹⁰¹ represents S and

A¹⁰² represents CR¹¹²R¹¹³, O, S or S(═O)₂, preferably CR¹¹²R¹¹³, S orS(═O)₂, particular preferably CR¹¹²R¹¹³.

Further preferred embodiments of the compounds of the general formula(1-I) according to the invention have the general formula (1-I-a),(1-I-b), (1-I-c), (1-I-d), (1-I-e) or (1-I-f):

Compounds of the general formulae (1-I-a), (1-I-b) and (1-I-c) are mostparticularly preferred.

Compounds of the general formula (1-1a) are especially preferred.

In a further preferred embodiment the radical R¹⁰¹ represents

-   -   C₁₋₁₀-alkyl or C₂₋₁₀-heteroalkyl, in each case saturated or        unsaturated, branched or unbranched, unsubstituted or mono- or        poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CF₃, CN, OH, ═O, C(═O)—OH, OCF₃, NH₂, S(═O)₂OH, SH,        SCF₃, C₁₋₈-alkyl, O—C₁₋₈-alkyl, S—C₁₋₈-alkyl, NH—C₁₋₈-alkyl,        N(C₁₋₈-alkyl)₂, C₃₋₁₀-cycloalkyl and heterocyclyl, wherein the        above alkyl radicals can in each case be saturated or        unsaturated, branched or unbranched, unsubstituted or mono- or        poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and wherein C₃₋₁₀-cycloalkyl        or heterocyclyl can in each case be saturated or unsaturated,        unsubstituted or mono- or poly-substituted by one or more        substituents each selected independently of one another from the        group consisting of F, Cl, Br, I, C₁₋₈-alkyl, OH, ═O,        O—C₁₋₈-alkyl, OCF₃, NH₂, NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂;    -   or C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or        unsaturated, unsubstituted or mono- or poly-substituted by one        or more substituents each selected independently of one another        from the group consisting of F, Cl, Br, I, NO₂, CN, OH,        O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂,        NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃,        S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl,        phenyl, pyridyl, thienyl can in each case be unsubstituted or        mono- or poly-substituted by one or more substituents selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,        CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃        and S(═O)₂OH;    -   or aryl or heteroaryl, in each case unsubstituted or mono- or        poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,        CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl,        SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein        benzyl, phenyl, pyridyl, thienyl can in each case be        unsubstituted or mono- or poly-substituted by one or more        substituents selected independently of one another from the        group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl,        OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl),        N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH;    -   or C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged C₃₋₁₀-cycloalkyl or        heterocyclyl, in each case saturated or unsaturated,        unsubstituted or mono- or poly-substituted by one or more        substituents each selected independently of one another from the        group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl,        OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl),        N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl,        phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl,        thienyl can in each case be unsubstituted or mono- or        poly-substituted by one or more substituents selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,        CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃        and S(═O)₂OH;        -   wherein the alkyl or heteroalkyl chain can in each case be            branched or unbranched, saturated or unsaturated,            unsubstituted or mono- or poly-substituted by one or more            substituents each selected independently of one another from            the group consisting of F, Cl, Br, I, NO₂, CF₃, CN, OH, ═O,            C(═O)—OH, OCF₃, NH₂, S(═O)₂OH, SH, SCF₃, C₁₋₈-alkyl,            O—C₁₋₈-alkyl, S—C₁₋₈-alkyl, NH—C₁₋₈-alkyl, N(C₁₋₈-alkyl)₂,            C₃₋₁₀-cycloalkyl and heterocyclyl, wherein the above alkyl            radicals can in each case be saturated or unsaturated,            branched or unbranched, unsubstituted or mono- or            poly-substituted by one or more substituents each selected            independently of one another from the group consisting of F,            Cl, Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and wherein            C₃₋₁₀-cycloalkyl or heterocyclyl can in each case be            saturated or unsaturated, unsubstituted or mono- or            poly-substituted by one or more substituents each selected            independently of one another from the group consisting of F,            Cl, Br, I, C₁₋₈-alkyl, OH, ═O, O—C₁₋₈-alkyl, OCF₃, NH₂,            NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂;    -   or C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl or heteroaryl,        in each case unsubstituted or mono- or poly-substituted by one        or more substituents each selected independently of one another        from the group consisting of F, Cl, Br, I, NO₂, CN, OH,        O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂,        NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃,        S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl,        phenyl, pyridyl, thienyl can in each case be unsubstituted or        mono- or poly-substituted by one or more substituents selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,        CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃        and S(═O)₂OH;    -   wherein the alkyl or heteroalkyl chain can in each case be        branched or unbranched, saturated or unsaturated, unsubstituted        or mono- or poly-substituted by one or more substituents each        selected independently of one another from the group consisting        of F, Cl, Br, I, NO₂, CF₃, CN, OH, ═O, C(═O)—OH, OCF₃, NH₂,        S(═O)₂OH, SH, SCF₃, C₁₋₈-alkyl, O—C₁₋₈-alkyl, S—C₁₋₈-alkyl,        NH—C₁₋₈-alkyl, N(C₁₋₈-alkyl)₂, C₃₋₁₀-cycloalkyl and        heterocyclyl,    -   wherein the above alkyl radicals can in each case be saturated        or unsaturated, branched or unbranched, unsubstituted or mono-        or poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and wherein C₃₋₁₀-cycloalkyl        or heterocyclyl can in each case be saturated or unsaturated,        unsubstituted or mono- or poly-substituted by one or more        substituents each selected independently of one another from the        group consisting of F, Cl, Br, I, C₁₋₈-alkyl, OH, ═O,        O—C₁₋₈-alkyl, OCF₃, NH₂, NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂.

In a further preferred embodiment the substituent R¹⁰¹ represents thefollowing partial structure (1-T1),—(CR^(114a)R^(114b))_(m1)—(Y¹)_(n1)—B¹  (1-T1),wherein

-   R^(114a) and R^(114b) each independently of the other represents H;    F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; NH₂; C₁₋₄-alkyl, O—C₁₋₄-alkyl,    NH—C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, in each case saturated or    unsaturated, branched or unbranched, unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, O—C₁₋₄-alkyl, OH and OCF₃; C₃₋₁₀-cycloalkyl or heterocyclyl, in    each case saturated or unsaturated, unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, C₁₋₄-alkyl, OH, ═O, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and    N(C₁₋₄-alkyl)₂;-   m1 represents 0, 1, 2 or 3;-   Y¹ represents O or NR¹¹⁵,    -   wherein R¹¹⁵ represents H; C₁₋₄-alkyl, saturated or unsaturated,        branched or unbranched, unsubstituted or mono- or        poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl        and N(C₁₋₄-alkyl)₂; or represents C₃₋₁₀-cycloalkyl, saturated or        unsaturated, unsubstituted or mono- or poly-substituted by one        or more substituents each selected independently of one another        from the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH,        O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and N(C₁₋₄-alkyl)₂;-   n1 represents 0 or 1,-   B¹ represents C₁₋₈-alkyl, saturated or unsaturated, branched or    unbranched, unsubstituted or mono- or poly-substituted by one or    more substituents each selected independently of one another from    the group consisting of F, Cl, Br, I, NO₂, CN, OH, ═O, O—C₁₋₄-alkyl,    OCF₃, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH,    S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH; C₃₋₁₀-cycloalkyl or heterocyclyl,    in each case saturated or unsaturated, unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂,    NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH,    benzyl, phenyl, pyridyl and thienyl,    -   wherein benzyl, phenyl, pyridyl, thienyl can in each case be        unsubstituted or mono- or poly-substituted by one or more        substituents selected independently of one another from the        group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl,        OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl),        N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH; aryl or        heteroaryl, in each case unsubstituted or mono- or        poly-substituted by one or more substituents each selected        independently of one another from the group consisting of F, Cl,        Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,        CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl,        SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein        benzyl, phenyl, pyridyl, thienyl can in each case be        unsubstituted or mono- or poly-substituted by one or more        substituents selected independently of one another from the        group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl,        OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl),        N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH.

Preferably,

-   R^(114a) and R^(114b) each independently of the other represents H;    F; Cl; Br; I; NO₂; CF₃; CH₂CF₃; CN; OH; OCF₃, NH₂; C₁₋₄-alkyl,    O—C₁₋₄-alkyl, O—C₁₋₄-alkyl-OH, O—C₁₋₄-alkyl-OCH₃, NH—C₁₋₄-alkyl,    N(C₁₋₄-alkyl)₂, in each case saturated or unsaturated, branched or    unbranched, unsubstituted; C₃₋₁₀-cycloalkyl, saturated or    unsaturated, unsubstituted or mono- or poly-substituted by one or    more substituents each selected independently of one another from    the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl;-   m1 represents 0, 1, 2 or 3;-   Y¹ represents O or NR¹¹⁵;    -   wherein R¹¹⁵ represents H; C₁₋₄-alkyl, saturated or unsaturated,        unsubstituted; or    -   represents C₃₋₁₀-cycloalkyl, saturated or unsaturated,        unsubstituted;-   n1 represents 0 or 1;-   B¹ represents C₁₋₈-alkyl, saturated or unsaturated, branched or    unbranched, unsubstituted or mono- or poly-substituted by one or    more substituents each selected independently of one another from    the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl,    OCF₃, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SCF₃;    C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or    unsaturated, unsubstituted or mono- or poly-substituted by one or    more substituents each selected independently of one another from    the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl,    OCF₃, C₁₋₄-alkyl, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SCF₃;    aryl or heteroaryl, in each case unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,    NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, S(═O)₂OH,    benzyl, phenyl and pyridyl, wherein benzyl, phenyl or pyridyl are in    each case unsubstituted or mono- or poly-substituted by one or more    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃,    C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH,    S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH.

Particularly preferably, R^(114a) and R^(114b) each independently of theother represents H; F; Cl; Br; I; NO₂; CF₃; CN; methyl; ethyl; n-propyl;isopropyl; cyclopropyl; n-butyl; sec-butyl; tert-butyl; CH₂CF₃; OH;O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; OCF₃; NH₂; NH-methyl;N(methyl)₂; NH-ethyl; N(ethyl)₂; or N(methyl)(ethyl);

-   m1 represents 0, 1 or 2;-   n1 represents 0; and-   B¹ represents C₁₋₄-alkyl, saturated, branched or unbranched,    unsubstituted or mono- or poly-substituted by one or more    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, OCF₃ and CF₃;    C₃₋₁₀-cycloalkyl, saturated, unsubstituted; phenyl, naphthyl,    pyridyl, thienyl, in each case unsubstituted or mono- or di- or    tri-substituted by one, two or three substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,    NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, S(═O)₂OH.

Most particularly preferably, R^(114a) and R^(114b) each independentlyof the other represents H; F; Cl; Br; I; methyl; ethyl; n-propyl;isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl;O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH;

-   m1 represents 0, 1 or 2;-   n1 represents 0; and-   B¹ represents methyl; ethyl; n-propyl; isopropyl; n-butyl;    sec-butyl; tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl;    cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl;    bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case    unsubstituted or mono-, di- or tri-substituted by one, two or three    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃,    C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH,    S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH.

For n1=0, the partial structure (1-T1) for R¹⁰¹ yields the partialstructure (1-T1-1):—(CR^(114a)R^(114b))_(m1)—B¹  (1-T1-1).

In a preferred embodiment for n1=0, R^(114a) and R^(114b) eachindependently of the other represents H; F; Cl; Br; I; methyl; ethyl;n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl;O-ethyl; O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH.

In a preferred embodiment for m1=0, B¹ represents phenyl, pyridyl orthienyl, mono- or di- or tri-substituted by one, two or threesubstituents each selected independently of one another from the groupconsisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl,C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl,SCF₃, S(═O)₂OH.

In a preferred embodiment for m1=1 or 2, B¹ represents cyclopropyl;cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl;bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl.

In a preferred embodiment for m1=0, 1 or 2, B¹ represents methyl; ethyl;n-propyl; isopropyl; n-butyl; sec-butyl or tert-butyl.

A further particularly preferred embodiment of the compounds of thegeneral formula (I-1) according to the invention has the general formula(I-1-2):

In a further preferred embodiment,

-   the radicals R¹⁰², R¹⁰³ and R¹⁰⁴ each independently of the others    represent H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl;    CH₂—O-methyl; CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl or S—C₁₋₆-alkyl, in    each case saturated or unsaturated, branched or unbranched,    unsubstituted or mono- or poly-substituted by one or more    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, OH, ═O and O—C₁₋₄-alkyl;    C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched,    unsubstituted; NR^(1a)R^(1b),    -   wherein R^(1a) and R^(1b) each independently of the other        represents H or C₁₋₄-alkyl, saturated or unsaturated, branched        or unbranched, unsubstituted or mono- or poly-substituted by one        or more substituents each selected independently of one another        from the group consisting of OH, ═O and O—C₁₋₄-alkyl,    -   or R^(1a) and R^(1b), together with the nitrogen atom joining        them, form a heterocyclyl, saturated or unsaturated,        unsubstituted or mono- or poly-substituted by C₁₋₄-alkyl.

Preferably,

-   the radicals R¹⁰², R¹⁰³ and R¹⁰⁴ each independently of the others    represent H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl;    ethyl; n-propyl; isopropyl; butyl; sec-butyl; tert-butyl; CH₂CF₃;    O-methyl; O-ethyl; O-n-propyl; O-isopropyl; O-butyl; O-sec-butyl;    O-tert-butyl; O—(CH₂)₂—O-methyl; O—(CH₂)₂—OH; O—(C═O)-methyl;    O—(C═O)-ethyl; S-methyl; S-ethyl; cyclopropyl; cyclobutyl;    NR^(1a)R^(1b),    -   wherein R^(1a) and R^(1b) each independently of the other is        selected from the group consisting of H, methyl, ethyl,        (CH₂)₂—O-methyl, (CH₂)₂—OH, (C═O)-methyl, (C═O)-ethyl,    -   or R^(1a) and R^(1b), together with the nitrogen atom joining        them, form a pyrrolidinyl, piperidinyl, 4-methylpiperazinyl or        morpholinyl.

Particularly preferably,

-   the radicals R¹⁰², R¹⁰³ and R¹⁰⁴ each independently of the others    represent H; F; Cl; Br; I; methyl; ethyl; n-propyl, isopropyl;    cyclopropyl; CN; CF₃; O-methyl; OCF₃; S-methyl; SCF₃, pyrrolidinyl,    N(methyl)₂.

Most particularly preferably, the radicals R¹⁰², R¹⁰³ and R¹⁰⁴ eachindependently of the others represent H; F; Cl; methyl; ethyl; O-methyl;CF₃; in particular H.

In a further preferred embodiment, the radicals R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸,R¹¹⁰, R¹¹¹, R¹¹² and R¹¹³ each independently of the others represents H;F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; C₁₋₆-alkyl; O—C₁₋₆-alkylor S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched orunbranched, unsubstituted or mono- or poly-substituted by one or moresubstituents each selected independently of one another from the groupconsisting of F, Cl, Br, I, OH and O—C₁₋₄-alkyl; C₃₋₇-cycloalkyl,saturated or unsaturated, branched or unbranched, unsubstituted or mono-or poly-substituted by one or more substituents each selectedindependently of one another from the group consisting of F, Cl, Br, I,OH, ═O and O—C₁₋₄-alkyl;

or R¹⁰⁵ and R¹⁰⁶ or R¹⁰⁷ and R¹⁰⁸ or R¹¹⁰ and R¹¹¹ or R¹¹² and R¹¹³ orR¹⁰⁵ and R¹¹¹ or R¹⁰⁵ and R¹⁰⁷ or R¹⁰⁵ and R¹¹³ or R¹⁰⁷ and R¹¹³ or R¹⁰⁷and R¹¹¹ or R¹¹¹ and R¹¹³, together with the carbon atom(s) joiningthem, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,pyrrolidinyl or piperidinyl, in each case unsubstituted or mono- orpoly-substituted by one or more substituents each selected independentlyof one another from the group consisting of F, Cl, Br, I, OH, ═O andO—C₁₋₄-alkyl; wherein the remaining substituents R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸,R¹¹⁰, R¹¹¹, R¹¹² and R¹¹³ in each case have the meaning given above.

Preferably, the radicals R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹¹⁰, R¹¹¹, R¹¹² andR¹¹³ each independently of the others represents H; F; Cl; Br; I; NO₂;CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; ethyl; n-propyl; isopropyl;n-butyl; sec-butyl; tert-butyl; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃;O—(CH₂)₂—OH; S-methyl; S-ethyl; cyclopropyl; cyclobutyl; cyclopentyl;cyclohexyl;

or R¹⁰⁵ and R¹⁰⁶ or R¹⁰⁷ and R¹⁰⁸ or R¹¹⁰ and R¹¹¹ or R¹¹² and R¹¹³ orR¹⁰⁵ and R¹¹¹ or R¹⁰⁵ and R¹⁰⁷ or R¹⁰⁵ and R¹¹³ or R¹⁰⁷ and R¹¹³ or R¹⁰⁷and R¹¹¹ or R¹¹¹ and R¹¹³, together with the carbon atom(s) joiningthem, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in eachcase unsubstituted; wherein the remaining substituents R¹⁰⁵R¹⁰⁶, R¹⁰⁷,R¹⁰⁸, R¹¹⁰, R¹¹¹, R¹¹² and R¹¹³ in each case have the meaning givenabove.

Particularly preferably, the radicals R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹¹⁰,R¹¹¹, R¹¹² and R¹¹³ each independently of the others represents H; F;Cl; Br; I; CN; CF₃; OCF₃; SCF₃; methyl; ethyl; n-propyl, isopropyl;cyclopropyl; O-methyl; S-methyl;

or R¹⁰⁵ and R¹⁰⁷ form a cyclopropyl, cyclobutyl, cyclopentyl orcyclohexyl ring substituted as desired by H, F, Cl, Me, Et, OMe,preferably an unsubstituted cyclopentyl or cyclohexyl ring.

Most particularly preferably, the radicals R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹¹⁰,R¹¹¹, R¹¹² and R¹¹³ each independently of the others represents F; Cl;H; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; in particular F; H;methyl; or ethyl.

In particular, the radicals R¹¹² and R¹¹³ each independently of theother represents H, F or methyl.

In a further preferred embodiment,

-   the radical R¹⁰⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in    each case saturated or unsaturated, unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, NO₂, CN, OH, ═O, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH,    S—C₁₋₄-alkyl and SCF₃; aryl or heteroaryl, in each case    unsubstituted or mono- or poly-substituted by one or more    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃,    C₁₋₄-alkyl, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH,    S—C₁₋₄-alkyl and SCF₃;    -   or represents CR^(1c)R^(1d),        -   wherein R^(1c) and R^(1d) each independently of the other            denotes C₁₋₄-alkyl, saturated or unsaturated, branched or            unbranched, unsubstituted or mono- or poly-substituted by            one or more substituents each selected independently of one            another from the group consisting of F, Cl, Br, I, OH,            O—C₁₋₄-alkyl, CF₃, OCF₃ and SCF₃.-   Preferably, R¹⁰⁹ represents C₃₋₇-cycloalkyl, saturated or    unsaturated, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl,    piperidinyl, morpholinyl, in each case unsubstituted or mono- or    poly-substituted by one or more substituents each selected    independently of one another from the group consisting of F, Cl, Br,    I, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and    SCF₃; phenyl, naphthyl, pyridyl or thienyl, in each case    unsubstituted or mono- or poly-substituted by one or more    substituents each selected independently of one another from the    group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃,    C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃;    -   or represents CR^(1c)R^(d),        -   wherein R^(1c) and R^(1d) each independently of the other            denotes C₁₋₄-alkyl, saturated or unsaturated, branched or            unbranched, unsubstituted or mono- or poly-substituted by            one or more substituents each selected independently of one            another from the group consisting of F, Cl, Br, I, OH and            O—C₁₋₄-alkyl.

Particularly preferably, the radical R¹⁰⁹ is selected from the groupconsisting of phenyl, pyridyl or thienyl, in each case unsubstituted ormono- or poly-substituted by one or more substituents each selectedindependently of one another from the group consisting of F, Cl, Br, I,CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.

Most particularly preferably, R¹⁰⁹ represents phenyl, pyridyl andthienyl, unsubstituted or mono- or poly-substituted by one or moresubstituents each selected independently of one another from the groupconsisting of F, Cl, Br, I, CN, methyl, ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, O-n-propyl,O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF₃, CF₃, SH,S—C₁₋₄-alkyl and SCF₃.

In particular, R¹⁰⁹ represents phenyl, unsubstituted or mono- orpoly-substituted by one or more substituents each selected independentlyof one another from the group consisting of F, Cl, Br, I, methyl, ethyl,n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl,OCF₃, CF₃ and SCF₃.

In a further, particularly preferred embodiment

A¹⁰¹ represents S and

A¹⁰² represents CR¹¹²R¹¹³;

R¹⁰¹ represents the partial structure (1-T1-1)—(CR^(114a)R^(114b))_(m1)—B¹  (1-T1-1),whereinR^(114a) and R^(114b) each independently of the other represents H; F;Cl; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl;tert-butyl; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH;m1 represents 0, 1 or 2;B¹ represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl;tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl;cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl;phenyl, pyridyl, thienyl, in each case unsubstituted or mono-, di- ortri-substituted by one, two or three substituents each selectedindependently of one another from the group consisting of F, Cl, Br, I,NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH;R¹⁰², R¹⁰³ and R¹⁰⁴ each independently of the others represents H; F;Cl; methyl; ethyl; CF₃ or O-methyl;R¹⁰⁵, R¹⁰⁶, R¹⁰⁷, R¹⁰⁸, R¹¹⁰, R¹¹¹, R¹¹² and R¹¹³ each independently ofthe others represents H; F; Cl; methyl; ethyl; n-propyl, isopropyl;cyclopropyl;R¹⁰⁹ represents phenyl, pyridyl or thienyl, unsubstituted or mono- orpoly-substituted by one or more substituents each selected independentlyof one another from the group consisting of F, Cl, Br, I, CN, methyl,ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl,O-ethyl, O-n-propyl, O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl,OH, OCF₃, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.

Another embodiment of the present invention relates to a compound ofgeneral formula (I), wherein the compound is selected from a compoundaccording to general formula (2-I).

wherein

-   R²⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; C(═O)—NH₂;    SCF₃; S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the    C₁₋₄ aliphatic residue may be in each case be unsubstituted or mono-    or polysubstituted; a O—C₁₋₄-aliphatic residue, a    O—C(═O)—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue,    wherein the C₁₋₄ aliphatic residue may be in each case be    unsubstituted or mono- or polysubstituted; a NH(C₁₋₄ aliphatic    residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic    residue, a NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic    residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic    residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄ aliphatic    residue may in each case be unsubstituted or mono- or    polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R²⁰⁷ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    in which an “aliphatic group” and “aliphatic residue” can in each    case be branched or unbranched, saturated or unsaturated,    in which a “cycloaliphatic residue” and a “heterocycloaliphatic    residue” can in each case be saturated or unsaturated,    in which “mono- or polysubstituted” with respect to an “aliphatic    group” and an “aliphatic residue” relates, with respect to the    corresponding residues or groups, to the substitution of one or more    hydrogen atoms each independently of one another by at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, a    NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue,    ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic    residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a    S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3    to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a    C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic    residue)₂;    in which “mono- or polysubstituted” with respect to a    “cycloaliphatic residue” and a “heterocycloaliphatic residue”    relates, with respect to the corresponding residues, to the    substitution of one or more hydrogen atoms each independently of one    another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue),    an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a    NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic    residue, a O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue,    a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphatic    residue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, a    C(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, a    C₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and a    C(═O)—N(C₁₋₄ aliphatic residue)₂;    in which “mono- or polysubstituted” with respect to “aryl” and a    “heteroaryl” relates, with respect to the corresponding residues, to    the substitution of one or more hydrogen atoms each independently of    one another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

The compounds according to general formula (2-I) are known from WO2012/025236 A1, which is fully included by reference.

Preferred embodiments of the compound according to general formula (2-I)have general formulae (2-Ia), (2-Ib), (2-Ic) or (2-Id):

Another preferred embodiment of present invention is a compoundaccording to general formula (2-I), wherein

-   R²⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH,

-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄ aliphatic residue may be in each case be        unsubstituted or mono- or polysubstituted;

-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and an O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,

-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group,    -   which in turn may be unsubstituted or mono- or polysubstituted        with at least one substituent selected from the group consisting        of F, Cl, Br, I, ═O, OH, an unsubstituted C₁₋₄-aliphatic residue        and an unsubstituted O—C₁₋₄-aliphatic residue,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H,

-   R²⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula(2-I), the residue

-   R²⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (2-I), the residue

-   R²⁰¹ represents the partial structure (2-T1)    —(CR^(208a)R^(208b))_(m2)—R^(208c)  (2-T1),    wherein-   m2 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, or 2,-   R^(208a) and R^(208b) each independently of one another represent H,    F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄ aliphatic residue    or C(═O)—OH, or together denote ═O,    -   preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   more preferably each independently of one another represent H,        F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   even more preferably each independently of one another represent        H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue,        and-   R^(208c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, preferably when m2 is ≠0, in each        case unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes—preferably when m2 is =0—an aryl or heteroaryl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄        aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted with at least one substituent selected            from the group consisting of F, Cl, Br, I, NO₂, NH₂, an            NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,            OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄            aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH.

Preferably,

-   R²⁰¹ represents the partial structure (2-T1),    -   wherein    -   m2 denotes 0, 1, or 2,    -   R^(208a) and R^(208b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue,        -   preferably each independently of one another represent H, F,            a O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and    -   R^(208c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and        C(═O)—OH,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, in each case            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic            residue, and a 3 to 6 membered heterocycloaliphatic residue,            -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue,                OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   or denotes—preferably when m2 is =0—an aryl or heteroaryl,            in each case unsubstituted or mono- or polysubstituted with            at least one substituent selected from the group consisting            of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,            SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic            residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6            membered heterocycloaliphatic residue, benzyl, phenyl,            thienyl, pyridyl, furyl, thiazolyl or oxazolyl,            -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein benzyl, phenyl, thienyl, pyridyl, furyl,                thiazolyl and oxazolyl may in each case may be                unsubstituted or mono- or polysubstituted, preferably                unsubstituted or mono- or disubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,                CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,                C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably                with at least one substituent selected from the group                consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue,                OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R²⁰¹ represents the partial structure (2-T1),    -   wherein-   m2 denotes 0, 1, or 2,-   R^(208a) and R^(208b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,-    preferably each independently of one another represent H, F, a    O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(208c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes—preferably when m2 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic    residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, benzyl, phenyl, thienyl or pyridyl,    -   wherein benzyl, phenyl, thienyl and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted, preferably        unsubstituted or mono- or disubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,        preferably with at least one substituent selected from the group        consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic        residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (2-I), the residue

-   R²⁰¹ represents the partial structure (2-T1),    -   wherein-   m2 is 0, 1 or 2 and-   R^(208a) and R^(208b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(208c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        aliphatic residue, CF₃, and an unsubstituted C₁₋₄-aliphatic        residue,    -   or    -   wherein-   m2 is 0,-   R^(208a) and R^(208b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(208c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (2-I)which has the following general formula (2-Ie):

In a preferred embodiment of the compound according to general formula(2-I), the residue

-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,    -   and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,        pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or        piperidinyl may in each case be optionally bridged via an C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, OH, an unsubstituted C₁₋₄-aliphatic        residue and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R²⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R²⁰² is selected from the group consisting of H; F; Cl; CF₃; CN;    SCF₃; OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; cyclopropyl;    O—CH₃ and O—C₂H₅;

In particular,

-   R²⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃;

In a particular preferred embodiment of the compound according togeneral formula (2-I), the residue

-   R²⁰² is ≠H.

In a preferred embodiment of the compound according to general formula(2-I), the residues

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

Preferably,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

More preferably,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; NO₂; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, and a O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, ═O,    OH, a C₁₋₄-aliphatic residue and a O—C₁₋₄-aliphatic residue, and in    each case optionally bridged via an unsubstituted C₁₋₄ aliphatic    group,    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

In a further preferred embodiment of the present invention

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; a (C═O)—C₁₋₄ aliphatic residue, a C₁₋₄ aliphatic    residue, O—C₁₋₄ aliphatic residue, a S—C₁₋₄ aliphatic residue,    wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, and O—CH₃;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

Preferably,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;    sec.-butyl; tert.-butyl; cyclopropyl; C(═O)-methyl; C(═O)-ethyl;    (C═O)-isopropyl; (C═O)-t-butyl; O-methyl; O-ethyl; O-isopropyl;    O-t-butyl; O—(CH₂)₂—O—CH₃; S-Methyl; S-Ethyl;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

In particular,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ are each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    (C═O)-methyl; (C═O)-ethyl; (C═O)-isopropyl; (C═O)-t-butyl; methyl;    ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl;    O-t-butyl; OCF₃; S-methyl; S-ethyl; and SCF₃;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

More particularly,

-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H.

Most preferred,

-   R²⁰³, R²⁰⁴ and R²⁰⁶ each independently of one another are selected    from the group consisting of H and F; and-   R²⁰⁵ denotes F; Br; CF₃; OCF₃; CN; or NO₂.

In a particular preferred embodiment of the compound according togeneral formula (2-I) at least one of the residues R²⁰³, R²⁰⁴, R²⁰⁵ andR²⁰⁶ is ≠H.

In a preferred embodiment of the compound according to general formula(2-I), the residue

-   R²⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to generalformula (2-I), the residue

-   R²⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN,    and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue.-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

-   R²⁰⁷ denotes a C₁₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue.-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

-   R²⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, CF₃, a C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic    residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue is bridged via a C₁₋₈ aliphatic group,    preferably a C₁₋₄ aliphatic group, which in turn may be    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue.

Even more preferably,

-   R²⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue is in each case bridged via a    unsubstituted C₁₋₈ aliphatic group, preferably an unsubstituted C₁₋₄    aliphatic group.

Still more preferably,

-   R²⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue is in each case bridged via a    unsubstituted C₁₋₄ aliphatic group.

In particular,

-   R²⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted.

Most preferred,

-   R²⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, CF₃, Cl, OH, and O-methyl.

Preferred is also a compound according to general formula (2-I), wherein

-   R²⁰¹ represents the partial structure (2-T1),    —(CR^(208a)R^(208b))_(m2)—R^(208c)  (2-T1),    -   wherein    -   m2 is 0, 1 or 2 and    -   R^(208a) and R^(208b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃;    -   R^(208c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, in each case            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, an unsubstituted O—C₁₋₄ aliphatic residue, CF₃, and an            unsubstituted C₁₋₄-aliphatic residue,            or    -   wherein    -   m2 is 0,    -   R^(208a) and R^(208b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃; and    -   R^(208c) denotes an aryl or heteroaryl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and        phenyl,        -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   R²⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃;-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H,-   R²⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted.

Particularly preferred is also a compound according to general formula(2-I), wherein

-   R²⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably    pyridyl or thienyl, in each case unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃,    preferably represents phenyl, unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃;-   R²⁰² is selected from the group consisting of H, F, Cl, CF₃, CH₃,    C₂H₅, iso-propyl, cyclopropyl, and O—CH₃; preferably is selected    from the group consisting of CH₃, C₂H₅, OCH₃ and CF₃;-   R²⁰³, R²⁰⁴, R²⁰⁵ and R²⁰⁶ are each independently of one another    selected from the group consisting of H, F, Cl, Br, CF₃, CN, OCF₃    and NO₂;-    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H, more preferably on the condition that R²⁰⁵ is ≠H;-   R²⁰⁷ denotes a saturated C₁₋₄-aliphatic residue, unsubstituted or    mono- or disubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, O—CH₃, OCF₃, SCF₃, and    CF₃.

Another embodiment of the present invention therefore relates to acompound of general formula (I), wherein the compound is selected from acompound according to general formula (3-I),

wherein

-   R³⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; O(═O)—NH₂;    SCF₃; S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the    C₁₋₄ aliphatic residue may be in each case be unsubstituted or mono-    or polysubstituted; a O—C₁₋₄-aliphatic residue, a    O—C(═O)—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue,    wherein the C₁₋₄ aliphatic residue may be in each case be    unsubstituted or mono- or polysubstituted; a NH(C₁₋₄ aliphatic    residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic    residue, a NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic    residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic    residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄ aliphatic    residue may in each case be unsubstituted or mono- or    polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is ≠H,-   R³⁰⁷ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R³⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the binding is carried out via a    carbon atom of the 3 to 10 membered heterocycloaliphatic residue;-   R³⁰⁸ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted;    or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted;    in which an “aliphatic group” and “aliphatic residue” can in each    case be branched or unbranched, saturated or unsaturated,    in which a “cycloaliphatic residue” and a “heterocycloaliphatic    residue” can in each case be saturated or unsaturated,    in which “mono- or polysubstituted” with respect to an “aliphatic    group” and an “aliphatic residue” relates, with respect to the    corresponding residues or groups, to the substitution of one or more    hydrogen atoms each independently of one another by at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, a    NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue,    ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic    residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a    S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3    to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a    C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic    residue)₂;    in which “mono- or polysubstituted” with respect to a    “cycloaliphatic residue” and a “heterocycloaliphatic residue”    relates, with respect to the corresponding residues, to the    substitution of one or more hydrogen atoms each independently of one    another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue),    an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a    NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic    residue, a O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue,    a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphatic    residue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, a    C(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, a    C₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and a    C(═O)—N(C₁₋₄ aliphatic residue)₂;    in which “mono- or polysubstituted” with respect to “aryl” and a    “heteroaryl” relates, with respect to the corresponding residues, to    the substitution of one or more hydrogen atoms each independently of    one another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

The compounds according to general formula (3-I) are known from WO2012/025237 A1, which is fully included by reference.

Preferred embodiments of the compound according to general formula (3-I)have general formulae (3-Ia), (3-Ib), (3-Ic) or (3-Id):

Another preferred embodiment of present invention is a compoundaccording to general formula (I), wherein

-   R³⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH,

-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted, preferably represents H; F; Cl; Br; I; CN; CF₃;    NO₂; OCF₃; SCF₃; a C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic    residue, a O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic    residue and an O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic    residue or the 3 to 6 membered heterocycloaliphatic residue may in    each case be optionally bridged via a C₁₋₄ aliphatic group, which in    turn may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group, on the condition that at    least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ is ≠H,

-   R³⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R³⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    and

-   R³⁰⁸ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue    and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or

-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

In a preferred embodiment of the compound according to general formula(3-I), the residue

-   R³⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or poly-substituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (I), the residue

-   R³⁰¹ represents the partial structure (3-T1)    —(CR^(308a)R^(308b))_(m3)—R^(308c)  (3-T1),    wherein    -   m3 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, or 2,    -   R^(308a) and R^(308b) each independently of one another        represent H, F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄ aliphatic residue or C(═O)—OH, or together denote ═O,        preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,        -   more preferably each independently of one another represent            H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄            aliphatic residue,        -   even more preferably each independently of one another            represent H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄            aliphatic residue, and    -   R^(308c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, preferably when m is            ≠0, in each case unsubstituted or mono- or polysubstituted            with at least one substituent selected from the group            consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic            residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄            aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic            residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆            cycloaliphatic residue and a 3 to 6 membered            heterocycloaliphatic residue,            -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic                residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an                O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄                aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and                C(═O)—OH,        -   or denotes—preferably when m3 is =0—an aryl or heteroaryl,            in each case unsubstituted or mono- or polysubstituted with            at least one substituent selected from the group consisting            of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an            N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,            C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue,            3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   -   -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein benzyl, phenyl, thienyl, pyridyl, furyl,                thiazolyl and oxazolyl may in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an                N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic                residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,                CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,                C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic                residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an                O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄                aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and                C(═O)—OH.

Preferably,

-   R³⁰¹ represents the partial structure (3-T1),    -   wherein    -   m3 denotes 0, 1, or 2,    -   R^(308a) and R^(308b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue,        -   preferably each independently of one another represent H, F,            a O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and    -   R^(308c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and        C(═O)—OH,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, in each case            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic            residue, and a 3 to 6 membered heterocycloaliphatic residue,            -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue,                OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   or denotes—preferably when m3 is =0—an aryl or heteroaryl,            in each case unsubstituted or mono- or polysubstituted with            at least one substituent selected from the group consisting            of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,            SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic            residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6            membered heterocycloaliphatic residue, benzyl, phenyl,            thienyl, pyridyl, furyl, thiazolyl or oxazolyl,            -   wherein the C₁₋₄-aliphatic residue in each case may be                unsubstituted or mono- or polysubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted                O—C₁₋₄-aliphatic residue, and            -   wherein benzyl, phenyl, thienyl, pyridyl, furyl,                thiazolyl and oxazolyl may in each case may be                unsubstituted or mono- or polysubstituted, preferably                unsubstituted or mono- or disubstituted with at least                one substituent selected from the group consisting of F,                Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,                CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,                C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably                with at least one substituent selected from the group                consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,            -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6                membered heterocycloaliphatic residue may in each case                may be unsubstituted or mono- or polysubstituted with at                least one substituent selected from the group consisting                of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue,                OCF₃, CF₃ a C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R³⁰¹ represents the partial structure (3-T1),    -   wherein    -   m3 denotes 0, 1, or 2,    -   R^(308a) and R^(308b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue,        -   preferably each independently of one another represent H, F,            a O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and    -   R^(308c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic        residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic        residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes—preferably when m3 is =0—an aryl or heteroaryl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue, benzyl, phenyl, thienyl or        pyridyl,        -   wherein benzyl, phenyl, thienyl and pyridyl, may in each            case may be unsubstituted or mono- or polysubstituted,            preferably unsubstituted or mono- or disubstituted with at            least one substituent selected from the group consisting of            F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,            CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅,            C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably with at least one            substituent selected from the group consisting of F, Cl,            CH₃, O—CH₃, CF₃ and OCF₃, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (3-I), the residue

-   R³⁰¹ represents the partial structure (3-T1),    -   wherein    -   m3 is 0, 1 or 2 and    -   R^(308a) and R^(308b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃;    -   R^(308c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, in each case            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, an unsubstituted O—C₁₋₄ aliphatic residue, CF₃, and an            unsubstituted C₁₋₄-aliphatic residue,    -   or    -   wherein    -   m3 is 0,    -   R^(308a) and R^(308b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃; and    -   R^(308c) denotes an aryl or heteroaryl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and        phenyl,        -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (3-I)which has the following general formula (3-Ie):

In a preferred embodiment of the compound according to general formula(3-I), the residue

-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue, and wherein cyclopropyl, cyclobutyl,    cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl,    4-methylpiperazinyl, morpholinyl or piperidinyl may in each case be    optionally bridged via an C₁₋₄ aliphatic group, which in turn may be    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, OH, an    unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R³⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec-butyl; tert-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R³⁰² is selected from the group consisting of H; F; Cl; Br; CF₃; CN;    SCF₃; OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; cyclopropyl;    O—CH₃ and O—C₂H₅.

In particular,

-   R³⁰² is selected from the group consisting of H; F; Cl; Br; CF₃;    CH₃; C₂H₅, iso-propyl; cyclopropyl; and O—CH₃.

In a particular preferred embodiment of the compound according togeneral formula (3-I), the residue

-   R³⁰² is ≠H.

In another preferred embodiment of the compound according to generalformula (3-I), the residues

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group, on the condition that at    least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ is ≠H.

Preferably,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group, on the condition that at    least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ is ≠H.

More preferably,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; NO₂; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and a O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic        residue, unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, ═O, OH, a C₁₋₄-aliphatic residue and a O—C₁₋₄-aliphatic        residue, and in each case optionally bridged via an        unsubstituted C₁₋₄ aliphatic group,    -   on the condition that at least one of R³⁰³R³⁰⁴, R³⁰⁵ and R³⁰⁶ is        ≠H.

In a further preferred embodiment of the present invention

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; a (C═O)—C₁₋₄aliphatic residue, a C₁₋₄aliphatic residue,    O—C₁₋₄ aliphatic residue, a S—C₁₋₄aliphatic residue, wherein the    C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, and O—CH₃;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is ≠H.

Preferably,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;    sec.-butyl; tert.-butyl; cyclopropyl; C(═O)-methyl; C(═O)-ethyl;    (C═O)-isopropyl; (C═O)-t-butyl; O-methyl; O-ethyl; O-isopropyl;    O-t-butyl; O—(CH₂)₂—O—CH₃; S-Methyl; S-Ethyl;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is ≠H.

In particular,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ are each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    (C═O)-methyl; (C═O)-ethyl; (C═O)-isopropyl; (C═O)-t-butyl; methyl;    ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl;    O-t-butyl; OCF₃; S-methyl; S-ethyl; and SCF₃;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is ≠H.

More particularly,

-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is ≠H.

Most preferred,

-   R³⁰³, R³⁰⁴ and R³⁰⁶ each independently of one another represent H or    F; and-   R³⁰⁵ denotes F; CF₃; OCF₃; CN; or NO₂.

In a preferred embodiment of the compound according to general formula(3-I), the residue

-   R³⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O) OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R³⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.    and-   R³⁰⁸ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue    and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (3-I), the residue

-   R³⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,-    on the condition that if R³⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    and-   R³⁰⁸ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, a C₃₋₆ cycloaliphatic residue, and a 3 to 6    membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue.

Preferably,

-   R³⁰⁷ denotes a C₁₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,-    on the condition that if R³⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    and-   R³⁰⁸ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 3 to 6    membered heterocycloaliphatic residue, more preferably selected from    the group consisting of morpholinyl, piperidinyl, pyrrolidinyl,    azetidinyl and piperazinyl, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue.

More preferably,

-   R³⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, CF₃, a C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue is in each case bridged via a C₁₋₈    aliphatic group, preferably a C₁₋₄ aliphatic group, which in turn    may be unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue,    and-   R³⁰⁸ denotes H or a C₁₋₆-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 6 membered heterocycloaliphatic residue, preferably selected    from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl,    azetidinyl and piperazinyl, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R³⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered        heterocycloaliphatic residue is in each case bridged via a        unsubstituted C₁₋₈ aliphatic group, preferably an unsubstituted        C₁₋₄ aliphatic group,        and-   R³⁰⁸ denotes H or an unsubstituted C₁₋₄-aliphatic residue,    preferably selected from the group consisting of methyl, ethyl,    n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl,    more preferably selected from the group consisting of methyl and    ethyl    or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    3 to 6 membered heterocycloaliphatic residue, preferably selected    from the group consisting of morpholinyl, piperidinyl, pyrrolidinyl,    and azetidinyl, unsubstituted or mono- or polysubstituted with at    least one substituent selected from the group consisting of F, Cl,    Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄ aliphatic residue.

Still more preferably,

-   R³⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue.-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue is in each case bridged via a    unsubstituted C₁₋₄ aliphatic group,-   R³⁰⁸ denotes H or an unsubstituted C₁₋₄-aliphatic residue,    preferably H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl or tert.-butyl,    or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue.

Most preferred,

-   R³⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, and O-methyl, preferably    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, and    O-methyl, more preferably unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F and O-methyl,-   R³⁰⁸ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl,    isobutyl, sec.-butyl or tert.-butyl, preferably methyl or ethyl,    or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, and a C₁₋₄-aliphatic residue, more    preferably unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl and a    O—C₁₋₄ aliphatic residue, preferably O-methyl.

Particularly preferred is also a compound according to general formula(I), wherein

-   R³⁰¹ represents the partial structure (3-T1),    —(CR^(308a)R^(308b))_(m3)—R^(308c)  (3-T1),    -   wherein    -   m3 is 0, 1 or 2 and    -   R^(308a) and R^(308b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃;    -   R^(308c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, in each case            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, an unsubstituted O—C₁₋₄ aliphatic residue, CF₃, and an            unsubstituted C₁₋₄-aliphatic residue,    -   or    -   wherein    -   m3 is 0,    -   R^(308a) and R^(308b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃; and    -   R^(308c) denotes an aryl or heteroaryl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and        phenyl,        -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   R³⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃,-   R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; CF₃; CN; OCF₃ and    NO₂;    -   on the condition that at least one of R³⁰³, R³⁰⁴, R³⁰⁵ and R³⁰⁶        is H,-   R³⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, and O-methyl, preferably    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, and    O-methyl, more preferably unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F and O-methyl,-   R³⁰⁸ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl,    isobutyl, sec.-butyl or tert.-butyl, preferably methyl or ethyl,    or-   R³⁰⁷ and R³⁰⁸ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, and a C₁₋₄-aliphatic residue, more    preferably unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl and a    O—C₁₋₄ aliphatic residue, preferably O-methyl.

Another embodiment of the present invention therefore relates to acompound of general formula (I), wherein the compound is selected from acompound according to general formula (4-I),

wherein

-   R⁴⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted,-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted,-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; C(═O)—NH₂;    SCF₃; S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the    C₁₋₄ aliphatic residue may be in each case be unsubstituted or mono-    or polysubstituted; a O—C₁₋₄-aliphatic residue, a    O—C(═O)—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue,    wherein the C₁₋₄ aliphatic residue may be in each case be    unsubstituted or mono- or polysubstituted; a NH(C₁₋₄ aliphatic    residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic    residue, a NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic    residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic    residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄ aliphatic    residue may in each case be unsubstituted or mono- or    polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   on the condition that at least one of R⁴⁰³R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ is        ≠H,-   R⁴⁰⁷ represents a C₂₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the binding is carried out via a    carbon atom of the 3 to 10 membered heterocycloaliphatic residue,    in which an “aliphatic group” and “aliphatic residue” can in each    case be branched or unbranched, saturated or unsaturated,    in which a “cycloaliphatic residue” and a “heterocycloaliphatic    residue” can in each case be saturated or unsaturated,    in which “mono- or polysubstituted” with respect to an “aliphatic    group” and an “aliphatic residue” relates, with respect to the    corresponding residues or groups, to the substitution of one or more    hydrogen atoms each independently of one another by at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, a    NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue,    ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic    residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a    S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3    to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a    C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic    residue)₂;    in which “mono- or polysubstituted” with respect to a    “cycloaliphatic residue” and a “heterocycloaliphatic residue”    relates, with respect to the corresponding residues, to the    substitution of one or more hydrogen atoms each independently of one    another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue),    an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a    NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic    residue, a O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue,    a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphatic    residue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, a    C(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, a    C₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and a    C(═O)—N(C₁₋₄ aliphatic residue)₂;    in which “mono- or polysubstituted” with respect to “aryl” and a    “heteroaryl” relates, with respect to the corresponding residues, to    the substitution of one or more hydrogen atoms each independently of    one another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, OH, OCF₃, a O—C₁₋₄-aliphatic residue, aO—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue,S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphaticresidue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, C(═O)H, C(═O)OH, aC₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, aC(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3 to 6membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl,C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄aliphatic residue)₂.

The compounds according to general formula (4-I) are known from WO2012/205238 A1, which is fully included by reference.

Preferred embodiments of the compound according to general formula (I)have general formulae (4-Ia), (4-Ib), (4-Ic) or (4-Id),

Another preferred embodiment of present invention is a compoundaccording to general formula (4-I), wherein

-   R⁴⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH,

-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted, preferably represents H; F; Cl; Br; I; CN; CF₃;    NO₂; OCF₃; SCF₃; a C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic    residue, a O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic    residue and an O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic    residue or the 3 to 6 membered heterocycloaliphatic residue may in    each case be optionally bridged via a C₁₋₄ aliphatic group, which in    turn may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,

-    on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ is    ≠H,

-   R⁴⁰⁷ denotes a C₂₋₁₀-aliphatic residue, preferably a C₂₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula(4-I), the residue

-   R⁴⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (4-I), the residue

-   R⁴⁰¹ represents the partial structure (4-T1)    —(CR^(408a)R^(408b))_(m4)—R^(408c)  (4-T1),    wherein-   m4 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, or 2,-   R^(408a) and R^(408b) each independently of one another represent H,    F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄ aliphatic residue    or C(═O)—OH, or together denote ═O,    -   preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   more preferably each independently of one another represent H,        F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   even more preferably each independently of one another represent        H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue,        and-   R^(408c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, preferably when m4 is ≠0, in each        case unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes—preferably when m is =0—an aryl or heteroaryl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄        aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted with at least one substituent selected            from the group consisting of F, Cl, Br, I, NO₂, NH₂, an            NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,            OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄            aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH.

Preferably,

-   R⁴⁰¹ represents the partial structure (4-T1),    wherein-   m4 denotes 0, 1, or 2,-   R^(408a) and R^(408b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,    -   preferably each independently of one another represent H, F, a        O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(408c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   or denotes—preferably when m4 is =0—an aryl or heteroaryl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a        C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl,        furyl, thiazolyl or oxazolyl,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, preferably with at least one substituent            selected from the group consisting of F, Cl, CH₃, O—CH₃, CF₃            and OCF₃,        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R⁴⁰¹ represents the partial structure (4-T1),    wherein-   m4 denotes 0, 1, or 2,-   R^(408a) and R^(408b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,-    preferably each independently of one another represent H, F, a    O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(408c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes—preferably when m4 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic    residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, benzyl, phenyl, thienyl or pyridyl,    -   wherein benzyl, phenyl, thienyl and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted, preferably        unsubstituted or mono- or disubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,        preferably with at least one substituent selected from the group        consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a C₁₋₄-aliphatic        residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (4-I), the residue

-   R⁴⁰¹ represents the partial structure (4-T1),    wherein-   m4 is 0, 1 or 2 and-   R^(408a) and R^(408b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(408c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        or        wherein-   m4 is 0,-   R^(408a) and R^(408b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(408c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (4-I)which has the following general formula (4-Ie),

In a preferred embodiment of the compound according to general formula(4-I), the residue

-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,-    and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,    pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or    piperidinyl may in each case be optionally bridged via an C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, an unsubstituted C₁₋₄-aliphatic    residue and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R⁴⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R⁴⁰² is selected from the group consisting of H; F; Cl; CF₃; CN;    SCF₃; OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; cyclopropyl;    O—CH₃ and O—C₂H₅.

In particular,

-   R⁴⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃; preferably selected from    the group consisting of H; F; Cl; CF₃; CH₃; and O—CH₃.

In a particular preferred embodiment of the compound according togeneral formula (4-I), the residue

-   R⁴⁰² is ≠H.

In a preferred embodiment of the compound according to general formula(4-I), the residues

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

Preferably,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    -   on the condition that at least one of R⁴⁰³R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ is        ≠H.

More preferably,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; NO₂; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, and a O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, ═O,    OH, a C₁₋₄-aliphatic residue and a O—C₁₋₄-aliphatic residue, and in    each case optionally bridged via an unsubstituted C₁₋₄ aliphatic    group,    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

In a further preferred embodiment of the present invention

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; a (C═O)—C₁₋₄aliphatic residue, a C₁₋₄aliphatic residue,    O—C₁₋₄aliphatic residue, a S—C₁₋₄aliphatic residue, wherein the    C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, and O—CH₃;    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

Preferably,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;    sec.-butyl; tert.-butyl; cyclopropyl; C(═O)-methyl; C(═O)-ethyl;    (C═O)-isopropyl; (C═O)-t-butyl; O-methyl; O-ethyl; O-isopropyl;    O-t-butyl; O—(CH₂)₂—O—CH₃; S-Methyl; S-Ethyl;    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

In particular,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ are each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    (C═O)-methyl; (C═O)-ethyl; (C═O)-isopropyl; (C═O)-t-butyl; methyl;    ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl;    O-t-butyl; OCF₃; S-methyl; S-ethyl; and SCF₃;    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

More particularly,

-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CH₃; CF₃; CN;    OCF₃ and NO₂;    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H.

Most preferred,

-   R⁴⁰³, R⁴⁰⁴ and R⁴⁰⁶ each independently are selected from the group    consisting of H and F;-   and-   R⁴⁰⁵ denotes F; Cl; Br; CH₃; CF₃; OCF₃; CN; or NO₂; preferably    denotes F, Br, CF₃ or CN.

In a particular preferred embodiment of the compound according togeneral formula (4-I) at least one of the residues R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ andR⁴⁰⁶ is ≠H.

In a preferred embodiment of the compound according to general formula(4-I), the residue

-   R⁴⁰⁷ denotes a C₂₋₁₀-aliphatic residue, preferably a C₂₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to generalformula (4-I), the residue

-   R⁴⁰⁷ denotes a C₂₋₁₀-aliphatic residue, preferably a C₂₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, OH, ═O,    an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue.-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

-   R⁴⁰⁷ denotes a C₂₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, OCF₃, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic    residue)₂, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue.-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

-   R⁴⁰⁷ denotes a C₂₋₈-aliphatic residue, preferably a C₂₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, a NH(C₁₋₄ aliphatic residue),    a N(C₁₋₄ aliphatic residue)₂, SH, SCF₃, a S—C₁₋₄-aliphatic residue,    CF₃, a C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue may in each case optionally bridged via    a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic group, which in    turn may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue,-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Even more preferably,

-   R⁴⁰⁷ denotes a C₂₋₈-aliphatic residue, preferably a C₂₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and    a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue may in each case optionally bridged via    a unsubstituted C₁₋₈ aliphatic group, preferably an unsubstituted    C₁₋₄ aliphatic group,-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Still more preferably,

-   R⁴⁰⁷ denotes a C₂₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic    residue)₂, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₁₀-cycloaliphatic residue, preferably a    C₃₋₆-cycloaliphatic residue, or a 3 to 10 membered    heterocycloaliphatic residue, preferably a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a unsubstituted C₁₋₄ aliphatic group,-    on the condition that if R⁴⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In particular,

-   R⁴⁰⁷ denotes a C₂₋₆-aliphatic residue, preferably selected from the    group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    ethenyl and propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃),    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, an NH(C₁₋₄ aliphatic residue), an    N(C₁₋₄ aliphatic residue)₂, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃,    SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue, preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, an O—C₁₋₄-aliphatic residue, an    NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, CF₃, and    a C₁₋₄-aliphatic residue, more preferably in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, OH, an O—C₁₋₄-aliphatic residue    and an N(C₁₋₄ aliphatic residue)₂, even more preferably in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of O-methyl, OH and    N(methyl)₂,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₆-cycloaliphatic residue, preferably selected from    the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and    cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue,    preferably selected from the group consisting of piperidinyl    (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl,    and tetrahydropyranyl, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    preferably in each case unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, OH, an O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue, more preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue,    preferably O-methyl,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case optionally bridged via    an unsubstituted C₁₋₄ aliphatic group, preferably via an    unsubstituted C₁₋₂ aliphatic group,-    on the condition that if R⁴⁰⁷ denotes a 3 to 6 membered    heterocycloaliphatic residue, the 3 to 6 membered    heterocycloaliphatic residue is linked via a carbon atom.

Most preferred,

-   R⁴⁰⁷ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    ethenyl or propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, OH, O—CH₃,    CF₃, and N(CH₃)₂, preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, O—CH₃, and N(CH₃)₂, more preferably    in each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of O—CH₃, OH and    N(CH₃)₂,-    or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,    piperidinyl (preferably piperidin-4-yl or piperidin-3-yl),    tetrahydrofuranyl, or tetrahydropyranyl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, OH, an O—C₁₋₄-aliphatic residue,    CF₃, and a C₁₋₄-aliphatic residue, preferably in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, and an    O—C₁₋₄-aliphatic residue, preferably O-methyl,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,    piperidinyl (preferably piperidin-4-yl or piperidin-3-yl),    tetrahydrofuranyl, and tetrahydropyranyl may in each case be    optionally bridged, preferably are bridged, via an unsubstituted    C₁₋₄ aliphatic group, preferably via an unsubstituted C₁₋₂ aliphatic    group,-    on the condition that if R⁴⁰⁷ denotes piperidinyl    tetrahydrofuranyl, or tetrahydropyranyl, piperidinyl    tetrahydrofuranyl, or tetrahydropyranyl, each of these residues is    linked via a carbon atom.

Particularly preferred is also a compound according to general formula(4-I), wherein

-   R⁴⁰¹ represents the partial structure (4-T1),    —(CR^(408a)R^(408b))_(m4)—R^(408c)  (4-T1),    wherein-   m4 is 0, 1 or 2 and-   R^(408a) and R^(408b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(408c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        or        wherein-   m4 is 0,-   R^(408a) and R^(408b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(408c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   R⁴⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃,-   R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; CF₃; CN; OCF₃ and    NO₂,    -   on the condition that at least one of R⁴⁰³, R⁴⁰⁴, R⁴⁰⁵ and R⁴⁰⁶        is ≠H,-   R⁴⁰⁷ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    ethenyl or propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, OH, O—CH₃,    CF₃, and N(CH₃)₂, preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, O—CH₃, and N(CH₃)₂, more preferably    in each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of O—CH₃, OH and    N(CH₃)₂,    -   or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,        piperidinyl (preferably piperidin-4-yl or piperidin-3-yl),        tetrahydrofuranyl, or tetrahydropyranyl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH, an        O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,        preferably in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue,        preferably O-methyl,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -   and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,        piperidinyl (preferably piperidin-4-yl or piperidin-3-yl),        tetrahydrofuranyl, and tetrahydropyranyl may in each case be        optionally bridged via an unsubstituted C₁₋₄ aliphatic group,        preferably via an unsubstituted C₁₋₂ aliphatic group,    -   on the condition that if R⁴⁰⁷ denotes piperidinyl,        tetrahydrofuranyl, or tetrahydropyranyl, each of these residues        is linked via a carbon atom.

Another embodiment of the present invention therefore relates to acompound of general formula (I), wherein the compound is selected from acompound according to general formula (5-I).

wherein

-   X⁵ denotes O or S, preferably O,-   R⁵⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; C(═O)—NH₂;    SCF₃; S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the    C₁₋₄ aliphatic residue may be in each case be unsubstituted or mono-    or polysubstituted; a O—C₁₋₄-aliphatic residue, a    O—C(═O)—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue,    wherein the C₁₋₄ aliphatic residue may be in each case be    unsubstituted or mono- or polysubstituted; a NH(C₁₋₄ aliphatic    residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic    residue, a NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic    residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic    residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄ aliphatic    residue may in each case be unsubstituted or mono- or    polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴,        R⁵⁰⁵ and R⁵⁰⁶ is ≠H,-   R⁵⁰⁷ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,        in which an “aliphatic group” and “aliphatic residue” can in        each case be branched or unbranched, saturated or unsaturated,        in which a “cycloaliphatic residue” and a “heterocycloaliphatic        residue” can in each case be saturated or unsaturated,        in which “mono- or polysubstituted” with respect to an        “aliphatic group” and an “aliphatic residue” relates, with        respect to the corresponding residues or groups, to the        substitution of one or more hydrogen atoms each independently of        one another by at least one substituent selected from the group        consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), a NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄        aliphatic residue, OH, OCF₃, a O—C₁₋₄-aliphatic residue, a        O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a S—C₁₋₄-aliphatic        residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue, a        S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphatic        residue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, a        C(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue,        a C₃₋₆-cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄        aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂;        in which “mono- or polysubstituted” with respect to a        “cycloaliphatic residue” and a “heterocycloaliphatic residue”        relates, with respect to the corresponding residues, to the        substitution of one or more hydrogen atoms each independently of        one another by at least one substituent selected from the group        consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄        aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH,        OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic        residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a        S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic        residue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH,        a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a        3 to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a        C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic        residue)₂;        in which “mono- or polysubstituted” with respect to “aryl” and a        “heteroaryl” relates, with respect to the corresponding        residues, to the substitution of one or more hydrogen atoms each        independently of one another by at least one substituent        selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

The compounds according to general formula (5-I) are known from WO2012/025239 A1, which is fully included by reference.

Preferred embodiments of the compound according to general formula (5-I)have general formulae (5-I-I), and/or (5-I-II),

Particularly preferred is a compound according to general formula(5-I-I), i.e. a compound according to general formula (5-I), wherein X⁵denotes O.

Further preferred embodiments of the compound according to generalformula (I) have general formulae (5-Ia), (5-Ib), (5-Ic) and/or (5-Id),

Another preferred embodiment of present invention is a compoundaccording to general formula (5-I), wherein

-   R⁵⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), OH, an O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₃, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN and C(═O)—OH,

-   X⁵ represents O or S,

-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted, preferably represents F; Cl; Br; I; CN; CF₃; NO₂;    OCF₃; SCF₃; a C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    OH, and an unsubstituted O—C₁₋₄-aliphatic residue; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and an O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue    in each case may be unsubstituted or mono- or polysubstituted with    at least one substituent selected from the group consisting of F,    Cl, Br, I, ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, a C₁₋₄-aliphatic residue and a    O—C₁₋₄-aliphatic residue, and in each case optionally bridged via an    unsubstituted C₁₋₄ aliphatic group, preferably on the condition that    at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ is ≠H,

-   R⁵⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), OH, an O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula(5-I), the residue

-   R⁵⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), OH, an O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or poly-substituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (5-I), the residue

-   R⁵⁰¹ represents the partial structure (5-T1),    —(CR^(508a)R^(508b))_(m5)—R^(508c)  (5-T1),    wherein-   m5 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, or 2,-   R^(508a) and R^(508b) each independently of one another represent H,    F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic residue), OH, an O—C₁₋₄    aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃,    CN, a C₁₋₄ aliphatic residue or C(═O)—OH,    -   preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), OH, O—C₁₋₄ aliphatic        residue or a C₁₋₄ aliphatic residue,    -   more preferably each independently of one another represent H,        F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   even more preferably each independently of one another represent        H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue,        and-   R^(508c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, preferably when m is ≠0, in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a    C₃₋₆ cycloaliphatic residue and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    or denotes—preferably when m5 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic    residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,        C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

Preferably,

-   R⁵⁰¹ represents the partial structure (5-T1),    wherein-   m5 denotes 0, 1, or 2,-   R^(508a) and R^(508b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,-    preferably each independently of one another represent H, F, a    O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(508c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue,    OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆    cycloaliphatic residue, and a 3 to 6 membered heterocycloaliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic        residue and C(═O)—OH,-    or denotes—preferably when m5 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic    residue, a 3 to 6 membered heterocycloaliphatic residue, benzyl,    phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted, preferably unsubstituted or mono- or        disubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably        with at least one substituent selected from the group consisting        of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a C₁₋₄-aliphatic        residue and C(═O)—OH.

More preferably,

-   R⁵⁰¹ represents the partial structure (5-T1),    wherein-   m5 denotes 0, 1, or 2,-   R^(508a) and R^(508b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,-    preferably each independently of one another represent H, F, a    O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(508c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes—preferably when m5 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic    residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, benzyl, phenyl, thienyl or pyridyl,    -   wherein benzyl, phenyl, thienyl and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted, preferably        unsubstituted or mono- or disubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,        preferably with at least one substituent selected from the group        consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a C₁₋₄-aliphatic        residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (5-I), the residue

-   R⁵⁰¹ represents the partial structure (5-T1),    wherein-   m5 is 0, 1 or 2 and-   R^(508a) and R^(508b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(508c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,    or    wherein-   m5 is 0,-   R^(508a) and R^(508b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(508c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (5-I)which has the following general formula (5-Ie):

In particular,

-   R⁵⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably    pyridyl or thienyl, in each case unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃,-    preferably represents phenyl, unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃,    or represents an unsubstituted C₁₋₆-aliphatic residue.

In a further preferred embodiment of the compound according to generalformula (5-I), the residue X⁵ denotes O.

In another preferred embodiment of the compound according to generalformula (5-I), the residue X⁵ denotes S.

In a preferred embodiment of the compound according to general formula(5-I), the residue

-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, or a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,-    and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,    pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or    piperidinyl may in each case be optionally bridged via an C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, an unsubstituted C₁₋₄-aliphatic    residue and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R⁵⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R⁵⁰² is selected from the group consisting of F; Cl; Br; CF₃; CN;    SCF₃; OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; cyclopropyl;    O—CH₃ and O—C₂H₅.

In particular,

-   R⁵⁰² is selected from the group consisting of F; Cl; Br; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃.

In a preferred embodiment of the compound according to general formula(5-I), the residues

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group, preferably on the    condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ is ≠H.

Preferably,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H.

More preferably,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; NO₂; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    OH, and a O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic residue,    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, ═O,    OH, a C₁₋₄-aliphatic residue and a O—C₁₋₄-aliphatic residue, and in    each case optionally bridged via an unsubstituted C₁₋₄ aliphatic    group,-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H.

In a further preferred embodiment of the present invention

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; a (C═O)—C₁₋₄aliphatic residue, a C₁₋₄aliphatic residue,    O—C₁₋₄ aliphatic residue, a S—C₁₋₄aliphatic residue, wherein the    C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, and O—CH₃; preferably on the    condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ is ≠H.

Preferably,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;    sec.-butyl; tert-butyl; cyclopropyl; C(═O)-methyl; C(═O)-ethyl;    (C═O)-isopropyl; (C═O)-t-butyl; O-methyl; O-ethyl; O-isopropyl;    O-t-butyl; O—(CH₂)₂—O—CH₃; S-Methyl; S-Ethyl;-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H.

In particular,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ are each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    (C═O)-methyl; (C═O)-ethyl; (C═O)-isopropyl; (C═O)-t-butyl; methyl;    ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl;    O-t-butyl; OCF₃; S-methyl; S-ethyl; and SCF₃;-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H.

More particularly,

-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H.

Most preferred,

-   R⁵⁰³, R⁵⁰⁴ and R⁵⁰⁶ each independently of one another represent H or    F, preferably each denotes H; and-   R⁵⁰⁵ denotes H; F; Cl; Br; CF₃; OCF₃; CN; or NO₂; preferably denotes    F; Cl; Br; CF₃; OCF₃; or CN.

In a particular preferred embodiment of the compound according togeneral formula (5-I) at least one of the residues R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ andR⁵⁰⁶ is ≠H.

In another particular preferred embodiment of the compound according togeneral formula (5-I) at least two of the residues R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ andR⁵⁰⁶ denote H, preferably at least two of R⁵⁰³, R⁵⁰⁴ and R⁵⁰⁶ denote H.

In a preferred embodiment of the compound according to general formula(5-I), the residue

-   R⁵⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), OH, an O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to generalformula (5-I), the residue

-   R⁵⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, COOH, CF₃, CN, and a    C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case be optionally    bridged, preferably is bridged, via a C₁₋₈ aliphatic group,    preferably a C₁₋₄ aliphatic group, which in turn may be    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, ═O, an O—C₁₋₄ aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

-   R⁵⁰⁷ denotes a C₁₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, an O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic    residue, COOH, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

-   R⁵⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, COOH, CF₃, a C(═O)—O—C₁₋₄-aliphatic residue, and a    C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue in each case may be bridged, preferably    is bridged, via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Even more preferably,

-   R⁵⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, COOH, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a    C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue may in each case be bridged, preferably    is bridged, via a unsubstituted C₁₋₈ aliphatic group, preferably an    unsubstituted C₁₋₄ aliphatic group,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Still more preferably,

-   R⁵⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, an O—C₁₋₄-aliphatic residue,    COOH, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, OH, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue.-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue in each case may be bridged,    preferably is bridged, via a unsubstituted C₁₋₄ aliphatic group,-    on the condition that if R⁵⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In particular,

-   R⁵⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, an O—C₁₋₄-aliphatic residue,    COOH, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    preferably unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, OH, an    O—C₁₋₄-aliphatic residue, OCF₃, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of OH, and an        unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 6 membered    heterocycloaliphatic residue, the 3 to 6 membered    heterocycloaliphatic residue is linked via a carbon atom.

Most preferred,

-   R⁵⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, OH, a C(═O)—O—C₁₋₄-aliphatic residue,    COOH and an O—C₁₋₄-aliphatic residue, preferably at least one    substituent selected from the group consisting of OH, a    C(═O)—O—C₁₋₄-aliphatic residue, COOH and an O—C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of OH, and an        unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 6 membered    heterocycloaliphatic residue, the 3 to 6 membered    heterocycloaliphatic residue is linked via a carbon atom.

In particular most preferred

-   R⁵⁰⁷ is selected from the group consisting of CH₃, C₂H₅, C₃H₇, C₄H₉,    C₅H₁₁, CH(CH₃)₂, C₂H₄—CH(CH₃)₂, C₃H₆—CH(CH₃)₂, CH₂OH, C₂H₄O,    CH₂—OCH₃, C₂H₄—OCH₃, C₃H₆—OCH₃, CH₂—O—C₂H₅, C₂H₄—O—C₂H₅,    CH₂—CH(CH₃)(OCH₃), CH₂—CH(C₂H₅)(OCH₃), CH(CH₃)(CH₂—OCH₃),    CH(C₂H₄—OCH₃)₂, CH(C₂H₅)(CH₂—OCH₃), C₂H₄—O—C₂H₄—O—CH₃,    CH₂—O—C₂H₄—O—CH₃, C₂H₄—O—C₂H₄—OH, CH₂—O—C₂H₄—OH, CH₂—C(═O)O—CH₃,    C₂H₄—C(═O)OCH₃, C₂H₄—C(═O)OH, CH₂—C(═O)OH,-    or denotes an unsubstituted C₃₋₆-cycloaliphatic residue or an    unsubstituted 3 to 6 membered heterocycloaliphatic residue,    preferably tetrahydropyranyl or piperidinyl.

Particularly preferred is also a compound according to general formula(I), wherein

-   R⁵⁰¹ represents the partial structure (5-T1),    —(CR^(508a)R^(508b))_(m5)—R^(508c)  (5-T1),    wherein-   m5 is 0, 1 or 2 and-   R^(508a) and R^(508b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(508c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,-   or-   wherein-   m5 is 0,-   R^(508a) and R^(508b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(508c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   X⁵ represents O or S, preferably O,-   R⁵⁰² is selected from the group consisting of F; Cl; Br; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃,-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H,-   R⁵⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, an O—C₁₋₄-aliphatic residue,    COOH, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    preferably unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, OH, an    O—C₁₋₄-aliphatic residue, OCF₃, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of OH, and an        unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes an unsubstituted C₃₋₆-cycloaliphatic residue or an    unsubstituted 3 to 6 membered heterocycloaliphatic residue,-    on the condition that if R⁵⁰⁷ denotes a 3 to 6 membered    heterocycloaliphatic residue, the 3 to 6 membered    heterocycloaliphatic residue is linked via a carbon atom.

Particularly preferred is also a compound according to general formula(5-I), wherein

-   R⁵⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably    pyridyl or thienyl, in each case unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃,-    preferably represents phenyl, unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃;

X⁵ is O;

-   R⁵⁰² is selected from the group consisting of F, Cl, CF₃, CH₃, C₂H₅,    iso-propyl, cyclopropyl, and O—CH₃; preferably is selected from the    group consisting of CH₃, C₂H₅, OCH₃ and CF₃;-   R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵ and R⁵⁰⁶ are each independently of one another    selected from the group consisting of H, F, Cl, Br, CF₃, CN, OCF₃    and NO₂;-    preferably on the condition that at least one of R⁵⁰³, R⁵⁰⁴, R⁵⁰⁵    and R⁵⁰⁶ is ≠H, more preferably on the condition that R⁵⁰⁵ is ≠H;-   R⁵⁰⁷ denotes a saturated C₁₋₆-aliphatic residue, unsubstituted or    mono- or disubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, O—CH₃, O—C₂H₅, OCF₃,    OC₂H₄—O—CH₃, COOH, C(═O)OCH₃, SCF₃, and CF₃,-    preferably denotes a saturated C₁₋₆-aliphatic residue,    unsubstituted or mono- or disubstituted with at least one    substituent selected from the group consisting of OH, O—CH₃, O—C₂H₅,    OCF₃, OC₂H₄—O—CH₃, COOH, and C(═O)OCH₃.

Another embodiment of the present invention therefore relates to acompound of general formula (I), wherein the compound is selected from acompound according to general formula (6-I).

wherein

-   R⁶⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₈-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₈-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰⁴ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged,    preferably in each case bridged, via a C₁₋₈ aliphatic group, which    in turn may be unsubstituted or mono- or polysubstituted;-    on the condition that if R⁶⁰⁴ denotes a 3 to 10 membered    heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered    heterocycloaliphatic residue or the heteroaryl is linked via a    carbon atom;-   R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted;    or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted, which may optionally be condensed with aryl or    heteroaryl, preferably selected from the group consisting of phenyl,    pyridyl and thienyl, wherein the aryl or heteroaryl residues    condensed in this way can for their part be respectively    unsubstituted or mono- or polysubstituted;-   R⁶⁰⁶ represents a C₂₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;    -   on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,    -   or    -   denotes S—R⁶⁰⁷, O—R⁶⁰⁸ or N(R⁶⁰⁹R⁶¹⁰),    -   wherein        -   R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₁₀-aliphatic            residue, unsubstituted or mono- or polysubstituted; a            C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered            heterocycloaliphatic residue, in each case unsubstituted or            mono- or polysubstituted and in each case optionally bridged            via a C₁₋₈ aliphatic group, which in turn may be            unsubstituted or mono- or polysubstituted;        -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10            membered heterocycloaliphatic residue, the 3 to 10 membered            heterocycloaliphatic residue is linked via a carbon atom,        -   R⁶⁰⁹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or            mono- or polysubstituted; a C₃₋₁₀-cycloaliphatic residue or            a 3 to 10 membered heterocycloaliphatic residue, in each            case unsubstituted or mono- or polysubstituted and in each            case optionally bridged via a C₁₋₈ aliphatic group, which in            turn may be unsubstituted or mono- or polysubstituted;        -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered            heterocycloaliphatic residue, the 3 to 10 membered            heterocycloaliphatic residue is linked via a carbon atom;        -   R⁶¹⁰ denotes H or a C₁₋₁₀-aliphatic residue, preferably a            C₁₋₄-aliphatic residue, unsubstituted or mono- or            polysubstituted;        -   or        -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom            connecting them a 3 to 10 membered heterocycloaliphatic            residue, preferably a 4 to 7 membered heterocycloaliphatic            residue, unsubstituted or mono- or polysubstituted; which            may optionally be condensed with aryl or heteroaryl, wherein            the aryl or heteroaryl residues condensed in this way can            for their part be respectively unsubstituted or mono- or            polysubstituted;            in which an “aliphatic group” and an “aliphatic residue” can            in each case be branched or unbranched, saturated or            unsaturated,            in which a “cycloaliphatic residue” and a            “heterocycloaliphatic residue” can in each case be saturated            or unsaturated,            in which “mono- or polysubstituted” with respect to an            “aliphatic group” and an “aliphatic residue” relates, with            respect to the corresponding residues or groups, to the            substitution of one or more hydrogen atoms each            independently of one another by at least one substituent            selected from the group consisting of F, Cl, Br, I, NO₂,            NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic            residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a            NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a            O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,            SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a            S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic            residue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO,            COOH, a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic            residue, a C(═O)—O—C₁₋₄-aliphatic residue, a            C₃₋₆-cycloaliphatic residue, a 3 to 6 membered            heterocycloaliphatic residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄            aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂;            in which “mono- or polysubstituted” with respect to a            “cycloaliphatic residue” and a “heterocycloaliphatic            residue” relates, with respect to the corresponding            residues, to the substitution of one or more hydrogen atoms            each independently of one another by at least one            substituent selected from the group consisting of F, Cl, Br,            I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a            NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a            O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,            SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a            S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic            residue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO,            COOH, a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic            residue, a C(═O)—O—C₁₋₄-aliphatic residue, a            C₃₋₆-cycloaliphatic residue, a 3 to 6 membered            heterocycloaliphatic residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄            aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂;            in which “mono- or polysubstituted” with respect to “aryl”            and a “heteroaryl” relates, with respect to the            corresponding residues, to the substitution of one or more            hydrogen atoms each independently of one another by at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄.-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

In an particularly preferred embodiment of the compound according togeneral formula (6-I) radicals R⁶⁰¹, R⁶⁰², R⁶⁰³, R⁶⁰⁴, R⁶⁰⁵ and R⁶⁰⁶have the meanings described herein in connection with the compoundsaccording to the invention and preferred embodiments thereof, with theproviso that R⁶⁰¹ comprises at least 4 atoms selected from the groupconsisting of carbon and heteroatoms, preferably at least 4 atomsselected from the group consisting of carbon atoms and heteroatomsselected from the group consisting of N, O and S.

The compounds according to general formula (6-I) are known from WO2012/052167 A1, which is fully included by reference.

The present invention further relates to a substituted compound ofgeneral formula (6-I),

wherein

-   R⁶⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀ cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₈-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁶⁰⁴ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged,    preferably in each case bridged, via a C₁₋₈ aliphatic group, which    in turn may be unsubstituted or mono- or polysubstituted;-    on the condition that if R⁶⁰⁴ denotes a 3 to 10 membered    heterocycloaliphatic residue or a heteroaryl, the 3 to 10 membered    heterocycloaliphatic residue or the heteroaryl is linked via a    carbon atom;-   R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted;    or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted,-   R⁶⁰⁶ represents a C₂₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,-    or-    denotes S—R⁶⁰⁷, O—R⁶⁰⁸ or N(R⁶⁰⁹R⁶¹⁰),-    wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₁₀-aliphatic residue,        unsubstituted or mono- or polysubstituted; a        C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted and in each case optionally bridged via        a C₁₋₈ aliphatic group, which in turn may be unsubstituted or        mono- or polysubstituted;    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,    -   R⁶⁰⁹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or        mono- or poly-substituted; a C₃₋₁₀-cycloaliphatic residue or a 3        to 10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted and in each case        optionally bridged via a C₁₋₈ aliphatic group,    -    which in turn may be unsubstituted or mono- or polysubstituted;    -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom;    -   R⁶¹⁰ denotes a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted;    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 10 membered heterocycloaliphatic residue, preferably        a 4 to 7 membered heterocycloaliphatic residue, unsubstituted or        mono- or polysubstituted;        in which an “aliphatic group” and an “aliphatic residue” can in        each case be branched or unbranched, saturated or unsaturated,        in which a “cycloaliphatic residue” and a “heterocycloaliphatic        residue” can in each case be saturated or unsaturated,        in which “mono- or polysubstituted” with respect to an        “aliphatic group” and an “aliphatic residue” relates, with        respect to the corresponding residues or groups, to the        substitution of one or more hydrogen atoms each independently of        one another by at least one substituent selected from the group        consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄        aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH,        OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic        residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a        S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic        residue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH,        a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a        3 to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a        C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic        residue)₂;        in which “mono- or polysubstituted” with respect to a        “cycloaliphatic residue” and a “heterocycloaliphatic residue”        relates, with respect to the corresponding residues, to the        substitution of one or more hydrogen atoms each independently of        one another by at least one substituent selected from the group        consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄        aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH,        OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic        residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a        S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic        residue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH,        a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a        3 to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a        C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic        residue)₂;        in which “mono- or polysubstituted” with respect to “aryl” and a        “heteroaryl” relates, with respect to the corresponding        residues, to the substitution of one or more hydrogen atoms each        independently of one another by at least one substituent        selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

In another preferred embodiment of the compound according to formula(6-I), preferred substituents of “cycloaliphatic residue” and“heterocycloaliphatic residue” are selected from the group consisting ofF, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, aO—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue,S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphaticresidue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, aC₁₋₄-aliphatic residue, CH₂OH, CH₂—OCH₃, C₂H₄—OH, C₂H₄—OCH₃CH₂—CF₃, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and aC(═O)—N(C₁₋₄ aliphatic residue)₂.

In another preferred embodiment of the compound according to formula(6-I), preferred substituents of “aryl” and “heteroaryl” are selectedfrom the group consisting of F, Cl, Br, I, NO₂,

an NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCFH₂, OCF₂H, OCF₃, a O—C₁₋₄-aliphatic residue, SH, SCF₃, aS—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue, aS(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CF₂H, CHF₂, a C₁₋₄-aliphaticresidue, CH₂OH, CH₂—OCH₃, C₂H₄—OH, C₂H₄—OCH₃, a C(═O)—C₁₋₄-aliphaticresidue, a C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphaticresidue, a 3 to 6 membered heterocycloaliphatic residue, CONH₂, aC(═O)—NH(C₁₋₄ aliphatic residue), a C(═O)—N(C₁₋₄ aliphatic residue)₂,aryl, preferably phenyl, or benzyl, in each case unsubstituted or mono-or polysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, CN, CF₃, CH₃, C₂H₅, iso-propyl, tert.-butyl,C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, O—CH₃,OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, S—CH₃, SCF₃, NO₂, NH₂, N(CH₃)₂,N(CH₃)(C₂H₅) and N(C₂H₅)₂, heteroaryl, preferably pyridyl, thienyl,furyl, thiazolyl or oxazolyl, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, CN, CF₃, CH₃, C₂H₅, iso-propyl, tert.-butyl,C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, O—CH₃,OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, S—CH₃, SCF₃, NO₂, NH₂, N(CH₃)₂,N(CH₃)(C₂H₅) and N(C₂H₅)₂.

In yet another preferred embodiment of the compound according to generalformula (6-I) the particular radicals R⁶⁰¹-R⁶⁰⁵ have the meaningsdescribed herein in connection with the compounds according to theinvention and preferred embodiments thereof and

-   R⁶⁰⁶ represents a C₂₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,-    or-    denotes S—R⁶⁰⁷ or O—R⁶⁰⁸-    wherein R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₁₀-aliphatic    residue, unsubstituted or mono- or polysubstituted; a    C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₈    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In another preferred embodiment of the present invention the compoundaccording to general formula (6-I) has the general formula (6-I-a)

whereinthe particular radicals R⁶⁰¹-R⁶⁰⁵ and R⁶⁰⁷ have the meanings describedherein in connection with the compounds according to the invention andpreferred embodiments thereof.

In another preferred embodiment of the present invention the compoundaccording to general formula (6-I) has the general formula (6-I-b)

wherein the particular radicals R⁶⁰¹-R⁶⁰⁵ have the meanings describedherein in connection with the compounds according to the invention andpreferred embodiments thereof,and wherein

-   R⁶¹¹ represents O—R⁶⁰⁸ or N(R⁸⁰⁹R⁶¹⁰),    -   wherein R⁶⁰⁸, R⁶⁰⁹ and R⁶¹⁰ have the meanings described herein        in connection with the compounds according to the invention and        preferred embodiments thereof,-    or represents a C₂₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁶¹¹ denotes a 3 to 10 membered    heterocycloaliphatic residue, the binding is carried out via a    carbon atom of the 3 to 10 membered heterocycloaliphatic residue.

In a particular preferred embodiment of the present invention, radicalR⁶¹¹ in general formula (6-I-b) and radical R⁶⁰⁶ in general formula(6-I) represents O—R⁶⁰⁸, wherein R⁶⁰⁸ has the meanings described hereinin connection with the compounds according to the invention andpreferred embodiments thereof.

In another particular preferred embodiment of the present invention,radical R⁶¹¹ in general formula (6-I-b) and radical R⁶⁰⁶ in generalformula (6-I) represents N(R⁶⁰⁹R⁶¹⁰) wherein R⁶⁰⁹ and R⁶¹⁰ have themeanings described herein in connection with the compounds according tothe invention and preferred embodiments thereof.

In yet another particular preferred embodiment of the present invention,radical R⁶¹¹ in general formula (6-I-b) and radical R⁶⁰⁶ in generalformula (6-I) represents a C₂₋₁₀-aliphatic residue, unsubstituted ormono- or polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10membered heterocycloaliphatic residue, in each case unsubstituted ormono- or polysubstituted and in each case optionally bridged via a C₁₋₈aliphatic group, which in turn may be unsubstituted or mono- orpolysubstituted,

-    on the condition that if R⁶¹¹ denotes a 3 to 10 membered    heterocycloaliphatic residue, the binding is carried out via a    carbon atom of the 3 to 10 membered heterocycloaliphatic residue.

Another preferred embodiment of the compound according to generalformula (6-I) has the general formula (6-I-c),

wherein the particular radicals R⁶⁰¹, R⁶⁰², R⁶⁰⁴, R⁶⁰⁵ and R⁶⁰⁶ have themeanings described herein in connection with the compounds according tothe invention and preferred embodiments thereof.

Another preferred embodiment of the compound according to generalformula (6-I) has the general formula (6-I-e) or (6-I-f),

wherein the particular radicals R⁶⁰¹, R⁶⁰³, R⁶⁰⁴, R⁶⁰⁵ and R⁶⁰⁶ or R⁶⁰¹,R⁶⁰⁴, R⁶⁰⁵ and R⁶⁰⁶, respectively, have the meanings described herein inconnection with the compounds according to the invention and preferredembodiments thereof.

In yet another preferred embodiment of the compound according to generalformula (6-I) radicals R⁶⁰², R⁶⁰³, R⁶⁰⁴, R⁶⁰⁵ and R⁶⁰⁶ have the meaningsdescribed herein in connection with the compounds according to theinvention and preferred embodiments thereof, and R⁶⁰¹ represents aryl orheteroaryl, in each case unsubstituted or mono- or polysubstituted.

In case R⁶⁰⁴ and R⁶⁰⁵ of the compound of general formula (6-I) formtogether with the nitrogen atom connecting them a 3 to 10 memberedheterocycloaliphatic residue, preferably a 4 to 7 memberedheterocycloaliphatic residue, unsubstituted or mono- or polysubstituted,said heterocycloaliphatic residue may optionally be condensed with arylor heteroaryl or with a C₃₋₁₀ cycloaliphatic residue or with a 3 to 10membered heterocycloaliphatic residue, wherein the aryl, heteroaryl,C₃₋₁₀ cycloaliphatic or 3 to 10 membered heterocycloaliphatic residuescondensed in this way can for their part be respectively unsubstitutedor mono- or polysubstituted. Preferably, said heterocycloaliphaticresidue formed by R⁶⁰⁴ and R⁶⁰⁵ of the compound of general formula (6-I)together with the nitrogen atom connecting them may optionally becondensed with aryl or heteroaryl, wherein the aryl, or heteroaryl,preferably selected from the group consisting of phenyl, pyridyl andthienyl condensed in this way can for their part be respectivelyunsubstituted or mono- or polysubstituted.

Particularly preferably, in case R⁶⁰⁴ and R⁶⁰⁵ form together with thenitrogen atom connecting them a 3 to 10 membered heterocycloaliphaticresidue, preferably a 4 to 7 membered heterocycloaliphatic residue,unsubstituted or mono- or polysubstituted, said heterocycloaliphaticresidue may optionally be condensed with aryl or heteroaryl, preferablyselected from the group consisting of phenyl, pyridyl and thienyl,wherein the aryl or heteroaryl residues condensed in this way can fortheir part be respectively unsubstituted or mono- or polysubstituted.

In case R⁶⁰⁹ and R⁶¹⁰ of the compound of general formula (6-I) formtogether with the nitrogen atom connecting them a 3 to 10 memberedheterocycloaliphatic residue, preferably a 4 to 7 memberedheterocycloaliphatic residue, unsubstituted or mono- or polysubstituted,said heterocycloaliphatic residue may optionally be condensed with arylor heteroaryl or with a C₃₋₁₀ cycloaliphatic residue or with a 3 to 10membered heterocycloaliphatic residue, wherein the aryl, heteroaryl,C₃₋₁₀ cycloaliphatic or 3 to 10 membered heterocycloaliphatic residuescondensed in this way can for their part be respectively unsubstitutedor mono- or polysubstituted. Preferably, said heterocycloaliphaticresidue formed by R⁶⁰⁹ and R⁶¹⁰ of the compound of general formula (6-I)together with the nitrogen atom connecting them may optionally becondensed with aryl or heteroaryl, wherein the aryl, or heteroaryl,preferably selected from the group consisting of phenyl, pyridyl andthienyl condensed in this way can for their part be respectivelyunsubstituted or mono- or polysubstituted.

Particularly preferably, in case R⁶⁰⁹ and R⁶¹⁰ form together with thenitrogen atom connecting them a 3 to 10 membered heterocycloaliphaticresidue, preferably a 4 to 7 membered heterocycloaliphatic residue,unsubstituted or mono- or polysubstituted, said heterocycloaliphaticresidue may optionally be condensed with aryl or heteroaryl, preferablyselected from the group consisting of phenyl, pyridyl and thienyl,wherein the aryl or heteroaryl residues condensed in this way can fortheir part be respectively unsubstituted or mono- or polysubstituted.

Yet another preferred embodiment of present invention is a compoundaccording to general formula (6-I), wherein

-   R⁶⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, CF₃, CN,    a C₁₋₄-aliphatic residue and C(═O)—OH, preferably denotes a    C₁₋₁₀-aliphatic residue, more preferably a C₁₋₈-aliphatic residue,    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a S(═O)₂—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,    C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,preferably in each case unsubstituted or mono- or polysubstituted withat least one substituent selected from the group consisting of F, Cl,Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphaticresidue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH,

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted,

-    preferably represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and an O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue    in each case may be unsubstituted or mono- or polysubstituted with    at least one substituent selected from the group consisting of F,    Cl, Br, I, ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,    and wherein the C₃₋₈-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue,

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄ aliphatic residue may be in each case be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue;

-    a C₃₋₈-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,

-    and wherein the C₃₋₈-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue,

-   R⁶⁰⁴ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R⁶⁰⁴ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,

-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or poly-substituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged, preferably in each case is bridged, via a C₁₋₈    aliphatic group, preferably a C₁₋₄ aliphatic group, which in turn    may be unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN and C(═O)—OH,

-   R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue    and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or

-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a &C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        preferably selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁴ and R⁵ together with the nitrogen atom connecting them    may optionally be condensed with aryl or heteroaryl, preferably with    phenyl or pyridyl, wherein the aryl or heteroaryl residues condensed    in this way can for their part be respectively unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁴ and R⁵ together with the nitrogen atom connecting them    may optionally be condensed with a C₃₋₁₀ cycloaliphatic residue or a    3 to 10 membered heterocycloaliphatic residue, wherein the C₃₋₁₀    cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic    residue condensed in this way can for their part be respectively    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    ═O, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,    C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and    oxazolyl,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-   R⁶⁰⁶ denotes a C₂₋₁₀-aliphatic residue, preferably a C₂₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,-    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷, O—R⁶⁰⁸ or N(R⁶⁰⁹R⁶¹⁰),    wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₁₀-aliphatic residue,        preferably a C₁₋₈-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   or in each case represent a C₃₋₁₀-cycloaliphatic residue or a 3        to 10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom of the        3 to 10 membered heterocycloaliphatic residue,    -   R⁶⁰⁹ denotes a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₈-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a        C(═O)—O—C₁₋₄-aliphatic residue a C₃₋₆ cycloaliphatic residue,        and a 3 to 6 membered heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue and C(═O)—OH,    -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom of the        3 to 10 membered heterocycloaliphatic residue,    -   R⁶¹⁰ denotes H or a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH; preferably        denotes a C₁₋₁₀-aliphatic residue, more preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 10 membered heterocycloaliphatic residue, preferably        a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆        cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   and wherein the 3 to 10 membered heterocycloaliphatic residue        formed by R⁶⁰⁹ and R⁶¹⁰ together with the nitrogen atom        connecting them may optionally be condensed with aryl or        heteroaryl, preferably with phenyl or pyridyl, wherein the aryl        or heteroaryl residues condensed in this way can for their part        be respectively unsubstituted or mono- or polysubstituted with        at least one substituent selected from the group consisting of        F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄        aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted with at least one substituent selected            from the group consisting of F, Cl, Br, I, NO₂, NH₂, an            NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,            OH, an O—C₁₋₄ aliphatic residue, OCF₃, O—CH₂—OH,            O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN,            a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,            C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH.

In a preferred embodiment of the compound according to general formula(6-I), the residue

-   R⁶⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, CF₃, CN,    a C₁₋₄-aliphatic residue and C(═O)—OH, preferably denotes a    C₁₋₁₀-aliphatic residue, more preferably a C₁₋₈-aliphatic residue,    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    poly-substituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a S(═O)₂—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,    C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,preferably in each case unsubstituted or mono- or polysubstituted withat least one substituent selected from the group consisting of F, Cl,Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphaticresidue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (6-I), the residue

-   R⁶⁰¹ represents the partial structure (6-T1)    —(CR^(612a)R^(612b))_(m6)—R^(612c)  (6-T1),    -   wherein    -   m6 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, 2 or 3,        more preferably denotes 0, 1, or 2,    -   R^(612a) and R^(612b) each independently of one another        represent H, F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄ aliphatic residue or C(═O)—OH, or together denote ═O,        preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue, or together denote ═O,    -    more preferably each independently of one another represent H,        F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue, or together denote ═O,    -    even more preferably each independently of one another        represent H, F, OH, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue, or together denote ═O, and    -   R^(612c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, a S(═O)₂—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue and C(═O)—OH, preferably denotes a C₁₋₄        aliphatic residue, unsubstituted or mono- or polysubstituted        with at least one substituent selected from the group consisting        of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an        N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,        OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆        cycloaliphatic residue and a 3 to 6 membered        heterocycloaliphatic residue, preferably when m6 is ≠0,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes—preferably when m6 is 0 or 2, more preferably when        m6 is 0—an aryl or heteroaryl, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        S(═O)₂—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,preferably denotes an aryl or heteroaryl, in each case unsubstituted ormono- or polysubstituted with at least one substituent selected from thegroup consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphaticresidue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphaticresidue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, aC₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ andC(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 memberedheterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,preferably when m6 is =0,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted with at least one substituent selected            from the group consisting of F, Cl, Br, I, NO₂, NH₂, an            NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,            OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄            aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH.

Preferably,

-   R⁶⁰¹ represents the partial structure (6-T1),    -   wherein    -   m6 denotes 0, 1, 2 or 3, preferably denotes 0, 1 or 2,    -   R^(612a) and R^(612b) each independently of one another        represent H, F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue or a        C₁₋₄ aliphatic residue, or together denote ═O,        -   preferably each independently of one another represent H, F,            OH, a O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue,            or together denote ═O, and    -   R^(612c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, a        S(═O)₂—C₁₋₄-aliphatic residue and C(═O)—OH, preferably denotes a        C₁₋₄ aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic        residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes—preferably when m6 is 0 or 2, more preferably when        m6 is 0—an aryl or heteroaryl, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        S(═O)₂—C₁₋₄ aliphatic residue, NO₂, N(C₁₋₄ aliphatic residue)₂,        CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,        C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅,

a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl or oxazolyl,preferably denotes an aryl or heteroaryl, in each case unsubstituted ormono- or polysubstituted with at least one substituent selected from thegroup consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃,SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅,

-   -    a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl,        furyl, thiazolyl or oxazolyl, preferably when m6 is 0,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, preferably with at least one substituent            selected from the group consisting of F, Cl, CH₃, O—CH₃, CF₃            and OCF₃,        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R⁶⁰¹ represents the partial structure (6-T1),    -   wherein    -   m6 denotes 0, 1, 2 or 3, preferably denotes 0, 1 or 2,    -   R^(612a) and R^(612b) each independently of one another        represent H, F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue or a        C₁₋₄ aliphatic residue, or together denote ═O, preferably each        independently of one another represent H, F, OH, a O—C₁₋₂        aliphatic residue or a C₁₋₂ aliphatic residue, or together        denote ═O, and    -   R^(612c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄        aliphatic residue, CF₃, CN, a S(═O)₂—C₁₋₄-aliphatic residue and        a C₁₋₄-aliphatic residue, preferably denotes a C₁₋₄ aliphatic        residue, unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, an O—C₁₋₄ aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic        residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes—preferably when m6 is 0 or 2, more preferably when        m6 is 0—an aryl or heteroaryl, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄        aliphatic residue, OCF₂H, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, CH₂—OH, CH₂—OCH₃, S(═O)₂—CH₃,        SCF₃, NO₂, N(C₁₋₄ aliphatic residue)₂,

C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6membered heterocycloaliphatic residue, benzyl, phenyl, thienyl orpyridyl, preferably denotes—preferably when m6 is 0 or 2, morepreferably when m6 is 0—an aryl or heteroaryl, in each caseunsubstituted or mono- or polysubstituted with at least one substituentselected from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue,a 3 to 6 membered heterocycloaliphatic residue, benzyl, phenyl, thienylor pyridyl,

-   -   -   wherein benzyl, phenyl, thienyl and pyridyl, may in each            case may be unsubstituted or mono- or polysubstituted,            preferably unsubstituted or mono- or disubstituted with at            least one substituent selected from the group consisting of            F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,            CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅,            C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably with at least one            substituent selected from the group consisting of F, Cl,            CH₃, O—CH₃, CF₃ and OCF₃, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (6-I), the residue

-   R⁶⁰¹ represents the partial structure (6-T1),    -   wherein    -   m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, OH, a O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue or together denote ═O; preferably H, F, OH,        CH₃ or OCH₃ or together denote ═O;    -   R^(612c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, CN, OH, an        unsubstituted O—C₁₋₄ aliphatic residue, an unsubstituted        S(═O)₂—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue, preferably denotes a C₁₋₄ aliphatic        residue, unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, an unsubstituted O—C₁₋₄ aliphatic residue, CF₃, and an        unsubstituted C₁₋₄-aliphatic residue    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,    -   or    -   wherein    -   m6 is 0 or 2, more preferably 0, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, OH, a O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue; preferably H, F, OH, CH₃ or OCH₃; and    -   R^(612c) denotes an aryl or heteroaryl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, OCF₂H, CH₂—OH, CH₂—OCH₃,        S(═O)₂—CH₃, SCF₃, NO₂, N(C₁₋₄ aliphatic residue)₂,

CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl, preferably denotes an aryl or heteroaryl, ineach case unsubstituted or mono- or polysubstituted with at least onesubstituent selected from the group consisting of F, Cl, Br, I, OH, anO—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,

-   -   -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Preferably,

-   R⁶⁰¹ represents the partial structure (6-T1),    -   wherein    -   m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, OH, CH₃ or OCH₃ or together denote ═O, more        preferably H, F, OH or CH₃, even more preferably H,    -   R^(612c) denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, or        tert-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, CN, OH, S(═O)₂—CH₃, an unsubstituted O—C₁₋₄ aliphatic        residue, preferably O-methyl and O-tert.-butyl, and CF₃,        preferably denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or        tert.-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic residue, preferably        O-methyl and O-tert-butyl, and CF₃,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, preferably cyclopropyl,        cyclopentyl, cyclohexyl, morpholinyl, oxetanyl, or        tetrahydropyranyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄        aliphatic residue, preferably O-methyl and O-ethyl, CF₃, and an        unsubstituted C₁₋₄-aliphatic residue, preferably methyl or        ethyl,    -   or    -   wherein    -   m6 is 0 or 2, more preferably 0, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, OH, CH₃ or OCH₃; preferably H, OH or CH₃, and    -   R^(612c) denotes an aryl or heteroaryl, preferably phenyl or        pyridyl, in each case unsubstituted or mono- or polysubstituted        with at least one substituent selected from the group consisting        of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, preferably        OCH₃, OCF₃, OCF₂H, CH₂—OH, CH₂—OCH₃, S(═O)₂—CH₃, SCF₃, NO₂,        N(CH₃)₂,

CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl, preferably denotes an aryl or heteroaryl,preferably phenyl or pyridyl, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl,

-   -   -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (I)which has the following general formula (6-I-d),

wherein the particular radicals and parameters have the meaningsdescribed herein in connection with the compounds according to theinvention and preferred embodiments thereof.

In a preferred embodiment of the compound according to general formula(6-I), the residue

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-nnethylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,    -   and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,        pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or        piperidinyl may in each case be optionally bridged via an C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, OH, an unsubstituted C₁₋₄-aliphatic        residue and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    CH₂—OH; CH₂—O—CH₃; CH₂—CH₂—OH; CH₂—CH₂—OCH₃; O-methyl; O-ethyl;    O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-ethyl; cyclopropyl,    cyclobutyl, cyclopentyl, and cyclohexyl; preferably represents F;    Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl; ethyl; n-propyl;    iso-propyl; n-butyl; sec.-butyl; tert.-butyl; O-methyl; O-ethyl;    O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-ethyl; cyclopropyl,    cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R⁶⁰² is selected from the group consisting of F; Cl; CF₃; CN; SCF₃;    OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; CH₂—OH; CH₂—O—CH₃;    cyclopropyl; O—CH₃ and O—C₂H₅; preferably is selected from the group    consisting of F; Cl; CF₃; CN; SCF₃; OCF₃; CH₃; C₂H₅; n-propyl;    iso-propyl; t-butyl; cyclopropyl; O—CH₃ and O—C₂H₅.

In particular,

-   R⁶⁰² is selected from the group consisting of F; Cl; CF₃; CH₃; C₂H₅,    iso-propyl; CH₂—O—CH₃; cyclopropyl; and O—CH₃; preferably is    selected from the group consisting of F; Cl; CF₃; CH₃; C₂H₅,    iso-propyl; cyclopropyl; and O—CH₃.

More particular,

-   R⁶⁰² is selected from the group consisting of CF₃; CH₃; C₂H₅,    iso-propyl; 0H₂—O—CH₃; and O—CH₃; preferably is selected from the    group consisting of CH₃; C₂H₅, iso-propyl; CH₂—O—CH₃; and O—CH₃.

In a particular preferred embodiment of the compound according togeneral formula (6-I), the residue

-   R⁶⁰² denotes CH₃ or CF₃, most preferably R⁶⁰² denotes CH₃.

In a further preferred embodiment of the compound according to generalformula (6-I), the residue

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄ aliphatic residue may be in each case be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue;-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

Preferably,

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a    C₁₋₄-aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄ aliphatic residue may be in each case be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue.

More preferably,

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; or    S-Ethyl.

Even more preferably

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; OCF₃; methyl; ethyl;    O-methyl; or O-ethyl, preferably represents H; F; Cl; Br; I; CF₃;    SCF₃; OCF₃; methyl; ethyl; O-methyl; or O-ethyl.

Still more preferably

-   R⁶⁰³ represents H; F; Cl; Br; CN; CF₃; SCF₃; OCF₃; O-methyl or    methyl, preferably represents H; F; Cl; CF₃; SCF₃; OCF₃; O-methyl or    methyl.

In particular

-   R⁶⁰³ represents H; F; Cl; Br; CN; or methyl, preferably H, F, Cl, Br    or CN, more preferably H, Cl or Br, most preferably H.

In a further preferred embodiment of the compound according to generalformula (6-I), the residue

-   R⁶⁰⁴ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R⁶⁰⁴ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₅ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged, preferably in each case is bridged, via a C₁₋₈    aliphatic group, preferably a C₁₋₄ aliphatic group, which in turn    may be unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN and C(═O)—OH,

-   R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue    and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or

-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁴ and R⁵ together with the nitrogen atom connecting them    may optionally be condensed with aryl or heteroaryl, preferably with    phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues    condensed in this way can for their part be respectively    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁-4 aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic    residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, andwherein the 3 to 10 membered heterocycloaliphatic residue formed by R⁴and R⁵ together with the nitrogen atom connecting them may optionally becondensed with a C₃₋₁₀ cycloaliphatic residue or a 3 to 10 memberedheterocycloaliphatic residue, wherein the C₃₋₁₀ cycloaliphatic residueor a 3 to 10 membered heterocycloaliphatic residue condensed in this waycan for their part be respectively unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), anN(C₁₋₄ aliphatic residue)₂, ═O, OH, an O—C₁₋₄ aliphatic residue, OCF₃,SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic residue,benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (6-I), the residue

-   R⁶⁰⁴ represents the partial structure (6-T2)    —(CR^(613a)R^(613b))_(n6)—R^(613c)  (6-T2),    -   wherein    -   n6 denotes 0, 1, 2, or 3, preferably denotes 1, 2 or 3, more        preferably denotes 1 or 2, even more preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄ aliphatic residue or C(═O)—OH, or together denote ═O,    -    preferably each independently of one another represent H, F,        Cl, Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue or together denote ═O,    -    more preferably each independently of one another represent H,        F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue or together denote ═O,    -    even more preferably each independently of one another        represent H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue or together denote ═O, and    -   R^(613c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes—preferably when n6 is ≠0, more preferably when n is        1—a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆        cycloaliphatic residue and a 3 to 6 membered        heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    or denotes—preferably when n6 is ≠0, more preferably when n6 is    1,—an aryl or heteroaryl, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,        C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-   R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, preferably a    C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or

-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, or preferably selected from    the group consisting of morpholinyl, piperidinyl, pyrrolidinyl,    azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl,    thiomorpholinyl, azepanyl,

more preferably selected from the group consisting of morpholinyl,piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl,oxazepanyl, in each case unsubstituted or mono- or polysubstituted withat least one substituent selected from the group consisting of F, Cl,Br, I, NO₂, OH, ═O, C(═O)—OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,a C₃₋₆ cycloaliphatic residue, preferably cyclopropyl, cyclobutyl orcyclopentyl, and a 3 to 6 membered heterocycloaliphatic residue,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        preferably selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁴ and R⁵ together with the nitrogen atom connecting them    may optionally be condensed with aryl or heteroaryl, preferably with    phenyl, pyridyl or thienyl, wherein the aryl or heteroaryl residues    condensed in this way can for their part be respectively    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue,

benzyl, phenyl, thienyl, and pyridyl,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁴ and R⁵ together with the nitrogen atom connecting them    may optionally be condensed with a C₃₋₁₀ cycloaliphatic residue,    preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 3 to 10    membered heterocycloaliphatic residue, preferably oxetanyl or    oxiranyl, wherein the C₃₋₁₀ cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue condensed in this way can for    their part be respectively unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, ═O, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,    C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, NO₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, O—CH₂—OH,        O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue, and C(═O)—OH, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and        C(═O)—OH.

Preferably,

-   R⁶⁰⁴ represents the partial structure (6-T2),    -   wherein    -   n6 denotes 0, 1, 2, or 3, preferably denotes 1, 2 or 3, more        preferably denotes 1 or 2, even more preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue or together denote ═O, preferably each        independently of one another represent H, F, a O—C₁₋₂ aliphatic        residue or a C₁₋₂ aliphatic residue or together denote ═O, and    -   R^(613c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and        C(═O)—OH, or denotes—preferably when n6 is ≠0, more preferably        when n6 is 1—a C₃₋₁₀-cycloaliphatic residue or a 3 to 10        membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic        residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6        membered heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes—preferably when n6 is ≠0, more preferably when n6 is        1—an aryl or heteroaryl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,        C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3        to 6 membered heterocycloaliphatic residue, benzyl, phenyl,        thienyl, pyridyl, furyl, thiazolyl or oxazolyl,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, preferably with at least one substituent            selected from the group consisting of F, Cl, CH₃, O—CH₃, CF₃            and OCF₃,        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH,-   R⁶⁰⁵ denotes H or a C₁₋₆-aliphatic residue, preferably a    C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, preferably a 4 to 7    membered heterocycloaliphatic residue, or preferably selected from    the group consisting of morpholinyl, piperidinyl, pyrrolidinyl,    azetidinyl, piperazinyl, 4-methylpiperazinyl, oxazepanyl,    thiomorpholinyl, azepanyl,

more preferably selected from the group consisting of morpholinyl,piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl,oxazepanyl, unsubstituted or mono- or polysubstituted with at least onesubstituent selected from the group consisting of F, Cl, Br, I, OH, ═O,C(═O)—OH, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄ aliphaticresidue, CF₃, and a C₁₋₄-aliphatic residue, and a C₃₋₆ cycloaliphaticresidue, preferably cyclopropyl, cyclobutyl or cyclopentyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,        preferably selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   wherein the C₃₋₆ cycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and        C(═O)—OH,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁶⁰⁴ and R⁶⁰⁵ together with the nitrogen atom connecting    them may optionally be condensed with aryl or heteroaryl, preferably    with phenyl or pyridyl, wherein the aryl or heteroaryl residues    condensed in this way can for their part be respectively    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue,    CF₃, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic    residue, benzyl, phenyl, thienyl, and pyridyl,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁶⁰⁴ and R⁶⁰⁵ together with the nitrogen atom connecting    them may optionally be condensed with a C₃₋₁₀ cycloaliphatic    residue, preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 3    to 10 membered heterocycloaliphatic residue, preferably oxetanyl or    oxiranyl, wherein the C₃₋₁₀ cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue condensed in this way can for    their part be respectively unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, ═O, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,    C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, and C(═O)—OH, and    -   wherein the C₃₋₆ cycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R⁶⁰⁴ represents the partial structure (6-T2),    -   wherein    -   n6 denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more        preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue or together denote ═O,    -    preferably each independently of one another represent H, F, a        O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue or together        denote ═O, and    -   R^(613c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, ═O, an O—C₁₋₄        aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic        residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, CF₃            and an unsubstituted O—C₁₋₄-aliphatic residue,    -    or denotes an aryl or heteroaryl, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆        cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic        residue, benzyl, phenyl, thienyl or pyridyl,        -   wherein benzyl, phenyl, thienyl and pyridyl, may in each            case may be unsubstituted or mono- or polysubstituted,            preferably unsubstituted or mono- or disubstituted with at            least one substituent selected from the group consisting of            F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,            CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅,            C(═O)—O—CH₃ and C(═O)—O—C₂H₅, preferably with at least one            substituent selected from the group consisting of F, Cl,            CH₃, O—CH₃, CF₃ and OCF₃, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃ a            C₁₋₄-aliphatic residue and C(═O)—OH,-   R⁶⁰⁵ denotes H or an unsubstituted C₁₋₄-aliphatic residue or a    C₁₋₄-aliphatic residue monosubstituted with O-methyl, wherein the    C₁₋₄-aliphatic residue is in each case preferably selected from the    group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl,    isobutyl, sec.-butyl and tert.-butyl, more preferably selected from    the group consisting of methyl and ethyl,    or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    3 to 10 membered heterocycloaliphatic residue, more preferably    selected from the group consisting of morpholinyl, piperidinyl,    pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl,    oxazepanyl, thiomorpholinyl, azepanyl,

in each case unsubstituted or mono- or polysubstituted with at least onesubstituent selected from the group consisting of F, Cl, Br, I, OH, ═O,C(═O)—OH, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄ aliphaticresidue, CF₃, and a C₁₋₄-aliphatic residue, cyclopropyl, cyclobutyl andcyclopentyl,

-   -   wherein the C₁₋₄-aliphatic residue is in each case unsubstituted        or mono- or polysubstituted with at least one substituent        selected from the group consisting of F, Cl, OH, ═O, CF₃ and an        unsubstituted O—C₁₋₄-aliphatic residue, preferably is in each        case unsubstituted,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁶⁰⁴ and R⁶⁰⁵ together with the nitrogen atom connecting    them may optionally be condensed with phenyl or pyridyl, wherein the    phenyl or pyridyl residues condensed in this way can for their part    be respectively unsubstituted or mono- or polysubstituted with at    least one substituent selected from the group consisting of F, Cl,    Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, a C₁₋₄-aliphatic residue, C(═O)—OH, and a    C₃₋₆ cycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH,        OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, a C₁₋₄-aliphatic residue and C(═O)—OH,

-    and wherein the 3 to 10 membered heterocycloaliphatic residue    formed by R⁶⁰⁴ and R⁶⁰⁵ together with the nitrogen atom connecting    them may optionally be condensed with a C₃₋₆ cycloaliphatic residue,    preferably cyclopropyl, cyclobutyl or cyclopentyl, or a 4 to 7    membered heterocycloaliphatic residue, preferably oxetanyl or    oxiranyl, wherein the C₃₋₆ cycloaliphatic residue or the 4 to 7    membered heterocycloaliphatic residue condensed in this way can for    their part be respectively unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, Br, I, ═O, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃CF₃,    CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,    C(═O)—O—CH₃ and C(═O)—O—C₂H₅.

Even more preferably,

-   R⁶⁰⁴ represents the partial structure (I-T2),    -   wherein    -   n6 denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more        preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue or together denote ═O; preferably each independently of        one another represent H, F, CH₃ or OCH₃ or together denote ═O;    -   R^(613c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, ═O, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue, preferably selected        from the group consisting of cyclopropyl, cyclobutyl,        cyclopentyl and cyclohexyl, or a 3 to 10 membered        heterocycloaliphatic residue, preferably selected from the group        consisting of pyrrolidinyl, morpholinyl, piperazinyl,        piperidinyl and tetrahydropyranyl, more preferably        tetrahydropyranyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄        aliphatic residue, CF₃, and an unsubstituted C₁₋₄-aliphatic        residue,    -    or denotes an aryl or heteroaryl, preferably phenyl or pyridyl,        in each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,        C(═O)—O—C₂H₅ and phenyl,        -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   R⁶⁰⁵ denotes H or an unsubstituted C₁₋₄-aliphatic residue or a    C₁₋₄-aliphatic residue, which is monosubstituted with OCH₃,    preferably H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl or tert.-butyl or CH₂—OCH₃, C₂H₄—OCH₃ or C₃H₆—OCH₃, more    preferably H, methyl or ethyl, preferably denotes H or an    unsubstituted C₁₋₄-aliphatic residue, preferably H, methyl, ethyl,    n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl,    more preferably H, methyl or ethyl,    or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl,    4-methylpiperazinyl, oxazepanyl, thiomorpholinyl, azepanyl,

tetrahydroquinolinyl, tetrahydroisoquinolinyl,tetrahydroinnidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,

dihydroindolinyl, or dihydroisoindolyl, preferably a morpholinyl,piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, 4-methylpiperazinyl,oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl,dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted ormono- or polysubstituted with at least one substituent selected from thegroup consisting of F, Cl, Br, I, OH, ═O, C(═O)—OH, an O—C₁₋₄ aliphaticresidue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, and aC₁₋₄-aliphatic residue, cyclopropyl, cyclobutyl and cyclopentyl,

-   -   wherein the C₁₋₄-aliphatic residue is in each case unsubstituted        or mono- or polysubstituted with at least one substituent        selected from the group consisting of F, OH, ═O, CF₃ and an        unsubstituted O—C₁₋₄-aliphatic residue, preferably is in each        case unsubstituted.

Still more preferably,

-   R⁶⁰⁴ represents the partial structure (6-T2),    -   wherein    -   n6 denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more        preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, CH₃ or OCH₃ or together denote ═O, preferably        each independently of one another represent H or CH₃, more        preferably H,    -   R^(613c) denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, or        tert-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, ═O, an unsubstituted O—C₁₋₄ aliphatic residue, and        CF₃,    -    or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,        pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and        tetrahydropyranyl, more preferably tetrahydropyranyl or        morpholinyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄        aliphatic residue, CF₃, and an unsubstituted C₁₋₄-aliphatic        residue,    -    or denotes an aryl or heteroaryl, preferably phenyl or pyridyl,        more preferably phenyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, CF₃, CN, and a C₁₋₄-aliphatic residue,-   R⁶⁰⁵ denotes H, methyl or ethyl or C₂H₄OCH₃ or C₃H₆OCH₃, more    preferably H or methyl or ethyl, even more preferably methyl,    or-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl,    tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiomorpholinyl,    azepanyl,

tetrahydroinnidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,

dihydroindolinyl, or dihydroisoindolyl, preferably a a morpholinyl,piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, morepreferably a morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl,oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, morepreferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, ortetrahydroisoquinolinyl, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, OH, ═O, C(═O)—OH, C(═O)—CH₃, C(═O)—OCH₃, O-methyl,O-ethyl, OCF₃, SCF₃, CF₃, methyl, CH₂CF₃, CH₂OH, CH₂—OCH₃, CH₂CH₂—OCH₃,ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, preferablyselected from the group consisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl,O-ethyl, OCF₃, SCF₃, CF₃, methyl, ethyl, n-propyl, 2-propyl,cyclopropyl, and cyclobutyl.

In a preferred embodiment of the compound according to general formula(6-I), the residue

-   R⁶⁰⁶ denotes a C₂₋₁₀-aliphatic residue, preferably a C₂₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the binding is carried out via a    carbon atom of the 3 to 10 membered heterocycloaliphatic residue,-    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷, O—R⁶⁰⁸ or N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₁₀-aliphatic residue,        preferably a C₁₋₈-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   or in each case represent a C₃₋₁₀-cycloaliphatic residue or a 3        to 10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the binding is carried out via a        carbon atom of the 3 to 10 membered heterocycloaliphatic        residue,    -   R⁶⁰⁹ denotes a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₈-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a        C(═O)—O—C₁₋₄-aliphatic residue a C₃₋₆ cycloaliphatic residue,        and a 3 to 6 membered heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue and C(═O)—OH,    -    on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the binding is carried out via a        carbon atom of the 3 to 10 membered heterocycloaliphatic        residue,    -   R⁶¹⁰ denotes H or a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH, preferably        denotes a C₁₋₁₀-aliphatic residue, more preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 10 membered heterocycloaliphatic residue, preferably        a 3 to 6 membered heterocycloaliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an        O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic        residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆        cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄            aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue,            OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -   and wherein the 3 to 10 membered heterocycloaliphatic residue        formed by R⁶⁰⁹ and R⁶¹⁰ together with the nitrogen atom        connecting them may optionally be condensed with aryl or        heteroaryl, preferably with phenyl or pyridyl, wherein the aryl        or heteroaryl residues condensed in this way can for their part        be respectively unsubstituted or mono- or polysubstituted with        at least one substituent selected from the group consisting of        F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄aliphatic residue), an N(C₁₋₄        aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -    wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -    wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -    wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

Preferably,

-   R⁶⁰⁶ denotes a C₂₋₁₀-aliphatic residue, preferably a C_(m)-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue.-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case represent a C₁₋₈-aliphatic residue,        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄-aliphatic residue, an NH(C₁₋₄ aliphatic residue), an        N(C₁₋₄ aliphatic residue)₂, a C(═O)—O—C₁₋₄-aliphatic residue,        CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or in each case denote a C₃₋₁₀-cycloaliphatic residue or a 3 to        10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a        C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄ aliphatic residue, CF₃,        and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic        residue.    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes a C₁₋₈-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue,        a S—C₁₋₄ aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue may in each case        optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic        residue,    -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom, and    -   R⁶¹⁰ denotes H or a C₁₋₁₀-aliphatic residue, preferably a        C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, and a C₁₋₄-aliphatic residue, preferably denotes a        C₁₋₁₀-aliphatic residue, more preferably a C₁₋₆-aliphatic        residue, unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 10 membered heterocycloaliphatic residue, preferably        a 3 to 6 membered heterocycloaliphatic residue, more preferably        selected from the group consisting of morpholinyl, piperidinyl,        pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono-        or polysubstituted with at least one substituent selected from        the group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   and wherein the 3 to 10 membered heterocycloaliphatic residue        formed by R⁶⁰⁹ and R⁶¹⁰ together with the nitrogen atom        connecting them may optionally be condensed with aryl or        heteroaryl, preferably with phenyl or pyridyl, wherein the aryl        or heteroaryl residues condensed in this way can for their part        be respectively unsubstituted or mono- or polysubstituted with        at least one substituent selected from the group consisting of        F, Cl, Br, I, NO₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, a 3 to 6        membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, and pyridyl,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, and pyridyl, may in each            case may be unsubstituted or mono- or polysubstituted with            at least one substituent selected from the group consisting            of F, Cl, Br, I, NO₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃,            O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,            CF₃, CN, a C₁₋₄-aliphatic residue, and C(═O)—OH, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH,            SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic            residue and C(═O)—OH.

More preferably,

-   R⁶⁰⁶ denotes a C₂₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue,-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case denote a C₁₋₈-aliphatic residue,        preferably a C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, CF₃, a        C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or in each case denote a C₃₋₁₀-cycloaliphatic residue or a 3 to        10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄        aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a        C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and    -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered        heterocycloaliphatic residue may be bridged, preferably is        bridged, via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic        group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic        residue,    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes a C₁₋₈-aliphatic residue, preferably a        C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, a        C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and    -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered        heterocycloaliphatic residue may in each case be bridged,        preferably is bridged, via a C₁₋₈ aliphatic group, preferably a        C₁₋₄ aliphatic group, which in turn may be unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic        residue,    -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,    -   and    -   R⁶¹⁰ denotes H or a C₁₋₆-aliphatic residue, preferably a        C₁₋₄-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, and a C₁₋₄-aliphatic residue, preferably denotes a        C₁₋₆-aliphatic residue, more preferably a C₁₋₄-aliphatic        residue, unsubstituted or mono- or polysubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 10 membered heterocycloaliphatic residue, preferably        selected from the group consisting of morpholinyl, piperidinyl,        pyrrolidinyl, azetidinyl and piperazinyl, unsubstituted or mono-        or polysubstituted with at least one substituent selected from        the group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -    and wherein the 3 to 10 membered heterocycloaliphatic residue        formed by R⁶⁰⁹ and R⁶¹⁰ together with the nitrogen atom        connecting them may optionally be condensed with aryl or        heteroaryl, preferably with phenyl or pyridyl, wherein the aryl        or heteroaryl residues condensed in this way can for their part        be respectively unsubstituted or mono- or polysubstituted with        at least one substituent selected from the group consisting of        F, Cl, Br, I, NO₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,        SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—OH, residue,

benzyl, phenyl, thienyl, and pyridyl,

-   -   -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,            and        -   wherein benzyl, phenyl, thienyl, and pyridyl, may in each            case may be unsubstituted or mono- or polysubstituted with            at least one substituent selected from the group consisting            of F, Cl, Br, I, NO₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃,            O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,            CF₃, CN, a C₁₋₄-aliphatic residue, and C(═O)—OH.

Even more preferably,

-   R⁶⁰⁶ denotes a C₂₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₁₀-cycloaliphatic residue, preferably a    C₃₋₆-cycloaliphatic residue, or a 3 to 10 membered    heterocycloaliphatic residue, preferably a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a unsubstituted C₁₋₄ aliphatic group,-    on the condition that if R⁶⁰⁶ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case denote a C₁₋₈-aliphatic residue,        preferably a C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, an NH(C₁₋₄        aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or in each case denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to        10 membered heterocycloaliphatic residue, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄        aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a        C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and    -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered        heterocycloaliphatic residue in each case may be bridged,        preferably is bridged, via an unsubstituted C₁₋₈ aliphatic        group, preferably an unsubstituted C₁₋₄ aliphatic group,    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes a C₁₋₈-aliphatic residue, preferably a        C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and    -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered        heterocycloaliphatic residue is in each case bridged via a        unsubstituted C₁₋₈ aliphatic group, preferably an unsubstituted        C₁₋₄ aliphatic group,    -   on the condition that if R⁶⁰⁹ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom, and    -   R⁶¹⁰ denotes H or an unsubstituted C₁₋₄-aliphatic residue,        preferably selected from the group consisting of methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and        tert.-butyl, more preferably selected from the group consisting        of methyl and ethyl, preferably denotes an unsubstituted        C₁₋₄-aliphatic residue, preferably selected from the group        consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl,        isobutyl, sec.-butyl and tert.-butyl, more preferably selected        from the group consisting of methyl and ethyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a 3 to 6 membered heterocycloaliphatic residue, preferably        selected from the group consisting of morpholinyl, piperidinyl,        pyrrolidinyl, and azetidinyl, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,    -   and wherein the 3 to 6 membered heterocycloaliphatic residue        formed by R⁶⁰⁹ and R⁶¹⁰ together with the nitrogen atom        connecting them may optionally be condensed with phenyl or        pyridyl, wherein the phenyl or pyridyl residues condensed in        this way can for their part be respectively unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄        aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue,        CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, residue, benzyl,        phenyl, and pyridyl,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, OH,            and an unsubstituted O—C₁₋₄-aliphatic residue, and        -   wherein benzyl, phenyl, and pyridyl, may in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OCH₃, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, CF₃, and a            C₁₋₄-aliphatic residue.

Still more preferably,

-   R⁶⁰⁶ denotes a C₂₋₆-aliphatic residue, preferably selected from the    group consisting of ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    ethenyl and propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃),    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue,    OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, CF₃, and a    C₁₋₄-aliphatic residue, preferably in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, OH, an O—C₁₋₄-aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue, more preferably in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, and an    O—C₁₋₄-aliphatic residue, preferably O-methyl, even more preferably    in each case unsubstituted,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₆-cycloaliphatic residue, preferably selected from    the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and    cyclohexyl, or a 3 to 6 membered heterocycloaliphatic residue,    preferably selected from the group consisting of piperidinyl    (preferably piperidin-4-yl or piperidin-3-yl), tetrahydrofuranyl,    and tetrahydropyranyl, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    preferably in each case unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, OH, an O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue, more preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue,    preferably O-methyl, even more preferably in each case    unsubstituted,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case optionally bridged via    an unsubstituted C₁₋₄ aliphatic group, preferably via an    unsubstituted C₁₋₂ aliphatic group,-    on the condition that if R⁶⁰⁶ a 3 to 6 membered    heterocycloaliphatic residue, the 3 to 6 membered    heterocycloaliphatic residue is linked via a carbon atom,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case denote a C₁₋₆-aliphatic residue,        preferably selected from the group consisting of methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl,        n-pentyl, isopentyl, neopentyl, n-hexyl, ethenyl and propenyl        (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), unsubstituted or mono-        or polysubstituted with at least one substituent selected from        the group consisting of F, Cl, Br, I, OH, ═O, an        O—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue,        OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, CF₃, and a        C₁₋₄-aliphatic residue, more preferably in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH, and        an O—C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -   or denotes a C₃₋₆-cycloaliphatic residue, preferably        cyclopropyl, or a 3 to 6 membered heterocycloaliphatic residue,        preferably oxetanyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic        residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a        C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic        residue, preferably in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, OH, an O—C₁₋₄-aliphatic residue, CF₃,        and a C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with OH or an            unsubstituted O—C₁₋₄-aliphatic residue,    -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10        membered heterocycloaliphatic residue in each case may be        bridged, preferably is bridged, via an unsubstituted C₁₋₄        aliphatic group,    -   on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic        residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,        preferably an unsubstituted C₁₋₆-aliphatic residue, more        preferably selected from the group consisting of methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl,        n-pentyl, isopentyl, neopentyl, and n-hexyl,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -   or denotes a C₃₋₆-cycloaliphatic residue, preferably selected        from the group consisting of cyclopropyl, cyclobutyl,        cyclopentyl and cyclohexyl, or a 3 to 6 membered        heterocycloaliphatic residue, preferably selected from the group        consisting of piperidinyl (preferably piperidin-4-yl or        piperidin-3-yl), tetrahydrofuranyl, and tetrahydropyranyl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, a C₁₋₄-aliphatic residue and an O—C₁₋₄-aliphatic residue,        even more preferably in each case unsubstituted,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6        membered heterocycloaliphatic residue may in each case        optionally bridged via an unsubstituted C₁₋₄ aliphatic group,    -   on the condition that if R⁶⁰⁹ denotes a 3 to 6 membered        heterocycloaliphatic residue, the 3 to 10 membered        heterocycloaliphatic residue is linked via a carbon atom,    -   R⁶¹⁰ denotes H or an unsubstituted C₁₋₄-aliphatic residue,        preferably represents an unsubstituted C₁₋₄-aliphatic residue,        or denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl,        isobutyl, sec-butyl or tert-butyl, preferably denotes methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or        tert-butyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, and a C₁₋₄-aliphatic        residue        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with OH or an            unsubstituted O—C₁₋₄-aliphatic residue.

Most preferred,

-   R⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    ethenyl or propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, OH, an    O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    preferably in each case unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, and an O—C₁₋₄-aliphatic residue, preferably O-methyl, more    preferably in each case unsubstituted,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,    piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl, preferably    denotes cyclopropyl or tetrahydropyranyl, more preferably    cyclopropyl, in each case unsubstituted or mono- or polysubstituted    with at least one substituent selected from the group consisting of    F, Cl, OH, an O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue, preferably in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue,    preferably O-methyl, more preferably in each case unsubstituted,    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,    piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl may in each    case be optionally bridged via an unsubstituted C₁₋₄ aliphatic    group, preferably via an unsubstituted C₁₋₂ aliphatic group,-    on the condition that if R⁶⁰⁶ denotes piperidinyl,    tetrahydrofuranyl, or tetrahydropyranyl, piperidinyl,    tetrahydrofuranyl, or tetrahydropyranyl is linked via a carbon atom,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein    -   R⁶⁰⁷ and R⁶⁰⁸ in each case denote methyl, ethyl, n-propyl,        2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl,        isopentyl, neopentyl, n-hexyl, ethenyl and propenyl (—CH₂CH═CH₂,        —CH═CH—CH₃, —C(═CH₂)—CH₃), in each case unsubstituted or mono-        or polysubstituted with at least one substituent selected from        the group consisting of F, Cl, OH, N(C₁₋₄ aliphatic residue)₂        and an O—C₁₋₄-aliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -    or in each case denote cyclopropyl, cyclobutyl, cyclopentyl        cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, or        tetrahydropyranyl, preferably cyclopropyl or oxetanyl, in each        case unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH, an        O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,        preferably in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue, more        preferably in each case unsubstituted,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,    -    and wherein cyclopropyl, cyclobutyl, cyclopentyl and        cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, and        tetrahydropyranyl may in each case be optionally bridged via an        unsubstituted C₁₋₄ aliphatic group,    -    on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes piperidinyl,        oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl, each of these        residues is linked via a carbon atom,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, ═O, OH, and O-methyl, preferably        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, and        O-methyl, more preferably unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F and O-methyl, preferably denotes an        unsubstituted C₁₋₆-aliphatic residue, more preferably selected        from the group consisting of methyl, ethyl, n-propyl, 2-propyl,        n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,        neopentyl, and n-hexyl,    -   R⁶¹⁰ denotes H, methyl, ethyl, n-propyl, 2-propyl, n-butyl,        isobutyl, sec-butyl or tert-butyl, preferably methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl or tert-butyl,        more preferably methyl or ethyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, and a C₁₋₄-aliphatic        residue, more preferably unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl and a O—C₁₋₄ aliphatic residue,        preferably form together with the nitrogen atom connecting them        a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each        case unsubstituted.

In particular,

-   R⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    CH₂—CH(CH₃)(C₂H₅), C(CH₃)₂(C₂H₅), ethenyl or propenyl (—CH₂CH═CH₂,    —CH═CH—CH₃, —C(═CH₂)—CH₃), CH₂—OCH₃, C₂H₄—OCH₃, C₃H₆—OCH₃,    cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case    unsubstituted,    or-   R⁶⁰⁶, denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein R⁶⁰⁷ and R⁶⁰⁸ in each case denote methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl,        n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH, a        N(C₁₋₄ aliphatic residue)₂, and an O—C₁₋₄-aliphatic residue,        preferably with at least one substituent selected from the group        consisting of F, OH, N(CH₃)₂, O-methyl and O-ethyl, or in each        case denote CH₂-cyclopropyl or oxetanyl, preferably, R⁷ and R⁸        in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl,        isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,        neopentyl, or n-hexyl, CH₂—CH₂—F, CH₂CHF₂, CH2-OCH3,        CH₂CH₂—OCH₃, CH₂CH₂—N(CH₃)₂, CH₂-cyclopropyl or oxetanyl,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,            or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes methyl, ethyl, C(═O)—CH₃, n-propyl, 2-propyl,        n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,        neopentyl, or n-hexyl,    -   R⁶¹⁰ denotes H, methyl or ethyl, preferably methyl or ethyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in        each case unsubstituted.

Particularly preferred is a compound according to general formula (6-I),wherein

-   R⁶⁰¹ represents the partial structure (6-T1),    —(CR^(612a)R^(612b))_(m6)—R^(612c)  (6-T1),    -   wherein    -   m6 is 0, 1 or 2, preferably 0 or 2, more preferably 2, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, OH, CH₃ or OCH₃ or together denote ═O, more        preferably H, F, OH or CH₃, even more preferably H,    -   R^(612c) denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or        tert.-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, CN, OH, S(═O)₂—CH₃, an unsubstituted O—C₁₋₄ aliphatic        residue, preferably O-methyl and O-tert.-butyl, and CF₃,        preferably denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or        tert.-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic residue, preferably        O-methyl and O-tert.-butyl, and CF₃,        -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10            membered heterocycloaliphatic residue, preferably            cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, oxetanyl            or tetrahydropyranyl, in each case unsubstituted or mono- or            polysubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, an unsubstituted            O—C₁₋₄ aliphatic residue, preferably O-methyl and O-ethyl,            CF₃, and an unsubstituted C₁₋₄-aliphatic residue, preferably            methyl or ethyl,    -   or    -   wherein    -   m6 is 0 or 2, more preferably 0, and    -   R^(612a) and R^(612b) each independently of one another        represent H, F, CH₃ or OCH₃; and    -   R^(612c) denotes an aryl or heteroaryl, preferably phenyl or        pyridyl, in each case unsubstituted or mono- or polysubstituted        with at least one substituent selected from the group consisting        of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue. OCF₃, OCF₂H,        CH₂—OH, CH₂—OCH₃, S(═O)₂—CH₃, SCF₃, NO₂, N(CH₃)₂,

CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl, preferably denotes an aryl or heteroaryl,preferably phenyl or pyridyl, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl,

-   -   -   wherein phenyl may be unsubstituted or mono- or            polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,            preferably with at least one substituent selected from the            group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,

-   R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    CH₂—OH; CH₂—O—CH₃; CH₂—CH₂—OH; CH₂—CH₂—OCH₃; O-methyl; O-ethyl;    O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl; cyclopropyl,    cyclobutyl, cyclopentyl, or cyclohexyl; preferably represents F; Cl;    Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl; ethyl; n-propyl;    iso-propyl; n-butyl; sec.-butyl; tert.-butyl; CH₂—OH; O-methyl;    O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,

-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; or    S-Ethyl,

-   R⁶⁰⁴ represents the partial structure (6-T2),    —(CR^(613a)R^(613b))_(n6)—R^(613c)  (6-T2),    -   wherein    -   n6 denotes 0, 1, 2 or 3, preferably denotes 1 or 2, more        preferably denotes 1,    -   R^(613a) and R^(613b) each independently of one another        represent H, F, CH₃ or OCH₃, or together denote ═O, preferably        each independently of one another represent H or CH₃, more        preferably H,    -   R^(613c) denotes a C₁₋₄ aliphatic residue, preferably methyl,        ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or        tert.-butyl, unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, ═O, an unsubstituted O—C₁₋₄ aliphatic residue, and        CF₃,    -    or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,        pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl and        tetrahydropyranyl, more preferably tetrahydropyranyl or        morpholinyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄        aliphatic residue, CF₃, and an unsubstituted C₁₋₄-aliphatic        residue,    -    or denotes an aryl or heteroaryl, preferably phenyl or pyridyl,        more preferably phenyl, in each case unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, CF₃, CN, and a C₁₋₄-aliphatic residue,

-   R⁶⁰⁵ denotes H, methyl or ethyl, C₂H₄OCH₃ or C₃H₆OCH₃, more    preferably H or methyl, even more preferably methyl,    or

-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl,    tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or    dihydroisoindolyl, preferably a morpholinyl, piperidinyl,    pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl,    tetrahydroisoquinolinyl, thiomorpholinyl, azepanyl,

tetrahydroinnidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,

dihydroindolinyl, or dihydroisoindolyl, preferably a a morpholinyl,piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, dihydroindolinyl, or dihydroisoindolyl, morepreferably a morpholinyl, oxazepanyl, tetrahydroquinolinyl, ortetrahydroisoquinolinyl, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl, O-ethyl, OCF₃, SCF₃,CF₃, C(═O)—CH₃, C(═O)—OCH₃, CH₂CF₃, CH₂OH, CH₂—OCH₃, CH₂CH₂—OCH₃,methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl,preferably selected from the group consisting of F, Cl, OH, ═O,C(═O)—OH, O-methyl, O-ethyl, OCF₃, SCF₃, CF₃, methyl, ethyl, n-propyl,2-propyl, cyclopropyl, and cyclobutyl,

-   R⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl,    sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,    CH₂—CH(CH₃)(C₂H₅), C(CH₃)₂(C₂H₅), ethenyl or propenyl (—CH₂CH═CH₂,    —CH═CH—CH₃, —C(═CH₂)—CH₃), CH₂—OCH₃, C₂H₄—OCH₃, C₃H₆—OCH₃,    cyclopropyl, cyclobutyl, or tetrahydropyranyl, in each case    unsubstituted,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein R⁶⁰⁷ and R⁶⁰⁸ in each case denote methyl, ethyl,        n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl,        n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, OH, a        N(C₁₋₄ aliphatic residue)₂, and an O—C₁₋₄-aliphatic residue,        preferably with at least one substituent selected from the group        consisting of F, OH, N(CH₃)₂, O-methyl and O-ethyl, or in each        case denote CH₂-cyclopropyl or oxetanyl, preferably, R⁷ and R⁸        in each case denote methyl, ethyl, n-propyl, 2-propyl, n-butyl,        isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,        neopentyl, or n-hexyl, CH₂—CH₂—F, CH₂CHF₂, CH2-OCH3,        CH₂CH₂—OCH₃, CH₂CH₂—N(CH₃)₂, CH₂-cyclopropyl or oxetanyl,        -   wherein the C₁₋₄-aliphatic residue in each case is            unsubstituted,            or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes methyl, C(═O)—CH₃, ethyl, n-propyl, 2-propyl,        n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,        neopentyl, or n-hexyl,    -   R⁶¹⁰ denotes H, methyl or ethyl, preferably methyl or ethyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in        each case unsubstituted.

In another particularly preferred embodiment of the compound accordingto general formula (6-I),

-   R⁶⁰¹ represents phenyl or pyridyl, preferably phenyl, in each case    unsubstituted or mono- or disubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, OH,    OCH₃, OCF₃, CF₃, and CH₃,-   R⁶⁰² represents H; CF₃; methyl; ethyl; iso-propyl; O-methyl; or    cyclopropyl,-   R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃; methyl; or O-methyl,-   R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogen atom connecting them a    morpholinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazepanyl,    tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolinyl, or    dihydroisoindolyl, in each case unsubstituted,-   R⁶⁰⁶ denotes ethyl, n-propyl, 2-propyl (iso-propyl), tert.-butyl,    cyclopropyl, cyclobutyl or cyclopentyl or tetrahydropyranyl,    or-   R⁶⁰⁶ denotes S—R⁶⁰⁷ or O—R⁶⁰⁸,    -   wherein R⁶⁰⁷ and R⁶⁰⁸ in each case denote methyl, ethyl,        2-propyl, or tert-butyl,        or-   R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰),    -   wherein    -   R⁶⁰⁹ denotes methyl, ethyl, n-propyl, 2-propyl, or tert-butyl,    -   R⁶¹⁰ denotes H, methyl or ethyl, preferably methyl or ethyl,    -   or    -   R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atom connecting        them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl.

Another embodiment of the present invention relates to a compound ofgeneral formula (I), wherein the compound is selected from a compoundaccording to general formula (7-I).

wherein

-   R⁷⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted; aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, a    C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a    S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue    may be in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₈-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; C(═O)H; C(═O)—OH; C(═O)—NH₂;    SCF₃; S(═O)₂—OH; NO₂; OCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the    C₁₋₄ aliphatic residue may be in each case be unsubstituted or mono-    or polysubstituted; a O—C₁₋₄-aliphatic residue, a    O—C(═O)—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue,    wherein the C₁₋₄ aliphatic residue may be in each case be    unsubstituted or mono- or polysubstituted; a NH(C₁₋₄ aliphatic    residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic    residue, a NH—S(═O)₂—C₁₋₄-aliphatic residue, a N(C₁₋₄ aliphatic    residue)-C(═O)—C₁₋₄ aliphatic residue, or a N(C₁₋₄ aliphatic    residue)-S(═O)₂—C₁₋₄ aliphatic residue, wherein the C₁₋₄ aliphatic    residue may in each case be unsubstituted or mono- or    polysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-   R⁷⁰⁷ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or    polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted and in each case optionally bridged via a    C₁₋₈ aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted;-    on the condition that if R⁷⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom,    in which an “aliphatic group” and “aliphatic residue” can in each    case be branched or unbranched, saturated or unsaturated,    in which a “cycloaliphatic residue” and a “heterocycloaliphatic    residue” can in each case be saturated or unsaturated,    in which “mono- or polysubstituted” with respect to an “aliphatic    group” and an “aliphatic residue” relates, with respect to the    corresponding residues or groups, to the substitution of one or more    hydrogen atoms each independently of one another by at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, a    NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue,    ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic    residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a    S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a    S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3    to 6 membered heterocycloaliphatic residue, C(═O)—NH₂, a    C(═O)—NH(C₁₋₄ aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic    residue)₂;    in which “mono- or polysubstituted” with respect to a    “cycloaliphatic residue” and a “heterocycloaliphatic residue”    relates, with respect to the corresponding residues, to the    substitution of one or more hydrogen atoms each independently of one    another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue),    an N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a    NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic    residue, a O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue,    a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphatic    residue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, a    C(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, a    C₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and a    C(═O)—N(C₁₋₄ aliphatic residue)₂;    in which “mono- or polysubstituted” with respect to “aryl” and a    “heteroaryl” relates, with respect to the corresponding residues, to    the substitution of one or more hydrogen atoms each independently of    one another by at least one substituent selected from the group    consisting of F, Cl, Br, I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.

The compounds according to general formula (7-I) are known from WO2010/102811 A1, which is fully included by reference.

Preferred embodiments of the compound according to general formula (7-I)have general formulae (7-Ia), (7-Ib), (7-Ic) or (7-Id):

Another preferred embodiment of present invention is a compoundaccording to general formula (7-I), wherein

-   R⁷⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH,

-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted, preferably represents H; F; Cl; Br; I; CN; CF₃;    NO₂; OCF₃; SCF₃; a C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic    residue, a O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6    membered heterocycloaliphatic residue, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic    residue and an O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic    residue in each case may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, and an unsubstituted    O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic    residue or the 3 to 6 membered heterocycloaliphatic residue may in    each case be optionally bridged via a C₁₋₄ aliphatic group, which in    turn may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H,

-   R⁷⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,

-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,

-    on the condition that if R⁷⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a preferred embodiment of the compound according to general formula(2-I), the residue

-   R⁷⁰¹ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₅-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and    C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and    a 3 to 6 membered heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes an aryl or heteroaryl, in each case unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃    and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic residue, a 3 to 6 membered    heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, O—CH₂—OH, O—CH₂—O—CH₃, SH, SCF₃, a S—C₁₋₄        aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH,        C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,

-    and wherein the aryl or the heteroaryl residue may in each case be    optionally bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN and    C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (7-I), the residue

-   R⁷⁰¹ represents the partial structure (7-T1)    —(CR^(708a)R^(708b))_(m7)—R^(708c)  (7-T1),    wherein-   m7 denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, or 2,-   R^(708a) and R^(708b) each independently of one another represent H,    F, Cl, Br, I, NO₂, NH₂, a NH(C₁₋₄ aliphatic residue), an N(C₁₋₄    aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH,    SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄ aliphatic residue    or C(═O)—OH, or together denote ═O,    -   preferably each independently of one another represent H, F, Cl,        Br, I, NH₂, a NH(C₁₋₄ aliphatic residue), a N(C₁₋₄ aliphatic        residue)₂, OH, O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   more preferably each independently of one another represent H,        F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue,    -   even more preferably each independently of one another represent        H, F, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue,        and-   R^(708c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue and C(═O)—OH,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, preferably when m2 is ≠0, in each case    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, a    C₃₋₆ cycloaliphatic residue and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    or denotes—preferably when m2 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆ cycloaliphatic    residue, a 3 to 6 membered heterocycloaliphatic residue,

benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl,

-   -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and        oxazolyl may in each case may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic        residue), an N(C₁₋₄ aliphatic residue)₂, OH, an O—C₁₋₄ aliphatic        residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅,        C(═O)—O—CH₃ and C(═O)—O—C₂H₅, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH.

Preferably,

-   R⁷⁰¹ represents the partial structure (7-T1),    -   wherein    -   m7 denotes 0, 1, or 2,    -   R^(708a) and R^(708b) each independently of one another        represent H, F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄        aliphatic residue,    -    preferably each independently of one another represent H, F, a        O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and    -   R^(708c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue and        C(═O)—OH,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄        aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic residue,        C(═O)—OH, a C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered        heterocycloaliphatic residue,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue and C(═O)—OH,    -    or denotes—preferably when m7 is =0—an aryl or heteroaryl, in        each case unsubstituted or mono- or polysubstituted with at        least one substituent selected from the group consisting of F,        Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue,        C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a        C₃₋₆ cycloaliphatic residue, a 3 to 6 membered        heterocycloaliphatic residue, benzyl, phenyl, thienyl, pyridyl,        furyl, thiazolyl or oxazolyl,        -   wherein the C₁₋₄-aliphatic residue in each case may be            unsubstituted or mono- or polysubstituted with at least one            substituent selected from the group consisting of F, Cl, Br,            I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic            residue, and        -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl            and oxazolyl may in each case may be unsubstituted or mono-            or polysubstituted, preferably unsubstituted or mono- or            disubstituted with at least one substituent selected from            the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄            aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue,            C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and            C(═O)—O—C₂H₅, preferably with at least one substituent            selected from the group consisting of F, Cl, CH₃, O—CH₃, CF₃            and OCF₃,        -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6            membered heterocycloaliphatic residue may in each case may            be unsubstituted or mono- or polysubstituted with at least            one substituent selected from the group consisting of F, Cl,            Br, I, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a            C₁₋₄-aliphatic residue and C(═O)—OH.

More preferably,

-   R⁷⁰¹ represents the partial structure (7-T1),-    wherein-   m7 denotes 0, 1, or 2,-   R^(708a) and R^(708b) each independently of one another represent H,    F, Cl, Br, I, an O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic    residue,-    preferably each independently of one another represent H, F, a    O—C₁₋₂ aliphatic residue or a C₁₋₂ aliphatic residue, and-   R^(708c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an O—C₁₋₄ aliphatic residue, CF₃,    and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, CF₃ and        an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes—preferably when m7 is =0—an aryl or heteroaryl, in each    case unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic    residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅, a C₃₋₆    cycloaliphatic residue, a 3 to 6 membered heterocycloaliphatic    residue, benzyl, phenyl, thienyl or pyridyl,    -   wherein benzyl, phenyl, thienyl and pyridyl, may in each case        may be unsubstituted or mono- or polysubstituted, preferably        unsubstituted or mono- or disubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and C(═O)—O—C₂H₅,        preferably with at least one substituent selected from the group        consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, a C₁₋₄-aliphatic        residue and C(═O)—OH.

In a further preferred embodiment of the compound according to generalformula (7-I), the residue

-   R⁷⁰¹ represents the partial structure (7-T1),-    wherein-   m7 is 0, 1 or 2 and-   R^(708a) and R^(708b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃;-   R^(708c) denotes a C₁₋₄ aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, an unsubstituted aliphatic    residue, CF₃, and an unsubstituted C₁₋₄-aliphatic residue,-    or-    wherein-   m7 is 0,-   R^(708a) and R^(708b) each independently of one another represent H,    F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic residue;    preferably H, F, CH₃ or OCH₃; and-   R^(708c) denotes an aryl or heteroaryl, in each case unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic    residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃,    C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃.

Particularly preferred is a compound according to general formula (7-I)which has the following general formula (7-Ie):

In a preferred embodiment of the compound according to general formula(7-I), the residue

-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue may be    in each case be unsubstituted or mono- or polysubstituted; a    C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted and in each case optionally bridged via a C₁₋₄    aliphatic group, which in turn may be unsubstituted or mono- or    polysubstituted.

Preferably,

-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 6 membered    heterocycloaliphatic residue may in each case be optionally bridged    via a C₁₋₄ aliphatic group, which in turn may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, an unsubstituted    C₁₋₄-aliphatic residue and an unsubstituted O—C₁₋₄-aliphatic    residue.

More preferably,

-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a    C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, a    O—C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        ═O, OH, and an unsubstituted O—C₁₋₄-aliphatic residue,-    cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,    piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,    preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in    each case unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, an unsubstituted C₁₋₄-aliphatic residue and an unsubstituted    O—C₁₋₄-aliphatic residue,    -   and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,        pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or        piperidinyl may in each case be optionally bridged via an C₁₋₄        aliphatic group, which in turn may be unsubstituted or mono- or        polysubstituted with at least one substituent selected from the        group consisting of F, Cl, OH, an unsubstituted C₁₋₄-aliphatic        residue and an unsubstituted O—C₁₋₄-aliphatic residue.

Even more preferably,

-   R⁷⁰² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; methyl;    ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;    O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl;    cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R⁷⁰² is selected from the group consisting of H; F; Cl; CF₃; CN;    SCF₃; OCF₃; CH₃; C₂H₅; n-propyl; iso-propyl; t-butyl; cyclopropyl;    O—CH₃ and O—C₂H₅;

In particular,

-   R⁷⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃;

In a particular preferred embodiment of the compound according togeneral formula (7-I), the residue

-   R⁷⁰² is ≠H.

In a preferred embodiment of the compound according to general formula(7-I), the residues

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄    aliphatic residue, a C(═O)—N(C₁₋₄ aliphatic residue)₂, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, a NH(C₁₋₄    aliphatic residue), a N(C₁₋₄ aliphatic residue)₂, a NH—C(═O)—C₁₋₄    aliphatic residue, and a NH—S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

Preferably,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; C(═O)—OH;    C(═O)—NH₂; S(═O)₂—OH; NO₂; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄    aliphatic residue, a C(═O)—O—C₁₋₄ aliphatic residue, a    O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, wherein    the C₁₋₄-aliphatic residue in each case may be unsubstituted or    mono- or polysubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, ═O, OH, and a O—C₁₋₄-aliphatic    residue; a C₃₋₆-cycloaliphatic residue or a 3 to 6 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, ═O, OH, a C₁₋₄-aliphatic residue    and a O—C₁₋₄-aliphatic residue, and in each case optionally bridged    via an unsubstituted C₁₋₄ aliphatic group,    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

More preferably,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another    represent H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; C(═O)H; NO₂; a    C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄ aliphatic residue, a O—C₁₋₄-aliphatic residue, a    S—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each    case may be unsubstituted or mono- or polysubstituted with at least    one substituent selected from the group consisting of F, Cl, Br, I,    ═O, OH, and a O—C₁₋₄-aliphatic residue; a C₃₋₆-cycloaliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, ═O,    OH, a C₁₋₄-aliphatic residue and a O—C₁₋₄-aliphatic residue, and in    each case optionally bridged via an unsubstituted C₁₋₄ aliphatic    group,    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

In a further preferred embodiment of the present invention,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; a (C═O)—C₁₋₄ aliphatic residue, a C₁₋₄ aliphatic    residue, O—C₁₋₄ aliphatic residue, a S—C₁₋₄ aliphatic residue,    wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted    or mono- or polysubstituted with at least one substituent selected    from the group consisting of F, Cl, and O—CH₃;    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

Preferably,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    OCF₃; SCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;    sec.-butyl; tert.-butyl; cyclopropyl; C(═O)-methyl; C(═O)-ethyl;    (C═O)-isopropyl; (C═O)-t-butyl; O-methyl; O-ethyl; O-isopropyl;    O-t-butyl; O—(CH₂)₂—O—CH₃; S-Methyl; S-Ethyl;    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

In particular,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ are each independently of one another are    selected from the group consisting of H; F; Cl; Br; I; NO₂; CF₃; CN;    (C═O)-methyl; (C═O)-ethyl; (C═O)-isopropyl; (C═O)-t-butyl; methyl;    ethyl; isopropyl; t-butyl; O-methyl; O-Ethyl; O-isopropyl;    O-t-butyl; OCF₃; S-methyl; S-ethyl; and SCF₃;    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

More particularly,

-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is ≠H.

Most preferred,

-   R⁷⁰³, R⁷⁰⁴ and R⁷⁰⁶ each independently of one another are selected    from the group consisting of H and F; and-   R⁷⁰⁵ denotes F; Br; CF₃; OCF₃; CN; or NO₂;

In a particular preferred embodiment of the compound according togeneral formula (7-I) at least one of the residues R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ andR⁷⁰⁶ is ≠H.

In a preferred embodiment of the compound according to general formula(7-I), the residue

-   R⁷⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, and C(═O)—OH,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, CF₃, CN, a    C₁₋₄-aliphatic residue, C(═O)—OH, a C(═O)—O—C₁₋₄-aliphatic residue a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic        residue)₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃,        a S—C₁₋₄ aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue        and C(═O)—OH,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic    residue), an N(C₁₋₄ aliphatic residue)₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue and C(═O)—OH,-    on the condition that if R²⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

In a further preferred embodiment of the compound according to generalformula (7-I), the residue

-   R⁷⁰⁷ denotes a C₁₋₁₀-aliphatic residue, preferably a C₁₋₈-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, NO₂,    OH, ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN,    and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, a C₁₋₄-aliphatic residue, a    C₃₋₆ cycloaliphatic residue, and a 3 to 6 membered    heterocycloaliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and    -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 6 membered        heterocycloaliphatic residue may in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        NO₂, OH, ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a        S—C₁₋₄ aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue,-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, NO₂, OH, ═O, an O—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄    aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic residue.-    on the condition that if R⁷⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

Preferably,

-   R⁷⁰⁷ denotes a C₁₋₈-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a C(═O)—O—C₁₋₄-aliphatic residue, a S—C₁₋₄    aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue may in each case optionally    bridged via a C₁₋₈ aliphatic group, preferably a C₁₋₄ aliphatic    group, which in turn may be unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a C₁₋₄-aliphatic    residue.-    on the condition that if R⁷⁰⁷ denotes a 3 to 10 membered    heterocycloaliphatic residue, the 3 to 10 membered    heterocycloaliphatic residue is linked via a carbon atom.

More preferably,

-   R⁷⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, CF₃, a C(═O)—O—C₁₋₄-aliphatic residue, and a C₁₋₄-aliphatic    residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue is bridged via a C₁₋₈ aliphatic group,    preferably a C₁₋₄ aliphatic group, which in turn may be    unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄ aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄ aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, CN, and a    C₁₋₄-aliphatic residue.

Even more preferably,

-   R⁷⁰⁷ denotes a C₁₋₈-aliphatic residue, preferably a C₁₋₆-aliphatic    residue, unsubstituted or mono- or polysubstituted with at least one    substituent selected from the group consisting of F, Cl, Br, I, OH,    ═O, an O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a S—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic    residue    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue, and-    wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered    heterocycloaliphatic residue is in each case bridged via a    unsubstituted C₁₋₈ aliphatic group, preferably an unsubstituted C₁₋₄    aliphatic group.

Still more preferably,

-   R⁷⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted,-    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered    heterocycloaliphatic residue, in each case unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄ aliphatic    residue, OCF₃, SCF₃, a S—C₁₋₄ aliphatic residue, a    C(═O)—O—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue,    -   wherein the C₁₋₄-aliphatic residue in each case may be        unsubstituted or mono- or polysubstituted with OH or an        unsubstituted O—C₁₋₄-aliphatic residue.-    and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10    membered heterocycloaliphatic residue is in each case bridged via a    unsubstituted C₁₋₄ aliphatic group

In particular,

-   R⁷⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted.

Most preferred,

-   R⁷⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, CF₃, Cl, OH, and O-methyl.

Preferred is also a compound according to general formula (7-I), wherein

-   R⁷⁰¹ represents the partial structure (7-T1),    —(CR^(708a)R^(708b))_(m7)—R^(708c)  (7-T1),    -   wherein    -   m7 is 0, 1 or 2 and    -   R^(708a) and R^(708b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃;    -   R^(708c) denotes a C₁₋₄ aliphatic residue, unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,    -    or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered        heterocycloaliphatic residue, in each case unsubstituted or        mono- or polysubstituted with at least one substituent selected        from the group consisting of F, Cl, Br, I, an unsubstituted        O—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted        C₁₋₄-aliphatic residue,        or    -   wherein    -   m7 is 0,    -   R^(708a) and R^(708b) each independently of one another        represent H, F, a O—C₁₋₄ aliphatic residue or a C₁₋₄ aliphatic        residue; preferably H, F, CH₃ or OCH₃; and    -   R^(708c) denotes an aryl or heteroaryl, in each case        unsubstituted or mono- or polysubstituted with at least one        substituent selected from the group consisting of F, Cl, Br, I,        OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a C₁₋₄-aliphatic        residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃, C(═O)—O—C₂H₅ and        phenyl,    -   wherein phenyl may be unsubstituted or mono- or polysubstituted,        preferably unsubstituted or mono- or disubstituted with at least        one substituent selected from the group consisting of F, Cl, Br,        I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃, CN, a        C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ and        C(═O)—O—C₂H₅, preferably with at least one substituent selected        from the group consisting of F, Cl, CH₃, O—CH₃, CF₃ and OCF₃,-   R⁷⁰² is selected from the group consisting of H; F; Cl; CF₃; CH₃;    C₂H₅, iso-propyl; cyclopropyl; and O—CH₃;-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ are each independently of one another    selected from the group consisting of H; F; Cl; Br; CF₃; CN; OCF₃    and NO₂;    preferably on the condition that at least one of R²⁰³, R²⁰⁴, R²⁰⁵    and R²⁰⁶ is ≠H,-   R⁷⁰⁷ denotes a C₁₋₆-aliphatic residue, unsubstituted or mono- or    polysubstituted with at least one substituent selected from the    group consisting of F, Cl, Br, I, OH, ═O, an O—C₁₋₄-aliphatic    residue, a C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, a    S—C₁₋₄-aliphatic residue, CF₃, and a C₁₋₄-aliphatic residue    -   wherein the C₁₋₄-aliphatic residue in each case is        unsubstituted.

Particularly preferred is also a compound according to general formula(7-I), wherein

-   R⁷⁰¹ represents aryl, preferably phenyl, or heteroaryl, preferably    pyridyl or thienyl, in each case unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃,-    preferably represents phenyl, unsubstituted or mono- or    disubstituted with at least one substituent selected from the group    consisting of F, Cl, Br, I, OH, OCH₃, OCF₃, CF₃, CN, and CH₃;-   R⁷⁰² is selected from the group consisting of H, F, Cl, CF₃, CH₃,    C₂H₅, iso-propyl, cyclopropyl, and O—CH₃; preferably is selected    from the group consisting of CH₃, C₂H₅, OCH₃ and CF₃;-   R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵ and R⁷⁰⁶ are each independently of one another    selected from the group consisting of H, F, Cl, Br, CF₃, CN, OCF₃    and NO₂;-    preferably on the condition that at least one of R⁷⁰³, R⁷⁰⁴, R⁷⁰⁵    and R⁷⁰⁶ is, ≠H, more preferably on the condition that R⁷⁰⁵ is ≠H;-   R⁷⁰⁷ denotes a saturated C₁₋₄-aliphatic residue, unsubstituted or    mono- or disubstituted with at least one substituent selected from    the group consisting of F, Cl, Br, I, OH, O—CH₃, OCF₃, SCF₃, and    CF₃.

Another aspect of the present invention further relates to at least onecompound according to general formula (I) and also if appropriate of oneor more pharmaceutically acceptable auxiliaries for the use in thepreparation of a medicament for prophylaxis and/or treatment ofdisorders and/or diseases which are mediated, at least in part, by TSPOactivity.

The selection of the physiologically acceptable auxiliaries and also theamounts thereof to be used depend on whether the pharmaceuticalcomposition is to be applied orally, subcutaneously, parenterally,intravenously, intraperitoneally, intradermally, intramuscularly,intranasally, buccally, rectally or locally, for example to infectionsof the skin, the mucous membranes and of the eyes. Preparations in theform of tablets, dragées, capsules, granules, pellets, drops, juices andsyrups are preferably suitable for oral application; solutions,suspensions, easily reconstitutable dry preparations and also sprays arepreferably suitable for parenteral, topical and inhalative application.The substituted compounds according to the invention used in thepharmaceutical composition according to the invention in a repository,in a dissolved form or in a plaster, and further agents promoting skinpenetration being added if appropriate, are suitable percutaneousapplication preparations. Orally or percutaneously applicablepreparation forms can release the respective substituted compoundaccording to the invention also in a delayed manner.

The pharmaceutical compositions according to the invention can beprepared with the aid of conventional means, devices, methods andprocess known in the art, such as are described for example in“Remington's Pharmaceutical Sciences”, A. R. Gennaro (Editor), 17^(th)edition, Mack Publishing Company, Easton, Pa., 1985, in particular inPart 8, Chapters 76 to 93. The corresponding description is introducedherewith by way of reference and forms part of the disclosure. Theamount to be administered to the patient of the respective substitutedcompounds according to the invention of the above-indicated generalformula (I) may vary and is for example dependent on the patient'sweight or age and also on the type of application, the indication andthe severity of the disorder. Conventionally, 0.001 to 100 mg/kg,preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of atleast one compound according to the invention are applied per kg of thepatient's body weight.

Preference is given to at least one compound according to generalformula (I) and optionally one or more pharmaceutically acceptableauxiliaries for the use in the preparation of a medicament for theprophylaxis and/or treatment of disorders and/or diseases selected fromthe group consisting of

-   -   (i) neurological and neurodegenerative disorders, including    -    ischaemic stroke, Alzheimer's disease, frontotemporal dementia,        Huntington's disease, amyotrophic lateral sclerosis, Parkinson's        disease, multiple sclerosis, diabetic peripheral neuropathy,        chemotherapy-induced peripheral neuropathy, amyotrophic lateral        sclerosis, exictotoxic brain injury, traumatic brain injury,        ischaemic brain damage, cerebrovascular disorders and cerebral        ischemia;    -   (ii) psychiatric disorders, including    -    anxiety disorders, particularily panic disorders, post        traumatic stress disorder, panic and adult separation disorder,        social anxiety, major depression with adult separation anxiety        disorder and bipolar disorder with adult separation anxiety        disorder, dysthymia, angina pectoris, suicidality and        schizophrenia;    -   (iii) brain tumours;    -   (iv) immunological disorders and inflammatory diseases,        including    -    neuroinflammation and arthritis, encephalomyelitis and        irritable bowel syndrome.

Particular preference is given to at least one compound according togeneral formula (I) and optionally one or more pharmaceuticallyacceptable auxiliaries for use in the preparation of a medicament forthe prophylaxis and/or treatment of neurological and neurodegenerativedisorders, including Ischaemic stroke, Alzheimer's disease,frontotemporal dementia, Huntington's disease, amyotrophic lateralsclerosis, Parkinson's disease, multiple sclerosis, diabetic peripheralneuropathy, chemotherapy-induced peripheral neuropathy, amyotrophiclateral sclerosis, exictotoxic brain injury, traumatic brain injury,ischaemic brain damage, cerebrovascular disorders and cerebral ischemia.

Particular preference is given to at least one compound according togeneral formula (I) and optionally one or more pharmaceuticallyacceptable auxiliaries for use in the preparation of a medicament forthe prophylaxis and/or treatment of psychiatric disorders, includinganxiety disorders, particularily panic disorders, post traumatic stressdisorder, panic and adult separation disorder, social anxiety, majordepression with adult separation anxiety disorder and bipolar disorderwith adult separation anxiety disorder, dysthymia, angina pectoris,suicidality and schizophrenia.

Particular preference is given to at least one compound according togeneral formula (I) and optionally one or more pharmaceuticallyacceptable auxiliaries for use in the preparation of a medicament forthe prophylaxis and/or treatment of brain tumours.

Particular preference is given to at least one compound according togeneral formula (I) and optionally one or more pharmaceuticallyacceptable auxiliaries for use in the preparation of a medicament forthe prophylaxis and/or treatment of immunological disorders andinflammatory diseases, including neuroinflammation and arthritis,encephalomyelitis and irritable bowel syndrome.

Another aspect of the present invention is a method of treatment and/orprophylaxis of disorders and/or diseases, which are mediated, at leastin part, by TSPO activity, in a mammal, preferably of disorders and/ordiseases selected from the group consisting of

-   -   (i) neurological and neurodegenerative disorders, including    -    ischaemic stroke, Alzheimer's disease, frontotemporal dementia,        Huntington's disease, amyotrophic lateral sclerosis, Parkinson's        disease, multiple sclerosis, diabetic peripheral neuropathy,        chemotherapy-induced peripheral neuropathy, amyotrophic lateral        sclerosis, exictotoxic brain injury, traumatic brain injury,        ischaemic brain damage, cerebrovascular disorders and cerebral        ischemia;    -   (ii) psychiatric disorders, including    -    anxiety disorders, particularily panic disorders, post        traumatic stress disorder, panic and adult separation disorder,        social anxiety, major depression with adult separation anxiety        disorder and bipolar disorder with adult separation anxiety        disorder, dysthymia, angina pectoris, suicidality and        schizophrenia;    -   (iii) brain tumours;    -   (iv) immunological disorders and inflammatory diseases,        including    -    neuroinflammation and arthritis, encephalomyelitis and        irritable bowel syndrome, which comprises administering an        effective amount of at least one compound of general formula (I)        to the mammal.

The various, and in particular the preferred, embodiments of the firstaspect of the present invention apply in analogous manner—mutatismutandis—to the other aspects of the present invention.

PHARMACOLOGICAL EXPERIMENTS

Evaluation of the in vitro affinity of test substances for the ratperipheral BZD receptor was performed according to Le Fur et al. (1983).Life Sci., 33: 449-457. For this purpose, rat heart membranes and [3H]PK11195(1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide)were used in a radioligand binding test system.

In detail, membrane homogenates of heart (20 μg protein) are incubatedfor 15 min at 22° C. with 0.2 nM [3H]PK 11195 in the absence or presenceof the test compound in a buffer containing 50 mM Tris-HCl (pH 7.4) and10 mM MgCl₂ (96-well plate format). Compound addition is 100× solutionin solvent. Nonspecific binding is determined in the presence of 10 μMPK 11195. Following incubation, the samples are filtered rapidly undervacuum through glass fiber filters (GF/B, Packard) presoaked with 0.3%PEI and rinsed several times with ice-cold 50 mM Tris-HCl using a96-sample cell harvester (Unifilter, Packard). The filters are dried,then counted for radioactivity in a scintillation counter (Topcount,Packard) using a scintillation cocktail (Microscint 0, Packard). Theresults are expressed as a percent inhibition of the control radioligandspecific binding.

The standard reference compound is PK 11195, which is tested in eachexperiment concurrently with the test compounds.

For analysis, the specific ligand binding to the receptors is defined asthe difference between the total binding and the nonspecific bindingdetermined in the presence of an excess of unlabelled ligand. Theresults are expressed as a percent of control specific binding((measured specific binding/control specific binding)×100) obtained inthe presence of the test compounds. The data are summarized in table 1.

TABLE 1 %- Source of test Inhibition # Test Compound compound @ 10 μM 1N-[(3-Fluorophenyl)-methyl]-2-isopropyl-4-methyl-7- Example 8 in 87(trifluoromethyl)-quinoline-3-carboxylic acid amide WO2012/025238 A1 2N-(4,4-Dimethyl-pentyl)-2-ethylsulfanyl-4-methyl-6- Example 67 in 43morpholin-4-yl-pyridine-3-carboxylic acid amide WO2012/052167 A1 3N-[(4-Chlorophenyl)-methyl]-2-ethylsulfanyl-4- Example 124 in 91methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid WO2012/052167 amideA1 4 N-[(4-Chlorophenyl)-methyl]-2-methoxy-4-methyl-6- Example 165 in 49morpholin-4-yl-pyridine-3-carboxylic acid amide WO2012/052167 A1 52-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]- Example 124 in 102N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic WO2010/102809 acidamide A1 6 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro- Example115 in 99 3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3- WO2010/102809carboxylic acid amide A1 7 N-[(4-Chlorophenyl)-methyl]-2-cyclopropyl-4-Example 335 in 57 methyl-6-morpholin-4-yl-pyridine-3-carboxylic acidWO2012/052167 amide A1 8N-[(3-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6- Example 19 in 103morpholin-4-yl-pyridine-3-carboxylic acid amide WO2012/052167 A1 9N-[(4-Fluorophenyl)-methyl]-2-methoxy-4-methyl-6- Example 39 in 53morpholin-4-yl-pyridine-3-carboxylic acid amide WO2012/052167 A1 10N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin- Example 10 in 914-yl-2-propyl-pyridine-3-carboxylic acid amide WO2012/052167 A1 112-Cyclopropyl-N-[(4-fluorophenyl)-methyl]-4-methyl- Example 331 in 876-morpholin-4-yl-pyridine-3-carboxylic acid amide WO2012/052167 A1 122-[[3-(3,4-Difluoro-phenyl )-3,3-difluoro-propyl]- Example 209 in 97sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic WO2010/102809 acidamide A1 13 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- Example 2 in95 methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid WO2012/052167amide A1 14 N-[(4-Chlorophenyl)-methyl]-4-methyl-2-methyl- Example 168in 59 sulfanyl-6-morpholin-4-yl-pyridine-3-carboxylic acid WO2012/052167amide A1 15 2-Cyclopropyl-N-[(3-fluorophenyl)-methyl]-4-methyl- Example330 in 90 6-morpholin-4-yl-pyridine-3-carboxylic acid amideWO2012/052167 A1 162-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]- Example 169 in 96N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide WO2010/102809 A1

For the preparation of the test compounds, see referenced source.

The invention claimed is:
 1. A method for treating a disease and/ordisorder that is mediated at least in part by translocator protein(TSPO) activity in a patient in need thereof, wherein the disorderand/or the disease is selected from the group consisting of: (i)neurological and neurodegenerative disorders selected from the groupconsisting of: ischaemic stroke, Alzheimer's disease, frontotemporaldementia, Huntington's disease, amyotrophic lateral sclerosis,Parkinson's disease, multiple sclerosis, diabetic peripheral neuropathy,chemotherapy-induced peripheral neuropathy, amyotrophic lateralsclerosis, exictotoxic brain injury, traumatic brain injury, ischaemicbrain damage, cerebrovascular disorders and cerebral ischemia; (ii)brain tumours; (iii) immunological disorders and inflammatory diseasesselected from the group consisting of: neuroinflammation and arthritis,encephalomyelitis and irritable bowel syndrome; provided, again, thedisease and/or disorder in the patient undergoing such treating ismediated at least in part by TSPO, said method comprising administeringto said patient an effective amount therefor of a compound according togeneral formula (6-I), and achieving a modulation of TSPO activitybeneficial in treating said disease and/or disorder, wherein thecompound of the formula (6I) is:

wherein R⁶⁰¹ represents a C₁₋₁₀-aliphatic residue, unsubstituted ormono- or polysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10membered heterocycloaliphatic residue, in each case unsubstituted ormono- or polysubstituted and in each case optionally bridged via a C₁₋₈aliphatic group, which in turn may be unsubstituted or mono- orpolysubstituted; aryl or heteroaryl, in each case unsubstituted or mono-or polysubstituted and in each case optionally bridged via a C₁₋₈aliphatic group, which in turn may be unsubstituted or mono- orpolysubstituted; R⁶⁰² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂;OCF₃; SCF₃; a C₁₋₄-aliphatic residue, a C(═O)—C₁₋₄ aliphatic residue, aC(═O)—O—C₁₋₄ aliphatic residue, a C(═O)—NH—C₁₋₄ aliphatic residue, aC(═O)—N(C₁₋₄ aliphatic residue)₂, wherein the C₁₋₄ aliphatic residue maybe in each case be unsubstituted or mono- or polysubstituted; aO—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue, aS—C₁₋₄-aliphatic residue, a S(═O)₂—C₁₋₄-aliphatic residue, aS(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄ aliphatic residue mayin each case be unsubstituted or mono- or polysubstituted; aC₃₋₆-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphaticresidue, in each case unsubstituted or mono- or polysubstituted and ineach case optionally bridged via a C₁₋₄ aliphatic group, which in turnmay be unsubstituted or mono- or polysubstituted; R⁶⁰³ represents H; F;Cl; Br; I; CN; CF₃; SCF₃; NO₂; OCF₃; a C₁₋₄-aliphatic residue, aO—C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, wherein the C₁₋₄aliphatic residue may be in each case be unsubstituted or mono- orpolysubstituted; a C₃₋₆-cycloaliphatic residue or a 3 to 6 memberedheterocycloaliphatic residue, in each case unsubstituted or mono- orpolysubstituted and in each case optionally bridged via a C₁₋₄ aliphaticgroup, which in turn may be unsubstituted or mono- or polysubstituted;R⁶⁰⁴ represents a C₁₋₁₀-aliphatic residue, unsubstituted or mono- orpolysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 memberedheterocycloaliphatic residue, in each case unsubstituted or mono- orpolysubstituted and in each case optionally bridged via a C₁₋₈ aliphaticgroup, which in turn may be unsubstituted or mono- or polysubstituted;aryl or heteroaryl, in each case unsubstituted or mono- orpolysubstituted and in each case optionally bridged via a C₁₋₈ aliphaticgroup, which in turn may be unsubstituted or mono- or polysubstituted;on the condition that if R⁴ denotes a 3 to 10 memberedheterocycloaliphatic residue or a heteroaryl, the 3 to 10 memberedheterocycloaliphatic residue or the heteroaryl is linked via a carbonatom; R⁶⁰⁵ denotes H or a C₁₋₁₀-aliphatic residue, unsubstituted ormono- or polysubstituted; or R⁶⁰⁴ and R⁶⁰⁵ form together with thenitrogen atom connecting them a 3 to 10 membered heterocycloaliphaticresidue, unsubstituted or mono- or polysubstituted; R⁶⁰⁶ represents aC₂₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; aC₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphaticresidue, in each case unsubstituted or mono- or polysubstituted and ineach case optionally bridged via a C₁₋₈ aliphatic group, which in turnmay be unsubstituted or mono- or polysubstituted; on the condition thatif R⁶ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to10 membered heterocycloaliphatic residue is linked via a carbon atom, ordenotes S—R⁶⁰⁷, O—R⁶⁰⁸ or N(R⁶⁰⁹R⁶¹⁰), wherein R⁶⁰⁷ and R⁶⁰⁸ in eachcase represent a C₁₋₁₀-aliphatic residue, unsubstituted or mono- orpolysubstituted; a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 memberedheterocycloaliphatic residue, in each case unsubstituted or mono- orpolysubstituted and in each case optionally bridged via a C₁₋₈ aliphaticgroup, which in turn may be unsubstituted or mono- or polysubstituted;on the condition that if R⁶⁰⁷ or R⁶⁰⁸ denotes a 3 to 10 memberedheterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphaticresidue is linked via a carbon atom, R⁶⁰⁹ represents a C₁₋₁₀-aliphaticresidue, unsubstituted or mono- or polysubstituted; aC₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphaticresidue, in each case unsubstituted or mono- or polysubstituted and ineach case optionally bridged via a C₁₋₈ aliphatic group, which in turnmay be unsubstituted or mono- or polysubstituted; on the condition thatif R⁶⁰⁹ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3to 10 membered heterocycloaliphatic residue is linked via a carbon atom;R⁶¹⁰ denotes a C₁₋₁₀-aliphatic residue, unsubstituted or mono- orpolysubstituted; or R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atomconnecting them a 3 to 10 membered heterocycloaliphatic residue,unsubstituted or mono- or polysubstituted; in which an “aliphatic group”and an “aliphatic residue” can in each case be branched or unbranched,saturated or unsaturated, in which a “cycloaliphatic residue” and a“heterocycloaliphatic residue” can in each case be saturated orunsaturated, in which “mono- or polysubstituted” with respect to an“aliphatic group” and an “aliphatic residue” relates, with respect tothe corresponding residues or groups, to the substitution of one or morehydrogen atoms each independently of one another by at least onesubstituent selected from the group consisting of F, Cl, Br, I, NO₂,NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, aNH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄ aliphatic residue, ═O,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, CHO, COOH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphatic residue), and aC(═O)—N(C₁₋₄ aliphatic residue)₂; in which “mono- or polysubstituted”with respect to a “cycloaliphatic residue” and a “heterocycloaliphaticresidue” relates, with respect to the corresponding residues, to thesubstitution of one or more hydrogen atoms each independently of oneanother by at least one substituent selected from the group consistingof F, Cl, Br, I, NO₂, NH₂, an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄aliphatic residue)₂, a NH—C(═O)—C₁₋₄ aliphatic residue, a NH—S(═O)₂—C₁₋₄aliphatic residue, ═O, OH, OCF₃, a O—C₁₋₄-aliphatic residue, aO—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, a S—C₁₋₄-aliphatic residue,S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphatic residue, a S(═O)₂—O—C₁₋₄-aliphaticresidue, a S(═O)₂—NH—C₁₋₄-aliphatic residue, CN, CF₃, CHO, COOH, aC₁₋₄-aliphatic residue, a C(═O)—C₁₋₄-aliphatic residue, aC(═O)—O—C₁₋₄-aliphatic residue, a C₃₋₆-cycloaliphatic residue, a 3 to 6membered heterocycloaliphatic residue, C(═O)—NH₂, a C(═O)—NH(C₁₋₄aliphatic residue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂; in which“mono- or polysubstituted” with respect to “aryl” and a “heteroaryl”relates, with respect to the corresponding residues, to the substitutionof one or more hydrogen atoms each independently of one another by atleast one substituent selected from the group consisting of F, Cl, Br,I, NO₂, NH₂,

an NH(C₁₋₄ aliphatic residue), an N(C₁₋₄ aliphatic residue)₂, anNH—C(═O)—C₁₋₄ aliphatic residue, an NH—S(═O)₂—C₁₋₄ aliphatic residue,OH, OCF₃, a O—C₁₋₄-aliphatic residue, a O—C(═O)—C₁₋₄-aliphatic residue,SH, SCF₃, a S—C₁₋₄-aliphatic residue, S(═O)₂OH, a S(═O)₂—C₁₋₄-aliphaticresidue, a S(═O)₂—O—C₁₋₄-aliphatic residue, a S(═O)₂—NH—C₁₋₄-aliphaticresidue, CN, CF₃, C(═O)H, C(═O)OH, a C₁₋₄-aliphatic residue, aC(═O)—C₁₋₄-aliphatic residue, a C(═O)—O—C₁₋₄-aliphatic residue, aC₃₋₆-cycloaliphatic residue, a 3 to 6 membered heterocycloaliphaticresidue, benzyl, aryl, heteroaryl, C(═O)—NH₂, a C(═O)—NH(C₁₋₄ aliphaticresidue), and a C(═O)—N(C₁₋₄ aliphatic residue)₂.
 2. The methodaccording to claim 1, wherein: R⁶⁰¹ represents the partial structure(6-T1),—(CR^(612a)R^(612b))_(m6)-R^(612c)  (6-T1), wherein m6 is 0, 1 or 2, andR^(612a) and R^(612b) each independently of one another represent H, F,OH, CH₃ or OCH₃, or together denote ═O, R^(612c) denotes a C₁₋₄aliphatic residue, unsubstituted or mono- or polysubstituted with atleast one substituent selected from the group consisting of F, Cl, Br,I, CN, OH, S(═O)₂—CH₃, an unsubstituted O—C₁₋₄ aliphatic residue, andCF₃, or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 memberedheterocycloaliphatic residue, in each case unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, an unsubstituted O—C₁₋₄ aliphatic residue,CF₃, and an unsubstituted C₁₋₄-aliphatic residue, or wherein m6 is 0 or2, and R^(612a) and R^(612b) each independently of one another representH, F, OH, CH₃ or OCH₃; and R^(612c) denotes an aryl or heteroaryl, ineach case unsubstituted or mono- or polysubstituted with at least onesubstituent selected from the group consisting of F, Cl, Br, I, OH, anO—C₁₋₄ aliphatic residue, OCF₃, OCF₂H, CH₂—OH, CH₂—OCH₃, S(═O)₂—CH₃,SCF₃, NO₂, N(CH₃)₂,

CF₃, CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃,C(═O)—O—C₂H₅ and phenyl, wherein phenyl may be unsubstituted or mono- orpolysubstituted with at least one substituent selected from the groupconsisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃, CF₃,CN, a C₁₋₄-aliphatic residue, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—O—CH₃ andC(═O)—O—C₂H₅, R⁶⁰² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃;methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.-butyl; tert.-butyl;CH₂—OH; CH₂—O—CH₃; CH₂—CH₂—OH; CH₂—CH₂—OCH₃; O-methyl; O-ethyl;O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-Methyl; S-Ethyl; cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl, R⁶⁰³ represents H; F; Cl; Br; I; CN; CF₃;SCF₃; NO₂; OCF₃; methyl; ethyl; n-propyl; iso-propyl; n-butyl;sec.-butyl; tert.-butyl; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH;S-Methyl; or S-Ethyl, R⁶⁰⁴ represents the partial structure (6-T2)—(CR^(613a)R^(6113b))_(n6)+R^(613c)  (6-T2), wherein n6 denotes 0, 1, 2or 3, R^(613a) and R^(613b) each independently of one another representH, F, CH₃ or OCH₃, or together denote ═O, R^(613c) denotes a C₁₋₄aliphatic residue, unsubstituted or mono- or polysubstituted with atleast one substituent selected from the group consisting of F, Cl, Br,I, ═O, an unsubstituted O—C₁₋₄ aliphatic residue, and CF₃, or denotescyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl,morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each caseunsubstituted or mono- or polysubstituted with at least one substituentselected from the group consisting of F, Cl, Br, I, an unsubstitutedO—C₁₋₄ aliphatic residue, CF₃, and an unsubstituted C₁₋₄-aliphaticresidue, or denotes an aryl or heteroaryl, in each case unsubstituted ormono- or polysubstituted with at least one substituent selected from thegroup consisting of F, Cl, Br, I, OH, an O—C₁₋₄ aliphatic residue, OCF₃,CF₃, CN, and a C₁₋₄-aliphatic residue, R⁶⁰⁵ denotes H, methyl or ethyl,C₂H₄OCH₃ or C₃H₆OCH₃, or R⁶⁰⁴ and R⁶⁰⁵ form together with the nitrogenatom connecting them a morpholinyl, piperidinyl, pyrrolidinyl,azetidinyl, oxazepanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl,thiomorpholinyl, azepanyl,

tetrahydroimidazo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl,

dihydroindolinyl, or dihydroisoindolyl, in each case unsubstituted ormono- or polysubstituted with at least one substituent selected from thegroup consisting of F, Cl, OH, ═O, C(═O)—OH, O-methyl, O-ethyl, OCF₃,SCF₃, CF₃, C(═O)—CH₃, C(═O)—OCH₃, CH₂CF₃, CH₂OH, CH₂—OCH₃, CH₂CH₂—OCH₃,methyl, ethyl, n-propyl, 2-propyl, cyclopropyl, and cyclobutyl, R⁶⁰⁶denotes ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl,tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH₂—CH(CH₃)(C₂H₅),C(CH₃)₂(C₂H₅), CH₂—OCH₃, C₂H₄—OCH₃, C₃H₆—OCH₃, cyclopropyl, cyclobutyl,or tetrahydropyranyl, ethenyl or propenyl (—CH₂CH═CH₂, —CH═CH—CH₃,—C((═CH₂—CH₃), in each case unsubstituted, or R⁶⁰⁶ denotes S—R⁶⁰⁷ orO—R⁶⁰⁸ wherein R⁶⁰⁷ and R⁶⁰⁸ in each case denote methyl, ethyl,n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl,n-pentyl, isopentyl, neopentyl, or n-hexyl, in each case unsubstitutedor mono- or polysubstituted with at least one substituent selected fromthe group consisting of F, Cl, OH, N(C₁₋₄ aliphatic residue) and anO—C₁₋₄-aliphatic residue, or in each case denote CH₂-cyclopropyl oroxetanyl, wherein the C₁₋₄-aliphatic residue in each case isunsubstituted, or R⁶⁰⁶ denotes N(R⁶⁰⁹R⁶¹⁰), wherein R⁶⁰⁹ denotes methyl,C(═O)—CH₃, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl,tert.-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl, R⁶¹⁰ denotesmethyl or ethyl, or R⁶⁰⁹ and R⁶¹⁰ form together with the nitrogen atomconnecting them a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl,in each case unsubstituted.